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Abstract
From the start of the use of psychoactive prescription medications in the
1950s, physicians reported paradoxical adverse reactions, ranging from newly developing
depressions to an increase in existing mood disorders, and extremely violent and bizarre
acts of suicide and homicide. In this research, it is hypothesized that the pharmacological
properties of the prescribed drugs or the interaction between the drugs and the enzymes
that are primarily responsible for their metabolism (cytochrome P450s) could cause these
reactions. Given that acts of violence could be medication-induced, the role of the rate of
drug metabolism is discussed. Genetic testing of certain CYP450s could be helpful in
preventing the emergence of acts of violence. Genotyping is a powerful tool in
determining metabolic rates, but there are complicating issues, e.g., substrate specificity,
enzyme promiscuity, unreliability of the probe used for phenotesting,
phenoconversion, heterogeneity of CYP450 enzyme activity in different organs,
and altered sensitivity to inhibition. The best way to estimate the possible metabolic rate
is by combining genotyping, phenotyping, and therapeutic drug monitoring, in addition to
carefully observing and listening to the patient.
In this dissertation, three cases studies are presented in which the combination of
variant alleles and psychoactive medication may have led to extreme acts of violence. In
addition, a comparative study of violent offenders versus a control group indicates four
ii

risk factors for developing an altered emotional state which can develop into acts of
violence:
•

More than 4 variant alleles for CYP2B6, CYP2C8, CYP2C9, CYP2C19,
CYP2D6 or CYP3A4.

•

Three or more prescription medications, especially when an antidepressant or
other psychoactive medication is prescribed.

•

An intermediate phenotype for CYP3A4.

•

Fluctuating levels of psychoactive medication in the blood.

The guidelines set by the Clinical Pharmacogenetics Implementation
Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG) do not
apply in cases of polypharmacy or when there is more than one-drug-one gene interaction
involved. An easy-to-use protocol is described that could be used in general practice by
prescribing physicians to reduce the risk of dangerous side effects.
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Chapter One: Psychoactive Medication and Aggression, a Review

The discovery of truth
is prevented more effectively,
not by the false appearance things present
and which mislead into error,
not directly by weakness of the reasoning powers,
but by preconceived opinion,
by prejudice.
Arthur Schopenhauer

Introduction
For this review, Pubmed and Google scholar searches on ‘suicide’, ‘homicide’,’
violence’ ‘psychoactive medication’, and ‘SSRIs’ between 1950 and 2018 were done. In
addition, books addressing psychiatric disorders, medication use and violent behavior
were studied. Special attention was placed on papers from authors who are known or
presumed to be independent from the pharmaceutical industry. The development of
psychoactive drugs can be traced back to the 1950s, and they quickly became the first
choice of treatment for mental illness. This chapter documents the involvement of the
pharmaceutical industry in producing the myriad of available drugs.
From the start of the use of these drugs, physicians reported paradoxical adverse
reactions, ranging from newly developing depressions to an increase in existing mood
disorders, and extremely violent and bizarre acts of suicide and homicide. Several
1

mechanisms, e.g., the development of mania, agitation, emotional blunting, and/or
akathisia, are held responsible for these unexpected reactions. It is hypothesized that the
pharmacological properties of the prescribed drugs could cause these reactions. Through
the years, many researchers have investigated a possible association between
psychoactive drugs and acts of violence in an effort to substantiate causality. The
complex of symptoms known as akathisia, a movement disorder characterized by inner
restlessness, a need for constant movement and thoughts of death and dying, is
considered an important risk factor for violent behavior. Since akathisia can develops
insidiously, the dangers of not recognizing the symptoms in time are discussed.
A closer look at the history of the Diagnostic and Statistical Manual (DSM) sheds
light on the increase in the number of people supposedly suffering from psychiatric
disorders and the rise in the use of prescription medication. Most psychoactive
medication is metabolized by enzymes belonging to the cytochrome P450 family. Given
that acts of violence could be medication-induced, the role of the rate of metabolism of
the medication is discussed. Genetic testing of certain CYP450s could be helpful in
preventing the emergence of acts of violence.

From Pesticide to Psychoactive Medication
Around the second half of the 1800s, scientists were working on reaching agreement
on matters of atoms, molecules and structural formulas. German chemists used new
developments in the field of theoretical structural chemistry to synthesize new
compounds, e.g., synthetic dyes. One of the new dyes was methylene blue. In 1883,
2

Bernthsen was able to isolate the basic nucleus in methylene blue, thiodiphenylamin, also
known as phenothiazine. By 1934, entomologists were looking for a replacement for lead
arsenate as an insecticide. They tested different synthetic organic compounds and
discovered phenothiazine was extremely toxic for mosquitos. It also was successful in
treating worm disease in swine, but due to its toxicity was not used in humans. More
experiments lead to the discovery of the antihistaminic properties of phenothiazine and
the development of an even stronger phenothiazine derivate, promethazine.
Clinical studies revealed promethazine did not only have stronger antihistaminic
effects, but it could be beneficial in cases of motion sickness and as a sleeping aid. Dr.
Henri Laborit was a French navy surgeon. In 1949, he reported on using promethazine to
treat circulatory shock during and after surgery. Laborit noticed that patients on
promethazine became “calm and somnolent, with a relax and detached attitude.”[1] This
stimulated the manufacturer, the firm Rhône-Poulenc, to develop other substances aimed
at the central nervous system. In 1950, this resulted in the production of chlorpromazine
(Largactil) and the first benzodiazepine, chlordiazepoxide (Librium).[1, 2]
The first account of the effect of chlorpromazine was recorded on tape in 1951, when
psychiatrist Mrs. C. Quarti tested the psychologic effects on herself at the request of a
group of psychiatrists.[1] Her account after one intravenous injection:
“No subjective change was felt until 12:00, when I began to have the impression that
I was becoming weaker, that I was dying. It was very painful and agonizing.
At 12:55…I experienced an illness more pronounced than depression…. I tried to
describe my condition, of which I was perfectly conscious…. I was depressed,
extremely distressed.
At 1:00 an intense affective change appeared…the painful feeling of imminent death
disappeared to make room for a (sic) euphoric relaxation…. I felt incapable of being
3

angry about anything, irresistibly optimistic, and full of love for the whole world…. I
was more and more overcome by an extreme feeling of detachment from myself and
from others.
At 3:00, although lying down, I experienced a strong sensation of syncope….
The weakness and difficulty in speaking persisted for several days before gradually
disappearing….I felt…a complete detachment or neglect, and a certain lessening of
self-control.”[1]
Soon after, the use of chlorpromazine in psychiatric clinics took off. This was
especially the case in France, where Delay, Deniker and Harl were the first to use it.[3]
The goal was to get the patients in a state of “motor retardation, emotional indifference
and somnolence,” according to Lehmann in 1954.[4] Due to the fact that patients
developed tolerance after a few days, the dose needed to be increased to keep the desired
level of sedation. A sharp increase in the use of chlorpromazine followed. In 1952, 428
kg of chlorpromazine was used in French psychiatric hospitals, within five years this was
2,332,085 kg, an increase of over a half million percent.[5]
Experiments started with other substances as well. Reserpine, first derived in 1952
from the dried root of the Indian snakeroot plant, had been used in India for centuries and
was known as the “insanity herb”. It was initially used as an antihypertensive, but due to
its sedative effects it became the standard of care in a Swiss university clinic from 1953
on. Both chlorpromazine and reserpine were used for “schizophrenic states of excitement
and tension,” and in manic-depressive psychosis. [6] Since they were considered as
symptomatic treatments, they were used irrespective any underlying psychiatric
diagnosis.[7] It was assumed that these drugs had a similar effect as a lobotomy, but
chemically induced. During one of the first controlled trials, Elkes (1954), explicitly
noted that “the relief afforded by chlorpromazine appears to be principally
4

symptomatic.”[8] Kuhn (1958), who would later be involved in the development of the
first antidepressants, was sceptic about the effect of chlorpromazine and reserpine, and
described it as “slight or indeed absent altogether.”[9] The psychosis and hallucinations
were still present, but for the patients (and the staff) life was more bearable.[8, 10]
Gradually, the idea of symptomatic treatment gave way to the opinion that using these
drugs was actually treating certain disorders instead of just sedating patients.[11] In 1954,
Winkelman stated that “chlorpromazine should not be considered merely a chemical
restraint that has no real effect on the patients illness.”[8, 12] Ten years later, the National
Institute of Mental Health (NIMH) published a report stating that phenothiazines should
be regarded as “antischizophrenic”, and they suggested the term “tranquilizer” be
terminated for these drugs.[13] “Antischizophrenics” became “antipsychotics”, and the
idea that they were just a symptomatic treatment was abandoned.
Psychiatry became an interesting and productive area for the pharmaceutical industry
and additional substances were rapidly developed. Collaboration between French
pharmaceutical company, Rhône-Poulenc, and the American pharmaceutical company,
Smith, Kline & French (SK&F) paved the way for the introduction of chlorpromazine
under the name “Thorazine” on the American market.[1] Within eight months an estimated
two million patients received Thorazine, increasing the company sales by a third.[1]
Research into the effects of new drugs were increasingly directed by the pharmaceutical
companies and financial gain became the driving force.[1, 5, 14]
Physicians of the last century were limited in the types of psychoactive medication at
their disposal. However, the medication that was available, was broadly used. Research
5

performed by Moncrieff in 1999, on case notes between 1930-1940 from two psychiatric
institutions in the UK, revealed that almost every patient was taking at least one drug and
most of the time, several medications.[5, 11]
A study by Braslow (1997), involving treatments used during the first part of the last
century, showed that medication was primarily used for sedation, and it was assumed that
it had no influence on the course of the disease.[15] Drugs were not considered a causal
treatment but a form of chemical restraint.[11, 15] The medications that were used at the
time, such as opium, bromides, barbiturates and paraldehyde, were known for their
sedating properties. In addition, amphetamines were widely used as stimulants.
Publications of psychoactive drug research from those days are scarce and mainly
concern the treatment of epilepsy. The exception was insulin, which was used for the
treatment of schizophrenia, starting in the late 1920s and extending through the 1950s.
The idea was that inducing a hypoglycemic coma via insulin injections would somehow
act on the cause of the disease. That treatment, however, did not always go as planned,
and the mortality was high.[11, 16] In 1953, Bourne published a paper on the “myth” of
insulin in which he argued there was no scientific evidence for the concept that insulincoma therapy in any way countered the progress of schizophrenia.[17] Shortly after, this
procedure was declared obsolete.
Before 1950, there were only two categories of drugs available to be prescribed for
patients with different mental disorders. After 1950, drugs were developed aimed at
patients with a specific diagnosis, see Table 1.1.[11] These drugs were supposed to target
the disease directly.
6

Starting in the middle of the last century, the development of a series of psychoactive
drugs was the beginning of what was considered a revolution within the world of
psychiatry. Coincidentally, there was a massive discharge of patients from psychiatric
facilities, and this was initially thought to be the result of drug development. However,
the decline in numbers of admitted patients had already began before the introduction of
psychoactive medication. Research by Shepherd (1961) showed that the influence of
psychoactive medication on the discharge numbers was limited. The increased discharge
numbers applied to both treated and untreated patients.[18] The decrease of admissions was
more due to improved patients care, changing discharge criteria and social-economic
circumstances.[5, 18, 19]

Table 1.1: Development from Symptomatic Drugs to Therapeutic Concepts
(Taken from Moncrieff, 2002)
Pre 1950s

Post 1950s
Antipsychotics

Sedatives

Antidepressants
Anxiolytics
Hypnotics

Stimulants

Mood stabilizers
Treatment Resistant Schizophrenia

The role that the pharmaceutical companies played in the expansion of drug use
within psychiatric health care should not be ignored. Swazey (1974), described the
extensive marketing by SK&F to boost the sale of thorazine in the US. Legislators were
pressed to increase hospital drug budgets, and physicians were targeted with promotional
7

activities. Pharmaceutical manufacturers started to endorse their psychiatric medication
through commercials on radio and television.[1]
Pharmaceutical companies also engaged increasingly in studies regarding the effects
of the new drugs. In 1958, Kuhn was the first to report on the antidepressive effect of
imipramine hydrochloride, although he didn’t consider it more than a band-aid: “In view
of the symptomatic nature of the action of imipramine hydrochloride, therapy must be
maintained as long as the illness lasts.”[9] Healy (1997) described how the Swiss
pharmaceutical company, Geigy, became deeply involved in the studies about
imipramine.[20] Due to the marketing strategy of Merck, Geigy, and Roche, amitriptyline
became available worldwide at the beginning of the 1960s. Merck distributed 50,000
copies of the book “Recognizing the Depressed Patient,” which was written by Frank
Ayd, a practicing psychiatrist. It stated that depression is not limited to psychiatric
hospitals, but can be diagnosed anywhere, in general hospitals as well as in family
practices. This strategy was fairly effective, and imipramine was the first antidepressant
that was sold widely.[20]
In a 1994 paper, Shepard recalled his criticism towards the introduction of these new
substances, as it was published in the first textbook of clinical psychopharmacology in
1968. He noted that the enthusiasm with which the new medication and its many followups had been accepted could not be explained by any convincing evidence about their
effectiveness. To the contrary, a large amount of evidence was lacking. Shepherd thought
that acceptance was influenced by strong social factors that influence clinical practice
(e.g., the general feeling that psychological and physical treatments lacked efficiency, and
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the idea that psychopharmacology would bring psychiatry in line with other medical
practitioners). There were also problems with the way research was carried out (e.g., no
double-blind, placebo-controlled studies). He pointed to the boldness and the strategy
conducted by the pharmaceutical companies, as well as pressure by consumer groups,
whose members wanted relief from their psychological problems by way of
medication.[14]
The social factors created the right atmosphere for this new generation of
psychoactive drugs to get a foothold. Neuroleptics, a term introduced by Delay and
Deniker in 1955 to illustrate the mechanisms of the drugs which “attached to the neuron,”
became increasingly popular. By shifting their focus from asylums where psychiatric
patients with severe mental conditions were locked up, to milder forms of mental illness
where newer pharmacotherapies were available for specific disorders, psychiatrists some have argued - saw a way to increase their “failing status” within the medical
hierarchy.[1, 5]
In scientific studies, papers and books, often guided by pharmaceutical companies,
the use of psychotropic medication was heralded as beneficial for the patients and the
side effects were considered by some to be acceptable.
The indications for psychopharmacology were expanded. Anxiety was now an
indication for benzodiazepines, and new drugs, like oxazepam and diazepam, became
available.[21] Long acting neuroleptics were developed, where the amount given in one
day now would work for weeks.[2] By the 1970s, according to Deniker, millions of people
were on neuroleptics. He emphasized the necessity for patients to stay on the medication
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because relapses occurred when medication was discontinued for a few weeks. He also
supported the idea of mental disorders having a biochemical origin.
Within a decade, psychopharmacology became the cornerstone of psychiatric
treatment.[11] In the 1950s, monoamine oxidase inhibitors (e.g., iproniazid) were marketed
as “psychic energizers,” but they were the first drugs allowed for the use as
antidepressants. By the end of that decade, imipramine was the first of the tricyclic
antidepressants. After the introduction of imipramine, many similar drugs were
developed, but they were not more effective than the early tricyclics. At the beginning of
the 1980’s, there were 17 benzodiazepines available in the UK. It took a decade before it
became clear how addictive the benzodiazepines were, and, in the 1990, the popularity of
the benzodiazepines and the tricyclics decreased, in favor of the tetracyclics (e.g.,
mianserin), which were promoted as safer in cases of overdose, and a new class of
antidepressants, the selective serotonin reuptake inhibitors (SSRIs).[22]
In 1988, fluoxetine (Prozac) was one of the first SSRIs. The Food and Drug
Administration (FDA) gathered data from over 47 clinical studies between 1987 and
1997, regarding seven of these new antidepressants, including fluoxetine, paroxetine,
venlafaxine and sertraline. Kahn et al. (2003) analyzed these data regarding symptom
reduction and suicide risk, compared to the “old” antidepressants, imipramine,
amitriptyline and trazodone. The results were similar between the treatment drug, the
active comparator and the placebo group. There were no statistically significant
differences in suicide or attempted suicide rates. Depression decreased in 41% with the
new antidepressants, 42% with the old antidepressants and 31% on placebo, as measured
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with the mean total Hamilton Depression Rating (HAM-D) scores at double-blind
randomization (baseline) and the last observation carried forward.[23, 24] In addition, there
were more people who discontinued the trials than there were people who finished the 46 weeks trials. The Number Needed to Treat (NNT) provides information about the value
of a treatment. It is the number of patients that need to be treated for one patient to benefit
from the treatment.[25] In this study by Kahn, out of 100 patients, 41 were better (41%).
However, the improvement rate on placebo was 31%, which means 31 patients. From the
41 patients, 31 would have improved anyway due to the placebo effect. That means 10
extra patients benefit from the medication. To get those 10 extra patients, 100 patients
need to be treated, an NNT of 10. The ideal number is one: each patient that gets the drug
improves. An NNT of 10 is rather low, given that drugs have side effects. A cost-benefit
calculation is needed to determine if it is acceptable to put 90 people at risk for the
benefit of 10.[25]
In 1989, Fisher and Rogers pointed out the methodological shortcomings in the years
long research into the efficacy of antidepressants and other psychoactive medication. The
lack of an active placebo in double-blind research will create the impression that
antidepressants are more effective than they are. Overall, it turns out that in 30% to 40%
of the studies reviewed by Fisher and Rogers, there is no difference between the
medication and placebo, and only in 25% of the studies is there “substantial
improvement.”[26] The use of the Hamilton Rating Scale for Depression (HAM-D)
overestimates the positive effect of drug treatment. Depression free on the HAM-D scale
corresponds to a score of six or lower. Clinical studies generally last six to eight weeks.
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Recovery is not to be expected in that time. A drop from a score of 24 to 12 in a study is
no exception. However, such a drop reflects improvement, but not recovery. A score of
12 is still double the score of being depression free.[27] There are only small differences
between antidepressants and placebo. It could be that in the case of antidepressants these
are medication-induced mental effects e.g., sedation and emotional blunting. For as far as
improvement on placebo occurs, that could be the placebo effects itself. These
improvements are not true “antidepressant” effects. To measure a minimal clinically
relevant improvement a drop of at least seven to eight points on the HAM-D is necessary.
Every treatment, even placebo gives that improvement. Not any of them has a significant
better result than placebo. This means that the difference between the effect of
antidepressants or placebo is difficult to measure using the HAM-D. A clinician will not
be able to detect the difference between the treatments by using the HAM-D.[28] Valid
scientific conclusions about the efficacy of an antidepressant cannot be drawn from such
studies.
In a 2001 review paper regarding the methodologically problems in antidepressant
trials, Moncrieff reached similar conclusions .[29] She noted that not counting the dropouts
produced a bias in favor of the antidepressant treatment.[11] The question is what would
be left of “improvement” when an active placebo is used, a substance with
anticholinergic side effects, but no antidepressants activity, e.g., atropine. A review by
Moncrieff et al. for the Cochrane Collaboration in 2003 of trials comparing active
placebo with antidepressants showed no significant difference between tricyclic
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antidepressants and placebo.[30] She concluded “that unblinding may inflate the efficacy of
antidepressants in trials using inert placebos.”
A meta-analysis, performed by Fournier in 2010, on data from six trials which lasted
a maximum of six weeks, comparing tricyclic antidepressants with an SSRI (imipramine
and paroxetine respectively), showed that the SSRIs had no better effect than placebo
with mild or moderate depression (a score from 8 to 18 on the Hamilton scale). In cases
of severe depression, the benefit equaled 3.5 on the Hamilton scale, which is not a
clinically significant effect.[19, 28, 31] As before, “improvement” was measured, but not the
amount of “recovery” in the end.[32]
In summary, through serendipity, a substance was discovered that had a profound
effect on the human brain. On the outside, the persons taking these drugs, made a
sedative impression. For psychiatric patients, many who were kept in restraints, it offered
an acceptable alternative. For psychiatrists, it was an opportunity to increase their
standing among their colleagues practicing “real medicine.” It has been suggested by
some that pharmaceutical companies saw opportunities to expand and diversify their
market positions. Initially, new antidepressant medications were critiqued as more of a
Band-Aid®, than a treatment for the psychiatric illnesses the patients were suffering.
Critics pointed to what they viewed as the use of shrewd marketing strategies by
pharmaceutical companies to persuade doctors and patients that these drugs were solving
problems and improving mental health. Some independent research, however, appeared
to cast doubt on these claims.

13

Emerging Side Effects Related to Paradoxical Reactions
Contrary to what is often assumed, for a new drug to get approved, a couple of weeks
of testing in clinical trials with a limited number of test persons is sufficient. For instance,
the benzodiazepine alprazolam (Xanax) was tested on 226 patients for four weeks to get
FDA approval.[26] Consequently, only the short-term side effects would be noticed and
perhaps not even all of them, given the small amount of test participants. In the years
after the release of a new drug, more side effects would become evident. Freeman
mentioned in 1956 that, “in order to evaluate the true benefit of these new drugs on
remission, for example, the chances of relapse, the contents of the thought processes of
the patients, and the time they were admitted, large studies would be necessary.”
Otherwise, it would take at least a decade of trial and error before the value could be
established.[10]
That was the fate of these new psychoactive drugs. Shortly after the introduction of
reserpine and chlorpromazine as drugs to be used in patients with states of heighted
agitation, it became clear there were significant side effects as well. Lehmann (1954), one
of the first to start using chlorpromazine, described four patients with, what he called “an
interesting inversion of clinical manifestations,” as these patients became depressed.[4]
Reserpine is a highly purified alkaloid, prepared from Rauwolfia serpentine (Indian
snakeroot). It was primarily used to treat hypertension. Due to side effects like apathy
and an increased sleepiness, it became a drug used in psychiatry as well. Achor et al.
(1955) described that, in a cohort of 70 patients treated for hypertension with Rauwolfia,
15 cases of depression developed, one patient committed suicide, one attempted suicide,
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two were given electroshock treatment for the severity of the depression, four others
needed long term psychiatric care and seven others were taken of the drug.[33]
In 1955, Sarwer et al., in Canada, and Bleuler et al., in Switzerland, compared
chlorpromazine and reserpine. Sarwer discussed 14 cases where patients suffered
psychotic reactions and increased anxiety on either chlorpromazine or reserpine .[34]
Faucett (1957) reported on 42 previously mentally healthy patients who developed
depression while treated with reserpine for hypertension. Two of those patients
committed suicide.[35] Bleuler et al. noticed paradoxical reaction, e.g., restlessness,
unusual increase in bodily movements, and inner feelings of restlessness which were
mostly subjective.[6] This is a perfect description of what is now generally known as
akathisia. According to Bleuler, both drugs can cause an extrapyramidal syndrome, which
can develop into a therapy resistant Parkinson-like syndrome. Schiele et al. (1956)
mentioned neurological side effects on chlorpromazine, e.g., a Parkinson-like syndrome
and, in some patients, severe confusion and profound restlessness. On reserpine, Bleuler
et al. noted the same side effects with the addition of depressive reactions.[7]
A couple of years later, Ingram (1960) reported on paradoxical reactions in 15
patients on the benzodiazepine chlordiazepoxide. Among the side effects were severe
irritability, fatigue, apathy, dissociative reactions, hyperactivity and ataxia. Of these
patients, three stopped working due to the side effects, and two other patients refused to
take the drug any further. As an example, Ingram reported on a school teacher who struck
his wife after more than 20 years of marriage.[36] Ryan (1968) described increase in
depression, suicidal ideation and two suicides in eight patients on diazepam.[21]
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Similar paradoxical reactions appeared in patients on antidepressants. Kuhn (1958),
as one of the first to prescribe imipramine, noted that some patients reacted with mania,
an exacerbation of a psychosis, or with, what appeared to him, an “acute toxic psychosis
of the acute exogenous reaction type”, which is now called a substance-induced
psychosis.[9] He also noted that when patients received higher doses, they could develop
tension and agitation, which needed “an explosive outlet.” The same reactions could be
seen in schizophrenic patients on imipramine, e.g., they could become more agitated.
Seeman et al. mentioned in 1968 that they treated many patients who developed
paradoxical reactions on phenothiazines on low doses, with akathisia as one of the main
symptoms. She emphasized: “the drug-induced nature of the symptoms is often not
considered and the phenothiazine is increased instead of being stopped, thus aggravating
the reaction.”[37] Rampling (1978) reported four cases with severe aggressive outburst
which appeared, disappeared and re-appeared with the administration of imipramine and
amitriptyline.[38]
Although these drugs were prescribed regardless the psychiatric diagnoses, they
evolved from “one size fits all” tranquilizers (phenothiazines) to antipsychotics as a
separate group, antidepressants (tricyclics and later the SSRIs), and anxiolytics
(benzodiazepines). They could all be defined as neuroleptics as they were called by Delay
and Deniker, who were well aware of the dangers associated with these drugs. They
compared the effect of a small dose of neuroleptics with the symptoms of encephalitis
lethargica, caused by an extremely virulent virus that killed tens of thousands at the same
time as the Spanish Flu after World War I. Neuroleptics could cause “strange hysterical
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attacks both in women suspected of being neurotic and in soldiers in training.”[2] Deniker
et al. (1970) described such “hysteriform” conditions between 1920 and 1930 as a rest
condition in people who survived lethargic encephalitis.[2]
In patients on neuroleptics, nearly all the symptoms accompanying lethargic
encephalitis were recognizable. They included dyskinesia and hyperkinesia, parkinsonism
and psychosis. In children, the changes were even more profound. In 1929, Von
Economo, who described lethargic encephalitis for the first time, wrote about children
affected by this disease: “We see here how organic encephalitic lesions may produce in
previously normal individuals a strange alteration of personality which cannot be
otherwise described than as a kind of moral insanity or erethic imbecility.” He noted that
these children
“annoy strangers on the street, pluck their clothing, make faces at them or abuse
them; they tramp, beg, lie, steal, write on the walls, squander all the money they can
lay their hands on in sweets, cannot be controlled at school, run away from home and
spend their time at the cinema and in the streets, indulge in sexual misbehavior of
every kind and make other dangerous acts.”[39]
The personality changes were always negative, and aggressiveness, agitation and selfmutilation was often present. The worst cases were referred to as “Apache” as a reference
to the Native American tribe. Deniker and Delay contemplated the dangers of
neuroleptics and concluded: “It was found that neuroleptics could experimentally
reproduce almost all symptoms of lethargic encephalitis. In fact, it would be possible to
cause true encephalitis epidemics with the new drugs.”[2]
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Basically, all neuroleptics, as they were called then, or psychoactive drugs, as they are
called now, can cause paradoxical reactions. These side-effects are independent of the
chemical structure.[2] The neurological side effects of the neuroleptics, according to
Deniker, were noted from the beginning. It also became clear that when there were no
neurological side effects, there was hardly any therapeutic effect.[2, 40] In the years
following the 1960s and 1970s, an increasing number of reports surfaced about
aggression, suicide and homicide in relation to prescription psychoactive medication.

Psychoactive Medication and Violence
The notion that neuroleptics can cause paradoxical reactions was noted from the
beginning of their development. Schube described the deterioration of psychotic patients
on benzedrine, an amphetamine, in 1937.[41] Elkes noted depression and lethargy in
patients on chlorpromazine in 1954, and Deniker and Delay were able to experimentally
reproduce almost all symptoms of lethargic encephalitis using neuroleptics in their
patients in 1955.[2] Although the frequency was low, the possible consequences were
serious, unexpected reactions. They occurred in patients across the whole spectrum of
psychiatric disorders, involving all drugs that act on the brain chemistry. Because they
happened so rarely, it took a large number of patients before these side effects became
clear. In 2006, Healy et al. reported 60 patients out of 9,219 (0.65%) with hostile events
in trials with paroxetine, see Table 1.2.[42]
GlaxoSmithKline reported 44 violent events in 11,491 patients receiving paroxetine
(0.38%). In trials comparing paroxetine with a different SSRI, out of 2,418 patients, 16
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showed violent behavior (0.66%).[42] Moore et al. (2010) investigated 484 drugs for acts
of violence, and identified 1937 cases (0.25%), related to 31 drugs.[43] Given the
likelihood of underreporting side effects, their true incidence is probably higher.[27, 42, 44, 45]
Furthermore, patients are not likely to recognize aggression as related to their medication
if compared to, for example drowsiness, so they might not notify their doctors.[38] Road
rage, which could be drug-induced, will seldom be recognized as such, but more likely be
classified as due to visual problems related to sedative side effects of the medication
taken by these patients .[38]

Table 1.2: Hostility Events and Pediatric Placebo-Controlled Trials on Therapy and in
Withdrawal Phase (Taken from Healy, 2006)

Overall

Paroxetine
Events/Patients
60/9219 (0.65%)

Placebo
Events/Patients
20/6,455 (0.31%)

Depression

20/3,799 (0.53%)

8/2,402 (0.33%)

1.58 (0.70 - 3.58)

OCD*

19/737 (2.58%)

5/470 (1.06%)

2.43 (0.91 - 6.45)

Anxiety

16/3,823 (0.42%)

7/3,404 (0.21%)

2.03 (0.84 - 4.84)

5/760 (0.66%)

0/379

Condition

PMDD
*

**

Odds Ratio (95% CI)
2.10 (1.27 - 3.48)

OCD, Obsessive Compulsive Disorder
PMDD, Premenstrual Disorder

**

The most dramatic side effect is aggression resulting in violence, directed both inward
(suicide) and outward (homicide). Suicidal ideation and acts were noticed quickly after
the introduction of psychotropic prescription drugs.[21, 33, 35, 46-49] It took about ten years
before an association with homicide became apparent. In 1966, Brzezicki in France
treated a 40-year-old woman, with solely a history of depression, with imipramine. She
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developed a psychosis, during which she killed her three children and a rooster she dearly
loved.[50] Rampling reported four cases in 1978 with severe aggressive outburst on
imipramine and amitriptyline.[38] One patient attacked a nurse and accused the staff of
running a brothel, another patient try to throw herself out of a moving car. In the same
year, Keckich described a case in which a man, while in a state of akathisia due to
treatment with haloperidol, attacked his dog.[51] The patient himself recognized that as out
of character and checked himself into the hospital. Schulte (1985), reported on five
patients who, shortly after they were treated with haloperidol, developed akathisia and
committed extremely violent homicides: one patient beat his mother to death with a
hammer, and another stabbed himself repeatedly in the abdomen.[52] Shaw et al. (1986)
observed a man under a rigorous methodological regime, who acutely developed suicidal
and homicidal ideation on haloperidol.[53]
In 1989, Joseph Wesbecker killed eight people and injured 12 at his former
workplace, before committing suicide. He was prescribed fluoxetine just weeks before,
which made him, according to the people around him, severely agitated.[27, 54] This was the
beginning of what became known as “Prozac Killings,” homicides committed by persons
on SSRI antidepressants. Over the next years, more people who were prescribed the SSRI
fluoxetine committed suicide or homicide, and some of those cases made it to court. In
October 1990, a judge sentenced a man who had killed his father to four years’ probation.
In this case, it was the victim who was on fluoxetine. The son pleaded guilty and testified
his father had attacked him. In November of that year, the first “Prozac Defense” was put
forward in a case where a 74-years-old woman shot her husband. According to her
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lawyer, the jurors refused to convict her of murder, as it was their understanding that she
suffered from side effects of fluoxetine. She was convicted of voluntary manslaughter.[55]
By 1991, approximately 75 civil suits and more than a dozen criminal cases were pending
against Eli Lilly, the pharmaceutical company which manufactured fluoxetine.[55, 56]
In the spring of 1991, a consumer advocacy group founded by Ralph Nader, publicly
asked the FDA to put out a warning to physicians about the risks of violent events on
fluoxetine.[27] In reply, the FDA indicated that the warning label, which mentioned that
depressed patients are at a general risk of suicide and should be watched closely, was
sufficient. They were of the opinion that fluoxetine posed no unreasonable or unexpected
risk.[57] Some doctors wrote in support of the use of fluoxetine. Dr. Gary stated in the
American Journal of Psychiatry that many patients were helped by this new drug and that
raising the alarm “was potentially counterproductive” and could create a dangerous
“medical-legal precedent.” He failed to declare his conflict of interest as an employee of
Eli Lilly, the manufacturer of fluoxetine.[27]
Eli Lilly stood to lose a lot if fluoxetine was discredited. First marketed in 1987,
within four years, it was projected to bring in one billion in sales.[55] In an aggressive legal
strategy, the company started to assist the prosecution in criminal cases where defense
lawyers came up with the “Prozac defense”, claiming their clients were not responsible
because they were taking the prescribed medication. The Prozac defense is a generic term
that refers to the notion that several different SSRIs can cause a patient to make decisions
that they would not have made if they were not taking the drug. Eli Lilly offered to pay
all legal costs if a physician was sued for harm caused by prescribing the drug
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properly.[56-58] With these measures, Eli Lilly wanted to ensure physicians would continue
prescribing fluoxetine.[56] This meant that, in criminal cases, a defendant was not only up
against the lawyers of the District Attorney, but also against the lawyers of Eli Lilly.
Later that year, the FDA did evaluate the safety of fluoxetine and found no evidence
of an increased risk of suicide or acts of violence. According to the manufacturer, the
decision of the FDA Committee was “unanimous,” and there was no need for changes in
the guidelines or additional warnings on the drug’s label.[27] FDA approval has always
carried an enormous weight by the professionals and the public. After the FDA
reassurance, sales of fluoxetine went up again and were followed by the introduction of
similar serotonin boosters (e.g., sertraline).[27]
Despite the reassuring conclusions of the FDA, reports on violence in connection to
antidepressants and other psychoactive medication kept coming in, and, around 1995,
scientists started to take a closer look at the FDA panel’s investigation. Documents,
obtained through the Freedom of Information Act, revealed that five of the nine
physicians advising the FDA, had financial ties to pharmaceutical companies producing
serotonin boosters. In addition, four out of six consultants needed conflict-of-interest
waivers.[27] Two of the persons involved had been lead investigators for Eli Lilly in
clinical studies to win FDA approval. From the documents, it was clear that the FDA
worked with Eli Lilly on the suicide problem. During the FDA fluoxetine safety hearing
in 1991, the scientists left out information that fluoxetine increased the risk of suicide.[19]
Teichert, who had reported on six patients who developed violent suicidal thoughts after
2-6 weeks of fluoxetine treatment, was cut short repeatedly at the hearing and was not
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allowed to present his findings.[19, 27] This was in stark contrast to the people from Ely
Lilly. (As a tangential note: a few years later, Teichert’s wife was offered and accepted a
high position within Ely Lilly for which she had not applied. She then divorced
Teichert).[19, 45]
Despite the fact that the safety officers from the FDA itself and others, e.g., Teichert,
raised serious doubts about fluoxetine, the FDA panel approved it. In another vote during
that same hearing, the committee had to decide about adding a suicide warning on the
label of anti-depressants in general. The proposed text was: “In a small number of
patients, depressive symptoms have worsened during therapy, including the emergence of
suicidal thoughts and attempts.” However, Dr. Leber of the FDA stated that “the
possibility of a suicide attempt is inherent in depression.” Even though it was argued that
such a warning was not the same as warning physicians that the medication could
increase such feelings, Leber made it clear that he was more concerned about the
consequences for fluoxetine, because that drug was the best known. A minority of the
panel members were deeply concerned. It certainly was not unanimous, as Ely Lilly
wanted people to believe.[27] These decisions have not been made public and are only
available through the Freedom of Information Act.
Due to the interference of the pharmaceutical companies in court cases, negative
information was kept from the public. In the case of Reynaldo Lacuzong in 1999,
Dr. Breggin, a New York psychiatrist, author and expert witness, acted as a medical
expert.[59] Lacuzong had no history of mental illness, but was prescribed 10 mg of
paroxetine (Paxil) per day most likely to help him deal with work stress or smoking
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cessation. On the third day, he drowned his two children and himself in a bathtub. The
court ordered that Breggin was to be allowed access to the secret files of
GlaxoSmithKline (GSK), formerly Smith/Kline/Beecham (SKB). In an affidavit, Breggin
pointed to the flaws in the information from GSK concerning the dangers of paroxetine.
The case was settled, and GSK refused to release the records, including Breggin’s
affidavit. Making those records available would have benefited both professionals and the
public.
In 2005, Breggin’s affidavit became part of a motion in another case, and the results
of his 1999 investigation became public. In his original investigation, Breggin reanalyzed the suicide data in the secret SKB files on the world-wide development and
marketing of paroxetine, including the information provided to the FDA. In the trials that
were performed in the US, 14 suicide attempts were reported to the company. For
paroxetine, the number was 12 out of 1562 patients (0.77%, the FDA considers 1%
“frequent”). In the placebo group (497) and the imipramine group (464), one person
attempted suicide (0.20% and 0.21%). These data were left out of the 1991 report
“Suicidal Ideation and Behavior: Analysis of the Paroxetine Worldwide Clinical
Database” to the FDA.
In addition, Breggin found the following discrepancies: SKB left out two completed
suicides and two suicide attempts for patients outside the USA. This decreased the rate in
the group on paroxetine. Furthermore, he discovered two suicides and two suicide
attempts in the placebo wash-out group outside the USA. Wash-out is the period prior to
the start of the clinical trial. There are three reasons a placebo wash-out will create a bias
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in favor of the test medication. [19, 29, 60, 61] Firstly, all participants get a placebo and the
individuals reacting positive on placebo are excluded from the study. Eliminating these
persons from the study increases the chances that the drug that is to be tested will perform
better than if the people reacting favorable on placebo are kept in the trial. Secondly, the
placebo wash-out is not considered a part of the clinical trial. It is misleading to count the
two suicides and suicide attempts in the placebo group, thus increasing the suicide-related
numbers in this group.[59] Thirdly, in studies comparing psychoactive medication, patients
are often abruptly taken off their medication before randomization for the clinical trial,
which may put them into a state associated with drug withdrawal. This may increase the
chances they show improvement on the study medication.
Breggin then recalculated the following numbers based on his investigation. There
were seven completed suicide on 1,401 patients on paroxetine outside the USA (0.499%).
There was one completed suicide on 544 patients on placebo outside the USA (0.180%).
The suicide rate on paroxetine outside the USA is 2.7 times greater than on placebo. He
also recalculated the numbers for suicide attempts on paroxetine worldwide. There were
44 attempted suicide on 2,963 patients on paroxetine (1.48%). There was one attempted
suicide on 554 patients on placebo (0.18%). The attempted suicide rate on paroxetine was
8.2 times higher than on placebo. Yet, in the “Discussion and Conclusions” part of the
1991 report, SKB concluded: “The incidence of attempted suicides did not differ
substantively among the three treatment groups (paroxetine, placebo and active
controls).” GSK denied any wrongdoing and downplayed the dangers of paroxetine.
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In 1998, another event occurred when Don Schell, after 48 hours on paroxetine, shot
his wife, his daughter, his nine-month-old granddaughter and himself. His-son-in-law
filed a wrongful death suit against SKB. The case became known as Tobin vs
SmithKline.[62] In this case, David Healy was an expert witness, and he had examined the
healthy volunteer studies. Confidential documents from the manufacturer revealed the
results of the testing of 2,000 healthy volunteers on either paroxetine or placebo. Some
volunteers on paroxetine became highly agitated and developed other side effects, e.g.,
akathisia, anxiety, hallucinations, and nightmares. According to the documents of the
company itself, this was “definitely” caused by paroxetine.[19, 63] There were two healthy
volunteers who tried to commit suicide, one on day 11 and the other on day 18.[19, 45]
David Healy testified that the records indicated a 25% agitation rate. It is unusual to have
such side effects in healthy volunteers, in whom an underlying psychiatric disorder is
unlikely.[42] After a trial that lasted 2.5 weeks and less than three hours of jury
deliberations, SmithKline was found guilty. The family was awarded over six million
dollars. SmithKline appealed the decision, which they lost. This was the first time a
pharmaceutical company was convicted for causing a wrongful death through a
psychoactive prescription drug.
By 2003, regulators in the USA and the UK announced an increased risk of self-harm
and suicidal acts in children and adolescents on paroxetine.[64] This was followed in 2004
by a Public Health Advisory and a request to the pharmaceutical companies that produced
Paxil, Prozac, Zoloft, Luvox, Celexa, Lexapro, Wellbutrin, Effexor, Serzone and
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Remeron to revise their labels to include a warning for depression and suicidality in both
adults and children.[65]
From clinical trials and case histories, the mechanisms that cause violent behavior and
the way in which they represent in adults on psychoactive medication, do not differ from
that in children.[64] Breggin studied the data on which the FDA approved the use of the
SSRI fluvoxamine for children in 1998.[66] On the product information label, it was stated
that the adverse reaction profiles for children were similar to those for adults. This was
based on a study performed with 57 children in a trial that lasted 10 weeks. This
medication, however, is used for months, if not for years. If an adverse event is infrequent
but serious, and it occurs in 1 in 1000 people, or even 1 in 500, it would very likely be
missed in a trial with 57 participants. Though there was a growing concern about the
shortcomings of small trials (defined by the FDA as trials including 3,000 - 4,000
subjects), the FDA approved fluvoxamine for children based on the information provided
by Solvay Pharmaceuticals on those 57 participants.
When Breggin studied the data, he came to a different conclusion regarding the
adverse reaction profiles in children versus adults. The rate for mania was four-times
greater in the child group than among the adults (4% versus 1%). The rate for agitation
was six-times higher in the child group (12% versus 2%), and the rate for depression was
at least two and a half times higher (5% versus 2%). The rate for hyperkinesia in the
children was at least twelve times higher (12% versus < 1%).[66] When other, separate side
effects, e.g., nervousness (12%), anxiety (5%) and central nerve stimulation (2%) are
added, the total stimulant-like side effect in children is 43%. Mania is one of the most
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dangerous side effects that can lead to potentially lethal aggression. Four-times more
children than adults suffering mania, combined with the other discrepancies in
frequencies of dangerous adverse events, should have prompted the FDA to demand
rigorous and extensive testing in children before approving this drug (and other SSRIs).[66]
Children on SSRIs are at risk for suicide and homicide too. In 1991, Koizumi
reported on a thirteen-year-old boy on fluoxetine, who became uncharacteristically
explosive, with angry outbursts, and who heard a “weird and an ego-alien voice ordering
him to kill himself.”[67] The same year, King et al. treated 42 children and adolescents
with obsessive-compulsive disorder (OCD) with fluoxetine in a double-blind, placebocontrolled trial. He described intensifying or de novo self-injurious and violent ideation in
four patients. Especially of interest is the history of a 12-year-old boy. After an initial
improvement, on day 38, the boy reported having several “bad dreams” which became
increasingly vivid. He had extremely violent nightmares which felt “very real” and from
which he had trouble waking up. His nightmares were about killing his classmates until
he was shot, or that his parents were dying and he killed himself. He was agitated and
anxious, had suicidal ideation and did not feel safe at home. When the medication code
was broken, it turned out he was on fluoxetine 20 mg per day. The fluoxetine was
stopped, and he was hospitalized. Gradually, he improved, and he suffered no more
suicidal ideation. Unfortunately, his OCD symptoms recurred, and he was again
prescribed fluoxetine, after which he became suicidal again. Finally, the fluoxetine was
stopped for good.[68] This case was reported years before the Columbine High School
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shooting in 1999, so this could not have been a source of inspiration, as was recently
suggested.[69]
Kurt Danysh was 18 in 1996 when he was prescribed fluoxetine by a general
practitioner. He became restless and violent, and, 17 days later, in an out-of-character
action, he shot his father with whom he had an excellent relation. Eli Lilly stated in court
that fluoxetine does not cause aggressive behavior. However, they concealed data from
1988 that did link fluoxetine to violence.[19] Those documents were held secret for 10
years until an anonymous source leaked them to the British Medical Journal, which
subsequently published them in December 2004.[70]
Eric Harris was on fluvoxamine and Dylan Klebold on sertraline and paroxetine
when they committed the Columbine High School shooting and killed themselves in
1999.[19, 66]
In 2001, at the age of 12, Christopher Pittman was put on paroxetine for a mild
depression. When he was sent to live with his grandparents, the local general practitioner,
who had no access to paroxetine, switched him to sertraline 100 mg per day, which the
general practitioner subsequently doubled.[71] Two days later, he shot his grandparents, the
people he loved the most. He was tried as an adult and convicted to 30 years, which was
reduced to 25 years on appeal.[19]
Finally, in 2004, the FDA ordered the product information on all antidepressants
adjusted with this sentence:
“Anxiety, agitation, panic attacks, insomnia, irritability, hostility (aggressiveness),
impulsivity, akathisia, hypomania and mania have all been reported in adult and
29

pediatric patients, being treated for major depressive disorder as well as for other
indications, both psychiatric and non-psychiatric.”[72]
Paradoxical reactions are reactions that occur after psychoactive medication is
administered. They are unexpected reactions to a drug, generally opposite to the effect
that would normally be expected. People who are not depressed became depressed,
patients became more anxious instead of less, and people who were not suicidal
developed suicidal ideations and acts. Patients could behave in extremely violent ways,
without a history of violence. The pharmaceutical companies were aware of those side
effects but hid that information with help from the FDA. Children were at even a greater
risk for those side effects. Although noted by scientist from 1954 on, it took until 2004
for the FDA to demand a “Black Box Warning” on the product information for all
antidepressants.

Mechanisms of Medication-Induced Paradoxical Reactions, Including Violence
Several mechanisms have been proposed to explain the emergence of side effects
including suicide and homicide. In 1955, Bleuler noted that the emergence of an
extrapyramidal syndrome with symptoms like tremors, mask like face, stiff gait and loss
of movement were the side effects of both reserpine and chlorpromazine. Paradoxical
reactions included restlessness, which could be observed or was merely a subjective
feeling of inner restlessness and an increase in body movements. Bleuler attributed the
extrapyramidal syndrome to an involvement of the brain stem and considered that the
psychological side effects could be caused by the brainstem as well.[6]
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In studies regarding reserpine, subjects became dysphoric and agitated and were
diagnosed as being depressed. The idea at that time being that reserpine caused
depression by lowering brain catecholamines. Depression was associated with lowered
brain amine levels, and, because reserpine lowered amine levels, it could cause
depression.[73] The movement disorders were primarily diagnosed as “hysterical,” until
Haase introduced the term “akathisia” in 1955. This was a sign of the growing awareness
that neuroleptics could cause a drug-induced, often times unbearable, restlessness.[73, 74]
Several studies of the last century addressed potential causes of paradoxical reactions.
Chlorpromazine depresses the central nervous system, and, in 1956, Schiele postulated
that it would change synaptic transfer by increasing cortical inhibition of the brainstem,
which leads to sedation. It was a strong epinephrine blocker, and a mild blocker for
histamine, acetylcholine, noradrenaline and serotonin.[7] He blamed side effects on the
“capricious autonomic responses” that existed among people. In 1955, Sarwer et al.
explained the paradoxical reactions as the result of the fact that the sedation had
diminished the coping mechanisms through physical activity, for instance a man, who
had to reassure himself of his manhood through activity, became psychotic when the
sedation took that coping mechanisms away. For Sarwer, the psychodynamic component
was just as important as the physiological effect of the drugs.[34] In 1978, Rampling
suggested that the paradoxical response to tricyclic antidepressants might be related to a
site of action in the reticular formation, given the rapid onset and the type of aggression
exhibited by the patients.[38] The reticular formation is an area in the brainstem that
regulates consciousness.
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There were indications that benzodiazepines had an effect on neurotransmitters. They
decreased the K+/Na+ ratio in the synapse and increased membrane-associated nucleic
acids. They decreased catecholamine uptake, increased the concentration of acetylcholine
in the brain, and reduced the metabolism of serotonin in the cortex. Slight alterations in
this delicate equilibrium might very well lead to reactions other than those anticipated.[75]
Benzodiazepines activate the receptor site for the benzodiazepine-gamma-aminobutyricacid (GABAA) receptor complex in the central nerve system.[76] Activating this site
decreases action potentials leading to sedation. A study by Bramness et al. from 2006,
indicated that paradoxical reactions to flunitrazepam were independent from the drug
levels in the blood.[76]
According to Mancuso (2004), children, elderly people and alcoholics are especially
at risk for paradoxical reactions to benzodiazepines. Alcoholics might have a decreased
production and less functioning of GABA, which could result in less inhibition of the
neurotransmitter. Psychiatric patients or persons with prior aggressive behavior are also
at risk. The exact mechanism is still unclear.[77] It was hypothesized that genetic
polymorphisms in the GABA-chloride receptor site resulted in abnormal
pharmacodynamic responses.[77]
In 1992, Opler proposed a “three neuron model,” see Figure 1.1, to explain the
emergence of extrapyramidal motor side effects in the course of treatment with
neuroleptic drugs.[78] Movement is regulated through a pathway that is driven by
dopamine and connects two parts of the brain, the substantia nigra and the dorsal
striatum, hence the name nigrostriatal pathway. When the first neuron fires an impulse, it
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will inhibit the second neuron, which is driven by acetylcholine as the neurotransmitter.
However, the function of the first neuron may be decreased for instance by degeneration
of the nigrostriatal fibers (Parkinson’s disease) or by blockage of the dopamine receptors
by neuroleptics. If the first neuron fires less impulses, the second neuron will fire with a
rate above normal. The second neuron stimulates the third neuron, which produce gamma
aminobutyric acid, an inhibitory neurotransmitter. Its function is to “turn down”
voluntary movement.[78] It is understandable that, when the last neuron is
“overstimulated”, it will lead to greatly restricted motor activity. Neuroleptics can
produce super sensitivity at some striatal dopamine receptors. This could lead to less
firing than normal by the cholinergic neurons, with a subsequently decrease in GABA
and a decrease in regulation of movement, which could result in involuntary movement,
known as tardive dyskinesia.[78] These two mechanisms could explain the movement
disorders, but not the behaviorally aspects of neuroleptic-induced violence.

DA (-)

Ach (+)

GABA (-)

DA = Dopamine
Ach = Acetylcholine
GABA = Gamma-Aminobutyric Acid
- = Inhibitor
+ = Excitatory
Figure 1.1: Three Neuron Model (Taken from Opler, 1991)
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A year later, in 1992, Hamilton and Opler investigated the possibility that fluoxetine,
as an SSRI, could interfere with the nigrostriatal pathway as well and could induce de
novo or increase extrapyramidal symptoms (EPS) that could lead to akathisia.[47] In this
model, they considered akathisia as a form of EPS which can lead to changes in ideation
and behavior, e.g., suicide and homicide, and called it “behavioral toxicity,” a term
introduced by Van Putten in 1987.[40] They proposed an addition to the three-neuron
model, by placing a serotonergic neuron before the dopamine neuron, see Figure 1.2.
Impulses from this serotonin neuron would inhibit pulses from the dopamine neuron,
comparable to what damage to the nigrostriatal fibers or blockage of the dopamine
receptors by neuroleptics would do.[47]

5-HT (-)

DA (-)

Ach (+)

GABA (-)

5-HT = Serotonin
DA = Dopamine
Ach = Acetylcholine
GABA = Gamma-Aminobutyric Acid
- = Inhibitor
+ = Excitatory
Figure 1.2: Four Neuron Model (Taken from Hamilton, 1992)

This means that an increase in serotonin in the synapse could, in itself, induce EPS.
Hamilton and Opler considered the suicidal ideation as a sign of the unbearableness of
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akathisia. They described a patient on fluoxetine suffering from akathisia. She had to hold
on to the chair she was sitting in as she was afraid she would jump out a window. She
could distinguish the suicidal ideation, felt while in a state of akathisia, from the suicidal
ideation while in a state of a depression. Even though she was not depressed, she still had
this urge to commit suicide, which she blamed on the restlessness and the feelings she
was unable to control.[47]
Lane (1998) hypothesized along the same lines. According to him, the interaction
between the serotonin (5-hydroxytryptamine or 5-HT) system on the one hand and the
dopamine mediated neurotransmission on the other, is extremely complex, with each
system influencing the other. Different 5-HT receptor subtypes, located in different parts
of the brain, may mediate different reactions from the dopamine system.[79] It is likely this
complexity is one of the factors that explain the differences in patients responses.
Serotonergic overstimulation can lead to EPS due to toxicity, ranging from mild side
effects, e.g., a minor degree of restlessness or anxiety to full blown akathisia.[79] Every
SSRI and every antipsychotic, basically every kind of psychoactive drug, can cause
akathisia. SSRI-induced akathisia does not differ in presentation from neurolepticinduced akathisia. Lane (1998) emphasizes that the subjective symptoms of akathisia are
so typical and overpowering that akathisia should not be restricted to a motor disorder. [79]
What then causes the changes in behavior that can lead to suicide and homicide?
When a stimulus in the brain is conducted from a nerve cell to a muscle, the muscle
contracts. Movement, voluntary or involuntary, is the result. It is not clear however how
emotions and behavior are brought about. Certain areas in the brain are associated with
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certain emotions, but how excitation of neurons translate to mental processes and human
behavior, is basically unknown.[80] Circumscribed damage to specific areas of the brain
can produce a predictable pattern of behavior, but damage to different parts of the brain
can produce the same abnormal behavior.[81] From the mid-1700s, the prefrontal cortex
has been considered the end point for all information gathered from the senses. Emanuel
Swedenborg (1688-1772), called the frontal lobes “the highest court of the cerebrum.”[81]
The frontal lobes were involved in planning action, movement and abstract thought.
Fuster (1985) concluded that the prefrontal cortex integrates three functions pertaining to
basic executive cognitive processes: short-term memory, developing response strategies
and what Duffy (1994) refers to as “suppressing internal and external stimuli that might
disrupt the enactment of the prioritized behavioral strategy.”[81, 82]
In the last decades, doubt arose about whether the higher cortical functions could be
localized in a limited way, similar to the “sensory” and “motor” function. Goldman
(1988) proposed the idea of neural networks with “reciprocally interconnected areas” that
facilitate the higher cortical functions.[80] Neural networks, connecting areas throughout
the brain, would explain the fact that patients can exhibit executive cognitive problems
while suffering neuropathological abnormalities away from the prefrontal lobes.
According to Duffy (1994), patients who show the behavior characteristic for frontal lobe
damage without actual abnormalities in that area should be described as suffering from a
“dysexecutive syndrome.”[81]
Executive cognition is the ability to act in a socially acceptable fashion. Duffy (1994)
describes three clusters of behavior that indicate lesions in the neural network leading to
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dysfunctional behavior, 1) a dysexecutive, 2) a disinhibited and 3) an apathetic type. The
dysexecutive type is characterized by perseveration, impairment in reasoning, lack of
mental flexibility, judgement, planning, insight and self-care. Clinicians are inclined to
interpret these symptoms as signs of depression, passive-aggressiveness and personality
disorders instead of an organic disease. The disinhibition type can manifest with poor
impulse control, explosive aggressive outburst, inappropriate verbal lewdness and a no
concern for other people’s feelings. Those patients might be misdiagnosed as manic, antisocial, and psychopathic even without any history of mood or conduct disorders. The
apathetic type exhibits behavior ranging from apathy to akinetic mutism. They looked
depressed without feeling depressed. Their indifference can wrongfully be interpreted as
premeditated behavior, leading to tense relationships. Duffy (1994) emphasized that
lesions anywhere in the neural network related to executive cognition can cause the
described behavioral problems to a greater or lesser degree.[81]
Emotion can modulate executive cognitive processes. Research has identified brain
circuits that regulate “emotional attention.”[83] According to Vuilleumier (2005), the
amygdala is connected to the cortices to enhance processing emotions. This could mean
that emotions work in parallel with the frontoparietal areas, indicating that multiple areas
influence sensory information at the same time. This relates to how a person might react
to events and what actions to take.[83, 84] These different areas of the brain are connected
through axons, which release the neurotransmitters. The most important neurotransmitters
involved in emotion and behavior are serotonin, noradrenaline and dopamine, belonging
to the monoamine system.[84] Upon binding to their receptors, they adjust the sensitivity of
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the postsynaptic cell. For the majority of the receptors, when bound to their ligand, the
chances for an action potential starting in the postsynaptic cell is increased (excitation).
It is hypothesized that the monoamine system plays a major role in many psychiatric
disorders, hence many psychoactive drugs react with the monoamine neurotransmitters.[84,
85]

The amygdala and frontoparietal areas process the incoming information and contact

(which is called projecting) the cells that produce the neurotransmitters. The monoamine
transmitter system performs the final step in providing the information all over the
brain.[84]
Serotonin, dopamine and noradrenaline play different parts in the modulation of
behavior and emotion. They are the most important chemical substances that regulate the
brain inhibitory and excitation impulses pertaining to cognition, attention and perception.
Serotonin is involved in emotions as self-confidence, inner strength, satisfaction, joy,
interest, as well as in contempt and disgust. Dopamine plays an important role in
movement, and is connected to reward, motivation, reinforcement, but also fear and
terror. Noradrenaline appears to represent stress, anxiety, vigilance up to rage and
anger.[84, 86]
Lövheim introduced the “cube of emotions” in 2012, see Figure 1.3. Serotonin (5-HT)
is projected on the x-axis, noradrenaline (NE) on the y-axis and dopamine (DA) on the zaxis. At the left lower corner, point 0, there is no release of neurotransmitters. At the
other end of each axis, there is a maximum effect of each neurotransmitter. At the
corners, are the combination of the maximum effect for the different neurotransmitters.
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All combinations are possible between zero and maximum effect.[84] Lövheim emphasized
that
“the total ‘‘out-effect’’ in a monoamine axis is a function of the amount of signal
substance that is released into the synaptic cleft, the rate of reuptake and degradation of
the transmitter substance as well as the type, number, sensitivity and specificity of postsynaptic receptors.”[84]
In this model, there are 8 basic emotions, identified by the psychologist Tomkins,
which can appear in low and high intensity, two positive, e.g., interest/excitement,
enjoyment/joy, one neutral, surprise/startle and five negative, distress/anguish, fear/terror,
shame/humiliation, contempt/disgust and anger/rage.[84] Each of the 8 basic emotion can
be interpret in this model. Any combination of emotion can be fitted in this model and
can explain complex state of minds as well as pathological ones.
Fear/terror and anger/rage most likely are high-dopaminergic, and they will reinforce
one another. Supposedly, fear/terror and anger/rage are low-serotonergic, due to the fact
that when a person feels threatened, they probably also feel weak. Aggression has been
linked to low levels of serotonin and is also regularly seen in patients with depression,
indicating that anger is low-serotonergic. Fear/terror is considered low-serotonergic, low
noradrenergic and high-dopaminergic as opposed to anger/rage, which is placed in the
low-serotonergic, high-noradrenergic and high-dopaminergic corner of the model.[84]
Drug-induced movement disorders are caused by overstimulation through the
nigrostriatal pathway.[78, 79] Any medication that interferes with this pathway can induce or
increase extrapyramidal symptoms. This can be acute or happen later, which is called
tardive. Neurotransmitters involved in the development of EPS are serotonin, dopamine
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and noradrenaline.[84] The same neurotransmitters that regulate human emotions and
behavior.

Anger
Rage

Interest
Excitement

Distress
Anguish

Surprise

NE
Fear
Terror

Enjoyment
Joy
DA

Shame
Humiliation

Contempt
Disgust
5-HT

Figure 1.3: Cube of Emotions (Taken from Lövheim, 2011)

If certain medication induces EPS, it is likely they will affect other neurotransmitters
as well, causing disturbances in the regulation of emotions and behavior. Those
medications can create emotions at any point in the cube of emotions to a level at which
they can be considered side effects. The combination of a state of a high-serotonergic,
high dopaminergic and high noradrenergic emotion could very well exhibit as full-blown
akathisia. Given the neural network and the complex connection, any dysregulation from
the normal equilibrium due to interference with the neurotransmitters could lead to
malfunction in the connection between the frontal lobes and the amygdala, leading to a
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“chemical lobotomy” and “dysexecutive syndromes.” Several authors regard a chemical
lobotomy as one of the root causes for hostile events, due to the emotional blunting.[19, 42,
58, 87-89]

In 2003, Breggin formulated the main characteristics for SSRI-induced obsessive
suicidality and violence: [64]

1. A relatively sudden onset and rapid escalation of the compulsive aggression
against self and/others.
2. A recent (typically within two months) initial exposure to the medication, or a
recent change in the dose of the medication, or a recent addition or removal of
another psychoactive substance to the regimen.
3. The presence of other adverse drug reactions, often involving akathisia or
stimulation along a continuum from irritability and agitation to agitated
depression and mania.
4. Resolution of the syndrome after termination of the causative medication,
often with a marked overall improvement in the individual’s mental status.
5. An extremely violent and/or bizarre quality to the thoughts and actions.
6. An obsessive, compelling, unrelenting quality to the thoughts and actions.
7. An out-of-character quality for the individual as determined by the
individual’s history.
8. An alien or ego-dystonic quality as determined by the individual’s subjective
report.
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Although Breggin focused these characteristics on SSRI induces violence, they are
equally applicable to any drug-induced state of akathisia.[90] Breggin concluded that four
syndromes, that can occur simultaneously, can cause violent behavior: [64]

1. A “stimulant continuum,” ranging from sleep disturbances to irritability,
depression, suicidality agitation, uncontrollable aggressive behavior and
mania. Mania includes disinhibition and grandiosity.
2. Agitated depression.
3. Obsessive preoccupations with aggression against self and others.
4. Akathisia, usually but not always, identifiable by a necessity to move.

Psychoactive medication can cause movement disorders by interfering with the
neurotransmitters involved in the motor functions. In those cases, the patients show
symptoms similar to Parkinson’s disease. The same neurotransmitters regulate the higher
cortical functions. Most likely, the brain is a neural network with reciprocally
interconnected areas. How this translates into human behavior is still unknown. People
with lesions within this network, can show behavior that can easily be misdiagnosed as a
mental illness, e.g., personality disorders such as anti-social and psychopathic instead of
an organic syndrome. Interference, due to psychoactive medication in the delicate
equilibrium between the different neurotransmitters, can cause the same behavioral
disturbances as a factual injury to the brain.
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Akathisia
It is well known, that certain neurological diseases can be accompanied by movement
disorders. Akathisia, as a movement disorder was first described in the scientific
literature by Armand Trousseau in 1861.[91] He made several observations about a patient
suffering from Parkinson’s disease that James Parkinson himself had overlooked.[92] The
patient was a chamberlain in the entourage of Napoleon III. In violation of the etiquette,
the man could not sit still and had to keep running around.[74] Trousseau noted: “As his
center of gravity is thus displaced, he is obliged to run after himself, as it were, so that he
keeps trotting and hopping on.” According to Bing in 1947, in the “Lehrbuch der
Nervenkranken,” published in Basel, Switzerland, Trousseau designated this disorder
“Acathisia,” derived from the Greek “kathízein,” which means “to sit,” the “a” indicating
the impossibility to do so.[74]
Haase in 1955, reserved the term for symptoms caused by the use of reserpine. He
tested this on himself and experienced first-hand the necessity to move his legs and the
unpleasant feeling that came with it.[74] In 1975, Van Putten substantiated that akathisia is
more than a movement disorder and noted the emotional state of the patients suffering
from akathisia as a side effect of neuroleptic medication. He mentioned how difficult
akathisia is to bear for the patient, and he cited Kalinowsky, who pointed out akathisia
can be “more difficult to endure than any of the symptoms for which [the patient] was
originally treated.”[93]
Signs of akathisia can be difficult to recognize. They can be subtle, e.g., insomnia,
pacing, vague complaints about medication, uneasiness and hyperactivity. They can be
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mistakenly interpreted as exacerbations of a mental illness. Patients suffering from
psychosis may not be able to verbally express their inner restlessness and agitation. These
feelings may be described by the patients in terms which make it hard to relate them to
inner restlessness and agitation: “I feel like I am wired to the ceiling, I am quivering from
the waist up, it is like I got diaper rash inside.” Milder akathisia can be experienced by
the patients as vague feelings of anxiety.[93]
In 1968, Ryan et al. reported on the treacherous development of suicidal ideation in
patients on benzodiazepines. They called it “the smiling depression,” in which patients
deny being depressed but secretly harbor suicidal thoughts and could act on them.[21] For
patients on tricyclic antidepressants, it can be difficult for a bystander to differentiate
between subjective feelings of aggression as indicated by a patient, and actual aggressive
behavior.[38]
Van Putten (1987) also noted the communication gap between patients treated with
neuroleptic medication and their surroundings.[40]
“The patient talks less of psychotic material, but he talks less of everything; he is less
bothered by his hallucinations, but he is less bothered by everything else as well; he is
less invested in his delusions, but he is less invested in all else as well. Many patients
with akinesia experience a peculiar absence of emotions, appear emotionally dead,
and often state that everything is all right. It is a type of improvement that, at least in
some, approaches psychotic denial…it is one that we should not be proud of.”
In his study on healthy volunteers on one dose of an antipsychotic drug, Healy noted
the discrepancy between the relaxed appearance of some of these subjects and the
seething that went inside. He also mentioned the unwillingness of those test subjects to
report such feelings. He called this “the multi-faceted lack of insight that appears to go
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with akathisia and dysphoria.”[94] In Healy’s 2000 experiment comparing reboxetine with
sertraline in healthy volunteers, one subject reported that reboxetine calmed her while she
was still able to feel fear, but that sertraline made her both aggressive and fearless.[95]
All the ingredients for acts of violence are present in these descriptions. There is
emotional bluntness, deep depression, detachment from oneself and others, aggression,
and mania. These can all occur after one dose of neuroleptic medication. All psychoactive
medication can bring about these feelings. If one dose can bring someone to the brink of
suicide or homicide or, even worse, cause them to act on it, repeated doses can be even
more dangerous. It is known that hostile paranoid patients can deteriorate rapidly if they
suffer akathisia. They can interpret their feelings as being proof of being poisoned or
being threatened by forces out to get them.[93] If somebody is suffering depression, some
patients can become overwhelmed if they develop a paradoxical reaction on top of that.
The combination of aggression, fearlessness, not caring about oneself or others,
paranoia, harboring those feelings and the incapability of bystanders to recognize what is
going on, is a prescription for disaster. Such disasters were reported by Schulte in 1985
on 5 patients with akathisia and extremely violent acts of suicide and homicide. The
history of one of these patients is exemplary for the different aspects of medicationinduced violence. For that reason, the history is quoted in here:
“A 23-year old male, with a four-day history of progressive paranoia and
disorganized behavior, had been taken by the police department to a hospital at the
request of his parents. The physician insisted he receive an injection of haloperidol in
the emergency room while awaiting admission to the psychiatric unit where he had
previously been a patient on a number of occasions. He tried to resist but felt he had
no option with the staff and police surrounding him. He felt he was being
unnecessarily delayed in being admitted to the inpatient unit. In addition, he felt he
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had been lied to, in that apparently, he had been told he was going to see his wife who
had deserted him approximately 48 hours earlier. He then escaped from the
emergency room and the authorities, ran several miles to a park, tried to get a
policeman to help him, escaped again and totally disrobed. Within the next 45-minute
period of time, he assaulted one woman who was walking her dog and attempted to
rape her. When pulled off by the husband, he proceeded down the street, broke down
the front door of a house where an 81-year-old lady was sleeping. He severely beat
her with his fists, “to a pulp,” by his own description, following which he found
knives and stabbed her repeatedly, resulting in her death. Then, after being confronted
in the street by a policeman who sprayed him with mace, he returned through the
house, exiting the back door where he ran into another woman with her child. He
repeatedly stabbed the woman in front of the child, whereupon he moved on to the
next person he encountered, a woman whom he severely assaulted and stabbed to the
extent that an eye was lost and an opening into the anus was created resulting in
major surgery and serious residual problems, including a colostomy. He was then
finally captured and subdued by eight policemen and hospitalized.
He had ten previous psychiatric hospitalizations between 1975 and the present. All of
these hospitalizations have been only a matter of hours to several days. He would
always be placed on medication and released, following which he would stop taking
the medications and go along until another upheaval would occur.
He had a history of problems with anger and acute paranoid beliefs leading to
hyperactive behavior and one incident in which it was reported he tried to choke one
of his brothers. His description of his mental status at the time of his offense is quite
striking. He describes himself as feeling almost like a spectator in a movie. He makes
a point of describing how he had lost all sense of caring about anything or anyone in
life. Additionally, he describes a feeling of loss of physical sensation, including
feeling nothing when maced by the police. He felt enormous energy with a feeling of
needing to rid himself of it.
He gives the history of having been picked up by the police on a traffic violation in
1979 and placed in jail for the first time in his life. He became angry and was given a
series of haloperidol injections, becoming progressively more agitated and
unmanageable to the point he was rolled up in a mattress and handcuffed in order to
be transported to a psychiatric inpatient unit. In 1980, during another hospitalization,
he was, despite his protests, changed from chlorpromazine to haloperidol and within
hours became totally unmanageable, requiring six individuals to subdue him and
place him in seclusion and restraint.”[52]
Characteristic for full blown akathisia, is the extremely brutal injuries inflicted on
complete strangers, for which there is no motive. The emotional and physical numbness
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is a repetitive finding. The disinhibition is remarkable and recognizable. This patient had
sex while on a killing spree. The same disinhibition can be seen with respect to the use of
alcohol, drugs and gambling in some of the people with akathisia. The need to get rid of
the energy that has these people in its grip is typical. It is torture if they cannot get it out
of their system, and they are willing to commit suicide if necessary.
Keckich (1978), Schulte (1985), and Shaw et al. (1968) were among the first to
connect akathisia to violence and homicide. Others described the association between
akathisia and suicide. [47-49, 51-53, 96, 97] The suicides and homicides committed while in a
state of akathisia are frequently extremely violent and bloody.[27, 98] In Holland, a case was
investigated where a man suffered a violent paroxetine-induced psychosis. He killed his
fiancée with a fire extinguisher and shot a police officer with his own gun. The man was
maced and was shot several times, and it still took several police officers to restrain him.
Other examples are a mother who smothered her 2-year-old son with a pillow and then
strangled him with the belt of a bathrobe, a man who commits suicide by stuffing a Tshirt down his throat, a mother who repeatedly stabs her two children, a young man trying
to commit suicide by stabbing himself multiple times in the chest. Psychotropic
medication was involved in mass shootings and mass killings, e.g., the Columbine High
School shooting, the Sierre bus crash in Switzerland (where the driver was on paroxetine
when he crashed the bus deliberately into a wall and killed 22 children and 6 adults), the
Germanwings co-pilot who crashed his plane (killing 150 people), and the Aurora
Theater shooting.[19, 27, 90]

47

In 1995, Sachdev proposed diagnostic criteria for drug-induced akathisia:[99]
Prerequisites (necessary for all diagnoses) include:
1. A history of exposure to drugs known to cause akathisia (antipsychotics can
cause all subtypes; non-antipsychotics can cause acute akathisia and chronic
akathisia, acute onset).
2. Presence of characteristic subjective and/or objective features of akathisia.
3. Absence of other known causes of akathisia, e.g., restless legs syndrome,
Parkinson’s disease, subthalamic lesion, etc., and absence of peripheral
neuropathy, myelopathy or myopathy.
Diagnoses:
1. Acute akathisia (antipsychotic or non-antipsychotic drug-induced; if it has a
duration of ≥ 3 months, categorize as chronic akathisia, acute onset).
2. Tardive akathisia (if it has a duration of ≥ 3 months, categorize as chronic
akathisia, tardive onset).
3. Withdrawal akathisia (if it has a duration of ≥ 3 months, categorize as chronic
akathisia, withdrawal onset).
4. Chronic akathisia (acute, tardive or withdrawal onset; state if patient is not
currently receiving antipsychotics).
He listed the following symptoms for drug-induced akathisia:
1. Inner restlessness.
2. Inability to remain still (fidgetiness).
3. Inability to keep legs still.
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4. Inability to maintain one posture (e.g. sitting, standing, lying).
5. Feeling of tension in body or mind.
6. Apprehension, irritability, general unease, dysphoria.
7. Anxiety, tremor, rage, fear.
8. Uncomfortable limb sensations.
9. Vague somatic sensations.
10. Worsening of psychotic symptoms.
11. Aggressive thoughts and actions.
12. Suicidal thoughts and acts.
13. Sexual craving.
14. Poor concentration and memory.
15. Unwillingness to take medication.
16. Sleep difficulty.

Sachdev considered these symptoms as well as a wide range of bodily movements
and even vocal sounds.[99] Healy pointed out that the meaning of akathisia in English is
better described by “turmoil” or “agitation” than by “restlessness.”[45]
In 1958, Kuhn had already seen the dangers in the states of agitation suffered by some
patients on imipramine. He recognized them as toxic effects, which could lead to an
“explosive outlet.” He acknowledged that manic states can cause criminal action because
the normal inhibition and scruples are overtaken by the mania. He had the moral courage
to think this through. He raised the question of whether the antidepressant could affect the
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conscious, the awareness of guilt, the mechanisms that prevent people from committing
“criminal or immoral actions,” basically the moral compass of human beings. He warned
that the moral and social consequences could not be ignored, yet it looks like that is
exactly what happened through the years. He predicted that if medication like imipramine
can cause a state of mania, it is unavoidable that in certain persons “their moral structure
may be imperiled.”[9]
Many patients on neuroleptic medication develop akathisia. Van Putten (1975), one of
the first to describe akathisia as such, reported that of the 110 patients in his study, 45%
developed akathisia sooner or later.[93] Internal documents from Eli Lilly entitled
“Activation and Sedation in Fluoxetine Clinical Trials” revealed that 38% of fluoxetinetreated patients experienced “activation events.” This is probably an underestimation,
since activation events, such as panic attacks, hypomania and mania, were not
included.[64, 70] Healy testified in court to an agitation rate of 25% in healthy volunteers on
paroxetine.[19] Moore et al. (2010) reported that of all serious side effects 0.25% consists
of acts of aggression/violence. According to Moore this number is not a reliable estimate
of the real occurrence of these acts.[43] Underestimation is likely given that with
spontaneous reporting, less than 10% of all serious and 2-4% of non-serious adverse
events are reported.[100]
Akathisia was first described as a movement disorder, noticeable in people suffering
from Parkinson’s disease. When these movements became apparent in patients on
neuroleptic medication, an accompanying emotional component was suspected as well.
The restlessness and agitation can be so profound, that it is impossible to bear, and people
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end up committing suicide. What complicates this syndrome is the fact that the emotional
component is a subjective experience, which can be hard to recognize from the outside.
Akathisia can develop in healthy volunteers who are unlikely to suffer an underlying
mental illness. When a person suffers psychotic tendencies, the agitation can develop into
an explosive outburst of extreme violence. Akathisia occurs in different forms: acute or
late when psychoactive medication is involved, during withdrawal from medication, or
chronic, when no medication is present anymore in a person’s system.

Causality
Approximately 10 years before sertraline became available in the USA, Dr. Ian
Hindmarch ran a study on this drug on behalf of Pfizer. Twelve healthy female volunteers
were randomized, half to sertraline, half to placebo. Within the first week, the study was
terminated. Each person on sertraline and one, supposedly on placebo, suffered
apprehension, insomnia, movement disorders and tremors. One woman noted aggressive
impulses. The subject on placebo, who experienced these side effects, turned out to have
sertraline in her blood, supporting a causal relation. The diaries that the volunteers kept
revealed agitation and suicidality. According to Healy (2012), the report to Pfizer stated,
“that these side effects had been described previously by subjects on SSRIs (such as
Zelmid, Luvox, and Celexa), that they were well known to be linked to SSRIs, and that as
such these effects in this study were likely to be due to serotonin reuptake inhibition.”
This study was never published. Healy was told about this study by Hindmarch himself in
1998. [101]
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In 1985, an in-house analysis by Eli Lilly revealed that, in their placebo-controlled
trials, 12 subjects on fluoxetine, one on placebo and one on a tricyclic antidepressant tried
to commit suicide. However, consultants from Lilly hired after the results were reported
back to the company, dismissed six of the suicide attempts on fluoxetine.[90] This was
standard practice within Eli Lilly regarding unfavorable results, and the results were not
reported to any regulatory agency.[19] In 1990, Bouchy, an Eli Lilly employee in
Germany, contacted an Eli Lilly official in the USA and wrote:[19]
“I personally wonder whether we are really helping the credibility of an excellent
ADE [Adverse Drug Event] system by calling overdose what a physician reports as
suicide attempt and by calling depression what a physician is reporting as suicidal
ideation…….Of course by the end of the day we will do what we are told but Hans
and I felt we had to bring these to attention.”
In another memo, Bouchy wrote about hiding suicide data: “I do not think that I could
explain to the BGA [Germany regulatory agency], to a judge, to a reporter or even to my
family why we would do this especially on the sensitive issue of suicide and suicidal
ideation.”[19]
In 1995, Jick et al. calculated the relative risk on suicide among over 172,000 people
with at least one prescription for antidepressants, including fluoxetine (SSRI),
lofepramine (tricyclic antidepressant) mianserin (tetracyclic antidepressant) and dothiepin
(tricyclic antidepressant). Dothiepin was once the most prescribed antidepressant in Great
Britain and was assigned a relative risk (RR) of 1.0. Fluoxetine had a RR of 2.1,
lofepramine 0.5, and mianserin came with a RR of 1.8.[102] A relative risk greater than 1.0
means that the event is more likely to happen in the experimental group than in the
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control group. The number of death per 100,000 patient years was 47 for lofepramine, for
dothiepin 86, 165 for mianserin and 189 for fluoxetine.[58] In 1999, Healy calculated the
annual rates for suicide in the UK for all mood disorders: 50 suicides per 100,000 patient
years. When only the mild affective disorders are considered, according to Healy, the
number is probably limited to 25-40 per 100,000 years.[58] This number is in stark contrast
with the 189 for fluoxetine in the Jick study.
One of the problems with clinical trials performed by pharmaceutical companies, is
that they are not designed to detect side effects like violence, suicide and homicide. They
are aimed at demonstrating a therapeutic effect.[58] Another problem is the coding of side
effects. Beasley et al. (2000) reported on 1610 fluoxetine and 952 placebo patients. They
found statistically significant differences for insomnia (16.3 versus 9.0%), tremor (9.8%
versus 3.5%), anxiety (12.1% versus 6.9%) and nervousness (13.7% versus 8.8%)
between fluoxetine and placebo.[103] However, the terminology for monitoring side effects
is based on what patients report. Patients do not mention “akathisia.” The only way they
can report their feelings of inner restlessness and symptoms like sleep problems and
possible movement disorders e.g., trembling, is by referring to it as anxiety and
nervousness.
Donovan (1999) performed a population-based epidemiological study in England and
Ireland on 222 suicides committed between 1990 and 1994 by patients who had received
antidepressant medication the month before. He found that the suicide rate was the lowest
in patients on TCA and the highest in those prescribed SSRIs.[104] In 2000, Donovan
compared the frequencies of deliberate self-harm in 2776 patients taking different classes
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of antidepressants. He found significantly more events of deliberate self-harm in patients
on SSRIs compared to those on TCAs. The RR for TCAs was 1.9 and for SSRIs 5.5.[105]
In 2005, Fergusson et al. completed a systematic review on the association between
suicide attempts and SSRIs.[106] They reviewed all randomized controlled trials available
through Medline between 1967 and 2003, and added eligible trials from the Cochrane
Collaboration (a non-profit NGO that organizes medical research findings) with respect
to suicide attempts and SSRIs.[106] They ended up with 345 trials with a total of 36,445
patients. There was an increase in the odds ratio (OR) for suicide attempts for patients on
SSRI compared to placebo (OR 2.28, 95% CI: 1.14-4.55). Interestingly, they found no
difference in OR for suicide attempts when comparing SSRI to tricyclic antidepressants
(OR 0.88, 95% CI: 0.54-1.41). Also of importance is the conclusions that there was an
increase in the OR for suicides attempts between SSRIs and treatments other than TCA.
(OR 1.94, 95% CI: 1.06-3.57). These “other treatments” were not identified any further
than “active.”
Fergusson et al. (2005) emphasized that due to the increasing use of SSRIs,
medication-induced suicide is a growing population heath issue. In the USA in 2001, 24.5
million patients visited health care practitioners for depression, with 69% of patients
receiving a prescription for SSRIs. This resulted in an incremental risk of harmful events,
see Figure 1.4. [106]
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Year

Odds ratio (95% CI)

Odds ratio (95% CI)

1983

0.14 (0.00 to 6.80)

1984

0.14 (0.00 to 6.80)

1985

1.04 (0.07 to 16.58)

1986

1.04 (0.07 to 16.58)

1987

1.28 (0.11 to 15.55)

1988

2.93 (0.45 to 18.90)

1989

1.77 (0.32 to 9.56)

1990

1.77 (0.32 to 9.56)

1991

1.77 (0.32 to 9.56)

1992

2.06 (0.43 to 9.77)

1993

2.59 (0.66 to 10.21)

1994

2.59 (0.66 to 10.21)

1995

2.19 (0.73 to 6.56)

1996

1.90 (0.68 to 5.28)

1997

1.95 (0.71 to 5.30)

1998

1.95 (0.71 to 5.30)

1999

2.07 (0.87 to 4.96)

2000

2.07 (0.87 to 4.96)

2001

2.25 (1.08 to 4.73)

2002

2.05 (0.99 to 4.24)

2003

2.28 (1.14 to 4.55)

0.001

0.01

Placebo harmful

0.1

0.5 1 2

5 10

100

SSRI harmful

Figure 1.4: Cumulative Meta-Analysis of Fatal and Nonfatal Suicide Attempts in Placebo
Controlled Trials (Taken from Fergusson, 2005)

Björkenstam (2013) performed an observational study, which, evidence wise, is the
next best thing compared to a randomized trial. She investigated 5,913 patients aged 13
years and older who committed suicide in Sweden between 2007 and 2010, within one
month after starting SSRIs. This was a populated based, nationwide inclusion of all
suicides and all prescriptions, with a cross-over design where each patient was its own
control. She found a three-to-four-times increased risk of suicide, with an OR of 3.7 (95%
CI: 2.8-4.9).[107] The highest risk was in the second week with an overall OR of 9.7 (95%
CI: 2.9-31.7), see Figure 1.5.[107]
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Read et al. (2014) studied adverse drug reactions in 1,829 New Zealanders on
antidepressants.[108] They posted an anonymous questionnaire on line aiming at 20 adverse
effects, to gather information on biological, emotional and interpersonal adverse events.
Among the respondents, they reported 60% feeling emotionally numb, 46,9% suffered
agitation, and 42% cared less about others. These feelings were associated with a 39%
suicidality, which was considered caused by the side effects, 28% felt aggressive. The
39% patients reporting suicidality, is matched by the genome-wide association study of
increasing suicidal ideation during antidepressant treatment in the GENDEP study by
Perroud. This study found an 35% increase in “treatment-increasing suicidal ideation” in
204 of 706 participants.[109]
In 2016, the Cochrane Centre released a study by Sharma et al. who performed a
systematic review and meta-analysis on 70 trials including 18,526 patients. Despite
methodologically shortcomings in the majority of the trials that would lead to serious
underreporting of harmful side effects, they were able to detect that SSRIs compared to
placebo almost tripled the chances of aggression in children and adolescents, with an OR
of 2.79 (95% CI: 1.62-4.81).[110]
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Figure 1.5: Odds Ratios for Suicide, Days After Starting SSRIs
(Taken from Björkenstam, 2013)
Hemminki et al. (2016) followed the 1987 birth cohort of 59,120 Finnish youths and
analyzed antidepressants use and violent crimes in a longitudinal study in this group.
They found that young people convicted for violent crimes, when compared to youths
that had committed no or nonviolent crime, had an increased likelihood for
antidepressants use. Boys who had committed 2 violent crimes, had a OR of 8.49 (95%
CI: 3.69-19.53) of antidepressants use in the 6 months prior.[111]
Apart from the so called “gold standard” of placebo-controlled trials to substantiate
causality, trials with healthy volunteers, or with patients not suffering from mental illness,
can yield a strong indication for a causal relationship between psychoactive medication
and violence. Healy and Farquhar (1998) performed a revealing experiment with healthy
volunteers from the nursing and medical staff and members of the North West Wales
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district general hospital psychiatric unit. They were randomized to -one time- one tablet
of droperidol 5 mg, one tablet of lorazepam 1 mg, or placebo. The subjects were blinded
for which medication they received. None of the subjects on lorazepam or placebo had an
adverse reaction. All twenty subjects who received droperidol developed restlessness.
They had to complete a simple computer test, which provided great difficulty for all
subjects. Some of them became outright belligerent or felt “like putting a boot through
the computer screen.” These were out of character reactions, which did not occur in the
lorazepam or placebo group. Fifteen out of the twenty had mixed feelings towards the
experimenter in the room, consisting of both reassurance of his presence and irritation
about the person being there. All test persons felt subjectively restless and wanted to get
up and walk out of the testing room. This restlessness was not confined to the testing
setup and persisted with all subjects until at least the same evening. It also interfered with
their normal social contacts. They felt impatient, irritable and hostile. Ten subjects tried
to cope with the restlessness by lying in bed, probably trying to reduce stimulation. Six of
them were too restless to stay in bed. Some were apprehensive and felt that, if they
moved while snoozing or sleeping, something would happen. Seven subject used alcohol
despite being advised against it. They reported some positive effect for alcohol usage.
Thirteen subjects were still noticing the side effects through the following day and for
eight, although the feelings subsided gradually, the problems lasted days longer, without
any measures taken being helpful. Seventeen of participants reported feeling sedated,
eleven suffered dysphoria. One subject broke down in tears within an hour of taking the
medication. The subjects experienced anxiety out of fear that the state they were in would
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last forever and how much effort even the smallest action took. Some subjects started to
relive the unhappiest moments in their life, and four subjects developed suicidal ideation.
Some subjects feared they had suffered irreversible brain damage. All subject
experienced some sort of feeling of disengagement or uninvolvement. This varied from
“freezing” when they were supposed to interact with the computer, to being uninterested
while, at the same time, there was a heightening of visual and auditory perceptions. Three
remained unwell for a week. There were some minor changes in physiognomy, which
were likely early Parkinsonian signs. These signs were noticed in the way their hair fell
and the look of the skin. Some were described as having a “shrunken” appearance,
coming down with an influenza infection, or suffering chronic schizophrenia.
There was a discrepancy between eighteen subjects who reported no discomfort
during the test period, but, in consequent reports, admitted having suffered extreme
distress. They were aware of their discomfort, but they were reluctant to report it. They
hoped that, by not acknowledging the feeling, it would disappear. There was a general
disbelief in the subjects that a small amount of a psychoactive medication that is
prescribed so often, could have such a discomforting effect. Some observers noticed that
several subjects looked extraordinary calm and relaxed, while those subjects reported
being boiling inside. According to Healy et al. (1998), the discrepancy between looking
relaxed but simmering inside bears the risk of misinterpretation by observers or relatives.
Half of those who reported dysphoria blamed the drug and did not recognize any deeper
feeling of depressiveness. The other half were convinced that the medication triggered
some underlying depressive emotions. The subjects reported that they were more irritable
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in situations compared to the levels without the drug, e.g., driving a car. The volunteers
from the mental health services found the experience elucidating and useful for their
future clinical practice.[94]
This experiment is valuable, because it provides an insight in the effects of even a
small dose of a psychoactive prescription drug. These were healthy people, without
psychiatric illness that could obscure even the smallest of adverse events. They were able
to notice and verbalize the changes in a way a psychiatric patient would rarely be able to
do. If a psychiatric patient would have communicated these effects, it most likely would
have been attributed to the underlying disorder. In addition, there was the discrepancy
between how some of these persons looked and how they felt, and there was a lack of
willingness to communicate their distress. Psychiatric patients tend to get higher dose and
often a mix of medication, which subsequently increases in the chances of side effects.
With the inclination to hide their true feelings or the possibility of providing a misleading
impression of their inner feelings, they could pose a danger to others or themselves.[94]
King et al. (1995) performed a similar experiment three years earlier on fifty-one
healthy volunteers. [112] They received haloperidol, one tablet of 5 mg, on two consecutive
days. Almost half of the volunteers dropped out due to the side-effects, e.g., dysphoria or
agitation (Table 1.3). King et al. defined akathisia as mere motor restlessness, which was,
according to King, not very evident on the first day. However, on the second day
akathisia was noticed increasingly, due to a learning effect by the observers. When they
saw similar behavior appear in the test persons at more or less the same time as on the
first day, they recognized that behavior as a sign of developing akathisia (“I’ll have to get
60

out of here... I need to go home... I’ll be right outside...”). King et al. reported this study
because they wanted to distinguish between side effects and symptoms due to
psychopathology. By learning to recognize these effects in healthy volunteers, it would
be easier to recognize them in psychiatric patients, who might be less able to verbalize
those side effects.

Table 1.3: Diverse Drug Effects After 5 mg Haloperidol in Healthy Volunteers (Taken
from King, 1995)
Study I

Study II

Number of Volunteers

26

25

Sedation

17 (65)

19 (76)

Dysphoria

10 (38)

10 (40)

Akathisia Probable

2 (8)

4 (16)

Akathisia Definite

0 (0)

4 (16)

Dystonia

1 (4)

0 (0)

Total Dropouts
13 (50)
Percentages Shown in Parentheses

10 (40)

In 2000, Healy performed a randomized double-blind crossover study with
reboxetine, a selective noradrenaline reuptake inhibitor, and sertraline, a selective
serotonin reuptake inhibitor. The subjects were 20 healthy volunteers, members of the
North West Wales district general hospital psychiatric unit, either as nurses, medical, or
administrative staff. Two subjects on reboxetine became depressed, without developing
suicidal ideation. Two subjects on sertraline became extremely suicidal without being
depressed. Both subjects showed signs of akathisia and emotional blunting.[95]
Interestingly, one of the volunteers who became suicidal, reported that reboxetine made
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her calm but still capable of feeling fear, but that sertraline made her feel aggressive and
fearless.
In 2016, the Cochrane Centre released a study by Bielefeldt et al. They addressed
activation events or precursors to suicide and violence on antidepressants in a systematic
review of healthy volunteers. They screened 5,787 publications of which only 130 were
eligible. The vast majority were rejected due to methodological short comings. Bielefeldt
et al. concluded that antidepressant medication in healthy volunteers increased the risk of
events that can lead to violence e.g., restlessness, tremor, anxiety, agitation, and abnormal
thinking (OR 1.85, 95% CI: 1.11-3.08).[113]
Maund et al. reported in 2017 on the benefits and harms of duloxetine (Cymbalta, a
serotonin-norepinephrine reuptake inhibitor) sometimes prescribed for the treatment of
stress urinary incontinence. This was a meta-analysis of four randomized placebocontrolled trials, including 1,913 patients. Adverse events or activation events (e.g.,
anxiety, emotional disturbances, feeling abnormal, confusion) which increased the risk of
violence and suicide were reported in 187 patients in the duloxetine group and 42 in the
placebo group. The relative risk was 4-5 times higher in the duloxetine group than in the
placebo group (RR 4.45, 95% CI: 3.22-6.14)[114] These were patients who did not receive
this SSRI for a psychiatric illness. Twenty-seven patients from the duloxetine and one
patient from the placebo group dropped out due to activation events.
Case histories can also point to a relation between the medication and suicidal and
homicidal ideation. Shaw et al. (1986) performed a double-blind clinical trial with a new
antipsychotic drug, rimcazole, and compared it with haloperidol. One subject, a 43-year62

old male paranoid schizophrenic, was put on the experimental drug for two weeks, then
switched to haloperidol and consequently back to rimcazole. After starting haloperidol,
he rapidly declined with akathisia, suicidal and homicidal ideation, increased paranoia,
anxiety, tension and agitation. The symptoms disappeared when haloperidol was replaced
by rimcazole. The patient and his wife blamed the deterioration on the medication,
although they had no knowledge of the crossover. The author hypothesized that the
emergence of suicidal and homicidal ideation as well as akathisia, was caused by the
same pharmacological effect.[53] Another example is the case of the 12-year-old boy
described by King in his double-blind, placebo-controlled trial in 1991 with children and
adolescents. While on fluoxetine, the boy suffered extremely violent nightmares about
killing his classmates until he was shot and that his parents were dying and that he killed
himself. He experienced suicidal ideation. He improved when fluoxetine was
discontinued, relapsed when fluoxetine was prescribed again, after which the drug was
finally discontinued.[68]
Due to the double-blind test design and the challenge-dechallenge-rechallenge series
of events, valid scientific conclusions regarding causality can be drawn. [58, 66, 97, 103, 115]
Many such challenge-rechallenge occurrences have been described. [38, 49, 75] Challengerechallenge tests have been accepted in US courts as prove of causality. The Reference
Manual on Scientific Evidence (2011), a publication by the National Academy of
Science, accepts a dechallenge-rechallenge test as proof of causation.[116] It also
mentioned that ”most courts have appropriately declined to impose a threshold
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requirement that a plaintiff always must prove causation with epidemiologic evidence.”
Referring to this Manual, Healy (2015) remarked:
“Broadly speaking if exposure to a drug produces a problem (challenge) and the
problem clears up on stopping the drug or reducing the dose (de challenge) and
reappears on re exposure to the drug (re challenge) this is definitive evidence that the
drug can at least cause the problem in some of those who are exposed to it.”[117]
Challenge-rechallenge is one of the possible mechanisms that could substantiate
causal association. There are several others, based on the ones set by Sir Austin Bradford
Hill (1897-1991), the so-called “Bradford criteria.” He was an English epidemiologist
and statistician, and is considered the father of the randomized clinical trial.[58] Together
with Richard Doll, he determined the causality between smoking and lung cancer.[118]
In 1965, Bradford Hill came up with nine criteria for observations to be considered
before determining if causation is the most likely interpretation. [119]

1. Strength. As an example, Bradford Hill mentioned the number of deaths from
lung cancer in smokers compared to non-smokers.
2. Consistency. Has the phenomenon been observed repeatedly, by different
persons under different circumstances and at different times?
3. Specificity. How specific is the association? If specificity exists, there is little
doubt about the causality. If specificity is not clear, causality is still possible.
4. Temporality. As Bradford Hill put it: which is the cart, and which is the
horse?
5. Biological gradient. For instance, a dose-response curve.
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6. Plausibility. If there is a biological explanation, that would be helpful to
establish causation. That, however, depends of the biological knowledge of
the moment. Bradford Hill warned against dismissing causality to quickly as
just odd. He quoted Sherlock Holmes: “When you have eliminated the
impossible, whatever remains, however improbable, must be the truth.”
7. Coherence. The association should not be in serious conflict with the scientific
knowledge at that moment. Here also the caveat applies that future knowledge
might indeed prove causality.
8. Experiment. If it is possible to perform an experiment that affect the frequency
of the association. Persons stop smoking, does death rate decrease? Bradford
Hill considered this the strongest support for a causal association.
9. Analogy. Is there similar evidence with other situations, e.g., drugs?

Bradford Hill considered that none of these nine points can bring indisputable evidence
whether there is a causal relation, neither can they be seen as a conditio sine qua non (a
necessary condition). They can be helpful in deciding if there is any other way to explain
the observed association.[119]
Later those criteria were adapted by Edwards, Healy, Naranjo and the World Health
Organization (WHO).[97, 115, 120, 121] Edwards changed these criteria to specifically fit them
for an association between a drug and an adverse reaction. He narrowed it down to six
criteria: [115]

65

1. The reaction should be an authoritatively documented, unwanted effect of the
drug
2. The reaction should not be a manifestation of the illness being treated or of a
concurrent disorder.
3. No other substance that could have caused the reaction should have been
taken at the time of the reaction.
4. There should be a close temporal relationship between the reaction and the
administration of the drug, backed up if possible, by the demonstration of the
parent compound and/or its metabolites in body fluids.
5. The reaction should disappear on discontinuing the treatment.
6. Reappear with a rechallenge test.

Naranjo et al. (1981) proposed a method for establishing causality in which the use of a
specific antagonist and a dose-response reaction were introduced, see Table 1.4:[120]
In 2012, the World Health Organization published a modified version with the
emphasis on the different categories in combination with assessment criteria that should
be, within reason, met (Table 1.5).[121]
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Table 1.4: Adverse Drug Reaction Probability Scale (Taken from Naranjo et al., 1981)
Causality scale
Questions
Yes
No
Unknown
Are there previous conclusive reports on
1.
1
0
0
this reaction?
Did the adverse event appear after the
2.
2
-1
0
suspected drug was administered?
Did the adverse event improve when the
3.
drug was discontinued or a specific
1
0
0
antagonist was administered?
Did the adverse event reappear when the
4.
2
-1
0
drug was re-administered?
Are there alternative causes that could
5.
have on their own have caused the
-1
2
0
reaction?
Did the reaction reappear when a
6.
-1
1
0
placebo was given?
Was the drug detected in blood or other
7.
fluids in concentrations known to be
1
0
0
toxic?
Was the reaction more severe when the
8. dose was increased or less severe when
1
0
0
the dose was decreased?
Did the patient have a similar reaction to
9.
the same or similar drugs in any
1
0
0
previous exposure?
Was the adverse event confirmed by any
10.
1
0
0
objective evidence?
Score: >9 Definite; 5-8 Probable; 1-4 Possible; 0 Doubtful

67

Table 1.5: WHO-UMC Causality Categories
Causality
Term
•
•
•
Certain
•
•
•
Probable /
Likely

Possible

•
•
•
•
•
•
•

Unlikely

Conditional /
Unclassified
Unassessable /
Unclassifiable

•
•
•
•
•
•
•

Assessment Criteria
All Points Should Be Reasonable Complied With
Event or laboratory test abnormality, with plausible time
relationship to drug intake
Cannot be explained by disease or other drugs
Response to withdrawal plausible (pharmacologically,
pathologically)
Event definitive pharmacologically or phenomenologically
(i.e. an objective and specific medical disorder or a recognized
pharmacological phenomenon)
Rechallenge satisfactory, if necessary
Event or laboratory test abnormality, with reasonable time
relationship to drug intake
Unlikely to be attributed to disease or other drugs
Response to withdrawal clinically reasonable
Rechallenge not required
Event or laboratory test abnormality, with reasonable time
relationship to drug intake
Could also be explained by disease or other drugs
Information on drug withdrawal may be lacking or unclear
Event or laboratory test abnormality, with a time to drug
intake that makes a relationship improbable (but not
impossible)
Disease or other drugs provide plausible explanations
Event or laboratory test abnormality
More data for proper assessment needed, or
Additional data under examination
Report suggesting an adverse reaction
Cannot be judged because information is insufficient or
contradictory
Data cannot be supplemented or verified

The side effects investigated in this chapter, are the emergence of agitation, mania, de
novo depression, obsessive preoccupations with aggression against self and others,
akathisia and violence. By comparing the research as described above with the criteria of
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Bradford Hill, an indication can be acquired about the likelihood of a causal association
between the psychoactive medication and any violent side effect. Here are the criteria:

1. Strength: An observational study of Björkenstam (2013) found a three-to-fourtimes increased risk of suicide, with an odds ratio of 3.7 (95%CI: 2.8-4.9) in
5,913 patients who committed suicide in Sweden between 2007 and 2010,
within one month after starting SSRIs.[107] The review of all randomized
controlled trials (RCTs) between 1967 and 2003 by Fergusson et al. (2005)
yielded an OR for suicide attempts for patients on SSRI compared to placebo
of 2.28, (95% CI: 1.14-4.55).[106] This is substantiated by the studies of the
Cochrane Centre and by the work of Hemminki (2016).[110, 111, 113, 114] These
odds ratios are significant, substantiating the strength of the association.[122]
2. Consistency: Bradford Hill pointed out the importance of repeated
observations over time and in different circumstances by different people.[118]
This argument had already been put forward by Healy in 1999, when he noted
that similar reports regarding suicide while on treatment for depression have
been published by a great number of independent, respected researchers.[58]
Since the turn of the century, many more independent reports have been
released.[27, 64, 123, 124]
3. Specificity: Bradford Hill linked this to cause and effects of, for instance,
specific workers and a disease, but he also emphasized that the cause of a
disease can be expressed in a multitude of different forms. He used the
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example of milk as the carrier of pathogens that could cause sore throat,
scarlet fever, typhoid, diphtheria and tuberculosis. One might overlook the
underlying factor if specificity is pursued too stringently.[119] The same
accounts for psychoactive medication and acts of violence. The side effects of
the drugs can become evident through a series of symptoms, but they all
originate from the drug taken. Specificity is provided by studies with a built-in
control. This could be a group on placebo, or a person who acts as his own
control. The RCTs reviewed by Fergusson (2005), the studies by Sharma
(2016), and Hemminki (2016), the case of the 12-year-old boy reported by
King (1991), and the patient reported by Shaw (1986) all serve the purpose of
specificity.[53, 68, 106, 110, 111] Another way to substantiate specificity is through the
healthy volunteer studies.[94, 95, 112, 113] The common denominator shared by the
people who participated in these studies, is the use of psychoactive
medication, substantiating the likelihood of specificity. Bradford Hill
considered specificity a strong argument in favor of causation.[119]
4. Temporality: A temporal relationship between the use of psychoactive
medication and the emergence of paradoxical reactions have been reported
from the start of usage of these drugs. Achor et al. (1955) reported severe
depression, attempted- and completed suicide in patients, treated with
Rauwolfia (“the insanity herb”) for hypertension, after two months of
administration.[33] Others observed psychosis and enhanced anxiety on
reserpine and chlorpromazine within one to several days after starting
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treatment.[34] Cases that have been documented in the scientific literature,
include acts of violence after one week of treatment with chlordiazepoxide, an
increase in agitation, mania and psychosis in patients on imipramine after one
to several weeks, paradoxically reactions within one to two days after starting
phenothiazines, patients reacting with aggressiveness after one or two tablets
of imipramine, and aggression within a week of starting amitriptyline.[9, 36-38]
SSRIs show the same temporality. Joseph Wesbecker was on Prozac for a few
weeks before he went on a killing spree. Don Schelle was on paroxetine for
two days when he did the same.[19] Teichert reported on the six patients who
developed violent suicidal thought after 2-6 weeks of treatment with
fluoxetine.[48] Breggin testified on the case of Reynaldo Lacuzong who
drowned his two children and himself in the bathtub on the third day of
paroxetine treatment.[125] Christopher Pittman was on sertraline for two days
before he killed his grandparents.[19] The observational study by Björkenstam
(2013) of nearly 6000 patients who committed suicide, put the highest risk in
the second week after staring SSRIs.[107] With these numbers, temporality has
been made more than likely.
5. Biological Gradient: Bradford Hill is referring here to a dose-response
curve.[119] According to Lane, akathisia in patients on neuroleptics is doserelated.[79] The dysphoric responses can occur at low dose, [40, 47] but the higher
the dose, the greater the chances of side-effects.[58, 79, 126-128]
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6. Plausibility: A biological explanation would be helpful in establishing
causation. All substances that interfere with brain chemistry can provoke
negative behavioral changes. Psychoactive medication especially interacts
with the neurotransmitters that regulate human emotions and behavior. Lane
(1998), hypothesized that akathisia can be caused by serotonin
overstimulation and toxicity.[79] The serotonin system and dopamine mediated
neurotransmission influence each other. The kind of emotion and behavior
that could be the result of the interaction between the different
neurotransmitters depends on the amount of neurotransmitter released into the
synaptic cleft, its rate of reuptake and degradation, and the type, number,
sensitivity and specificity of post-synaptic receptors.[84] We are far from
knowing the exact mechanism behind the occurrence of akathisia and
violence, but the emergence of these side effects in situations of serotonergic
hyperstimulation and their response if the dose is reduced or discontinued,
fulfill the criterion of plausibility.
7. Coherence: The association should not be in serious conflict with the scientific
knowledge of the moment. In 2004, the FDA required an adaptation of the
warning labels on the Summary of Product Characteristics for all
antidepressants:
a. All patients being treated with antidepressants for any indication should be
monitored appropriately and observed closely for clinical worsening,
suicidality, and unusual changes in behavior, especially during the initial
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few months of a course of drug therapy, or at times of dose changes, either
increases or decreases.
b. The following symptoms, anxiety, agitation, panic attacks, insomnia,
irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor
restlessness), hypomania, and mania, have been reported in adult and
pediatric patients being treated with antidepressants for major depressive
disorder as well as for other indications, both psychiatric and nonpsychiatric.[72]
This indicates that a possible causal association between the medication
and acts of violence is not in conflict with the current scientific
knowledge.
8. Experiment: If possible, experimentation may help substantiate the
association. The challenge-dechallenge-rechallenge test can be considered as
such an experiment. Already in 1955, Delay and Deniker observed this with
the use of phenothiazine: “But the syndrome that we observed appeared upon
administration of the compound and disappeared when treatment was
discontinued.”[2] Many reports on challenge and rechallenge followed.[34, 37, 38,
49, 53, 68, 75, 129]

Bradford Hill considered experimentation the strongest support

for a causal association.[119]
9. Analogy: Is there similar evidence with other situations, e.g., drugs? Bradford
Hill mentioned the effects of thalidomide and rubella on birth defects. If other
drugs or viral infections cause comparable defects, that would support the
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causal relationship of the first association. The emergence of violence and
activation events have been described over a wide range of psychoactive
drugs, which include the phenothiazines, the benzodiazepines, the tricyclic
antidepressants, the anti-psychotics and the new-generations antidepressants
e.g., the SSRIs and the NSRIs.[2, 4, 9, 33, 35-37, 42, 43, 48, 64, 66, 79, 94, 95, 97, 130, 131] Basically,
any neuroleptic medication, no matter the chemical structure, can cause these
side effects.[2, 43, 79]

The nine criteria for causation according to Bradford Hill have been met. This is
significant support in favor of a causal relationship between the emerge of activation
events and violence and the use of psychoactive medication.
Edwards (1992) narrowed the criteria of Bradford Hill down to six:[115]

1. The reaction should be an authoritatively documented unwanted effect of the
drug; Given the amount of research and reports, that condition has been met.
2. The reaction should not be a manifestation of the illness being treated or of a
concurrent disorder.
3. No other substance that could have caused the reaction should have been
taken at the time of the reaction; This is the case in the healthy volunteer
studies and RCT’s.
4. There should be a close temporal relationship between the reaction and the
administration of the drug, backed up if possible by the demonstration of the
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parent compound and/or its metabolites in body fluids; This condition is
comparable to the biological gradient and plausibility criteria form Bradford
Hill, which were fulfilled.
5. The reaction should disappear on discontinuing treatment and
6. Reappear with a rechallenge test. Number 5 and 6 are consistent with the
experiment criterion.

The second criterion is one of the arguments frequently heard to disprove causality.
The Zoloft Litigation Manual that Pfizer supplies to lawyers for use in litigation offers
attorneys arguments they can use to “rebut scientifically unsubstantiated claims that
Zoloft can induce violent behavior.”[132] Pfizer claims causation is “difficult, if not
impossible to prove,” due to the fact that “Defendants for whom Zoloft has been
prescribed are most often individuals who were and are suffering from significant
disorders that are associated with violence or hostility.” However, this has been disproved
time and again. The emergence and resolution of akathisia is a rare event, and, once an
observer is familiar with it, it is easily recognized the next time, as was described in the
study by King (1995). These side effects were called “paradoxical” because they were not
expected given the condition of the patients. Once treatment of patients suffering from
mental illness was started in the 1950s, it became clear that these paradoxical reactions
differed essentially from the course the regular mental diseases take. Patients who were
not suicidal before, became suicidal after being treated with neuroleptics.[46] Patients
themselves identified the feelings brought about by akathisia as the reason for becoming
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suicidal.[49] A double-blind, randomized, placebo-controlled trial of fluoxetine in children
and adolescents with depression by Emslie (1997), revealed that 6% of the subjects on
fluoxetine developed mania.[133] The side effects were so severe, the children had to drop
out of the study. None of the children on placebo developed mania. Therefore, the mania
was caused by the fluoxetine and not an underlying mental disease.[66]
A convincing argument against an underlying disease as the cause of akathisia and
violence is the fact that healthy volunteers and people without psychiatric illnesses
exhibit the same tendencies and paradoxical reaction.[94, 95, 112-114] It is likely that certain
individuals who are vulnerable might become worse after taking psychoactive
prescription drugs. The medication might make the underlying mental illness worse by
triggering akathisia.[58] If healthy volunteers in trials become depressed after being put on
an antidepressants, it is understandable that those medications can make already
depressed patients worse.[134] Even so, suicidal ideation or violent actions can be
considered de novo if these patients were not prone to violence before taking the drugs.
Hamilton (1992) described a 32-year-old patient with a history of major depression and
panic attacks. She was started on fluoxetine and, after four weeks, she developed
symptoms she never had before. She was feeling restless and out of control. Although her
mood was good, she felt “like I need to hold onto my chair or else I’ll jump out the
window.” She stated that the way she felt was different and far more frightening than any
suicidal ideation she had experienced during previous episodes of depression. After the
fluoxetine was discontinued, the restlessness and suicidal ideation disappeared
simultaneously.[47] In individual cases, the medication should be ruled out as having
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contributed to acts of violence rather than blaming an underlying mental illness without
proper investigation.
Naranjo (1981) revised the criteria for adverse reactions and added some more,
specifically aimed at a single patient:

1. Are there previous conclusive reports on this reaction?
2. Did the adverse event appear after the suspected drug was administered?
3. Did the adverse reaction improve when the drug was discontinued or a
specific antagonist was administered?
4. Did the adverse reaction reappear when the drug was re-administered?
5. Are there alternative causes (other than the drug) that could on their own have
caused the reaction?
6. Did the reaction reappear when a placebo was given?
7. Was the drug detected in the blood (or other fluids) in concentrations known
to be toxic?
8. Was the reaction more severe when the dose was increased, or less severe
when the dose was decreased?
9. Did the patient have a similar reaction to the same or similar drugs in any
previous exposure?
10. Was the adverse event confirmed by any objective evidence?
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Numbers 1, 2, 3, 4, 5, and 7 are consistent with the criteria from Edwards. Regarding
point 6, whether the reaction reappeared on placebo, no studies could be found where this
was tried out with psychoactive medication. In one criminal case in Holland, this was
investigated in a N = 1 double-blind experiment with paroxetine. The subject did show
significantly increased irritably on the days he received paroxetine compared to the days
he was on placebo.
Regarding point 7 and point 8, akathisia and activation events can occur at any drug
level in the blood, within toxic levels or not. Lane (1998) considered them dose related
phenomena.[79] The higher the level, the greater the chances of these side effects and the
more severe they can be. [40, 79, 89, 126] Eikelenboom et al. (2016) described a patient with
toxic blood levels of venlafaxine and desvenlafaxine who killed her two-year-old son and
tried to kill her seven-year-old daughter and herself.[135] However, these side effects have
been described at non-toxic levels.[136, 137] Withdrawal phenomenon can take months to
resolve. It takes five half-lives for a substance to be considered expelled from the body.
Patients can experience withdrawal long after the drug levels have returned to
undetectable.
Point 9 is of importance for individual patients. What often happens, is that when a
patient develops side effects like akathisia, it is interpreted as worsening of an underlying
illness and more drugs are added or a patients is switched to another medication, which
often increases the problems.[19] Point 10 refers to professionals who might have
witnessed the occurrence of adverse events in a specific patient.[120] The causality
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categories of the WHO are essentially the same as Naranjo’s. The difference is the
classification of the level of causality.
The Diagnostic and Statistical Manual (DSM), with descriptions of diagnostic
categories, is a publication from the American Psychiatric Association (APA). It is a
manual for clinical use. It states that neuroleptic medication in general and SSRIs
specifically, can cause adverse reactions related to akathisia, mania, suicide and
violence.[64] With regards to manic episodes, it mentions: “Manic-like episodes that are
clearly caused by somatic antidepressant treatment e.g., medication…should not count
towards a diagnosis of Bipolar I disorder.”[138] The same applies to psychotic and mood
disorders. If they can be explained as caused by the physiological effect of a substance,
e.g., medication, they should not be labeled as a psychiatric disorder.[139] Special emphasis
is placed on the occurrence of “antisocial behavior” and violence while a person is in a
manic state. “Ethical concerns may be disregarded even by those who are typically very
conscientious.” “The person may be hostile and physically threatening to others,” “Mood
may shift rapidly to anger and depression,” “Some individuals, especially those with
psychotic features, may become physically assaultive or suicidal.” “The increase in goaldirected activity often involves excessive planning….”[138] It is important to realize that
such a person can use that goal-directed activity to plan and carry out acts of violence. As
Breggin pointed out: “…individuals undergoing mania often feel driven to carry out
elaborate plans, however bizarre, destructive, or doomed they may be.”[64]
In summary, indications of causality between psychoactive prescription drugs,
aggression, activation events and violence, include:
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1. In-house documents of pharmaceutical companies acknowledging aggression
as side effect.
2. Increased risk on suicide in epidemiological studies.
3. Increased risk on suicide in randomized controlled trials.
4. Increased risk on suicide in observational studies.
5. A three-time higher risk on aggression in children and adolescents in a metaanalysis of 70 trials.
6. A study concluding that boys, who commit a violent crime, have a greater
chance of being on antidepressants.
7. The emerge of akathisia in healthy volunteers after taking psychoactive
medication.
8. The development of suicidal and homicidal ideation in case control studies.
9. In the different studies mentioned here, over 100,000 patients have been
included.
10. When the criteria for causation as formulated by Sir Austin Bradford Hill,
Edward, Naranjo and the WHO, are applied to the results of these studies,
they support said causality.
11. The adaptation required by the FDA in 2004, of a “Black Box” warning label
an all antidepressants for, among others, suicidality, aggressiveness, akathisia
and mania.
12. The DSM-IV and 5 acknowledge akathisia, mania, suicide and violence as
possible side effects.
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If the causality between psychoactive medication and violence is clearly described in
the DSM, it raises the question as to why some many professionals still deny such an
association. Why medication-induced violent events are regarded as caused by an
underlying psychiatric disorder instead of considering the medication as the possible
cause. Without a doubt, depression is associated with suicide. Depression is also
associated with sexual dysfunction. There is consensus that antidepressants can cause
sexual dysfunction.[58] In case of sexual dysfunction, many prescriber will blame the
medication, not the depression. Yet, suicide is often blamed on the depression, not the
medication.
There are studies that do not support a causal association between psychoactive
medication and violence. There are indications, however, that the in-house clinical trial
reports produced by the pharmaceutical companies underestimate the numbers of suicide
attempts and completed suicides. In addition, not all placebo-controlled trials conducted
by the pharmaceutical companies have been made public. Some trial data were obtained
through the Freedom of Information Act or as part of ongoing court cases.[27, 59] Studies
that were published contained conclusions like: “The incidence of attempted suicide did
not differ substantively among the three treatment groups (paroxetine, placebo, active
control).” Regarding paroxetine, this result was reached by leaving out completed
suicides and suicide attempts and adding completed suicides and suicide attempts in the
placebo run-in period. The data obtained by Breggin revealed 14 suicide attempts in the
USA clinical data, with a rate 3.8 times higher for paroxetine compared to placebo and
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3.6 higher compared to TCAs. GSK kept these data out of the report to the FDA in
1991.[59]
Eli Lilly knew 10 years before fluoxetine was put on the market that its drug could
cause agitation in some people and that could lead to suicide and homicide. An FDA
safety officer noticed that some “Catastrophic and Serious Events” were not reported by
Eli Lilly. The reviewer concluded that the side effects of fluoxetine resembled those that
can be seen with a stimulant drug.[19] In the documents that contained that information and
which were leaked to the British Medical Journal in 2004, it was mentioned that Eli Lilly
coded suicide attempts as “overdose” and “suicidal ideation” as “depression.” The
company had left out 76 of 97 cases of suicidality. Fluoxetine was deemed safe by the
FDA despite concerns brought forward from within the FDA, due to the financial ties
from several of the panelists to Eli Lilly.[70]
In Sweden, the director of Eli Lilly found an independent expert in the person of
Anders Forsman, who was a forensic psychiatrist and member of the Swedish National
Board of Health. He was not in favor of fluoxetine, but he told Eli Lilly that for $20,000
and a substantial amount of money for his department, he was able to get fluoxetine
approved by the Swedish drug agency. He adjusted the results of the trials by, for
instance, rewriting “Five had hallucinations and tried to commit suicide, which four of
the test subjects succeeded in doing” into “Five of the other test subjects had
miscellaneous effects.” He also wrote a personal letter of recommendation.[19]
Study result can be influenced by using co-medication. Fluoxetine was approved by
the FDA based on four studies, three in which other psychoactive medication was
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allowed. That will lead to bias towards the test medication. It will also obscure the true
effect of the drugs.[19] Walsh (2002), performed a meta-analysis on random placebocontrolled trials between 1981 and 2000 and found that in 84% minor tranquillizers were
permitted.[140]
The fact that studies, sponsored by the pharmaceutical industry, show efficacy of
psychoactive medication whereas independent studies do not, is worrisome. Marcia
Angell, former editor of The New England Journal of Medicine, drew these conclusions:
“Similar conflicts of interest and biases exist in virtually every field of medicine,
particularly those that rely heavily on drugs or devices. It is simply no longer
possible to believe much of the clinical research that is published, or to rely on the
judgment of trusted physicians or authoritative medical guidelines. I take no pleasure
in this conclusion, which I reached slowly and reluctantly over my two decades as an
editor of The New England Journal of Medicine.”[141]
In 2011, after being fiercely attacked over her review of three books that were critical
of modern psychiatry she replied: [142]
“I have spent most of my professional life evaluating the quality of clinical research,
and I believe it is especially poor in psychiatry. The industry-sponsored studies
usually cited to support psychoactive drugs - and they are the ones that are selectively
published - tend to be short-term, designed to favor the drug, and show benefits so
small that they are unlikely to outweigh the long-term harms.”
Study 329 is another, recent example of the problem with studies favoring
antidepressants. This randomized controlled trial comparing paroxetine with imipramine
and placebo was published in 2001 by SmithKlineBeecham, now GSK, in the Journal of
the American Academy of Child and Adolescent Psychiatry (JAACAP). It stated that
paroxetine was well tolerated and “REMARKABLE” (uppercase from a management
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message to all Paxil sales representatives) effective for major depression in
adolescents.”[143, 144] For years, it has been referred to as the reason children and
adolescents could be prescribed paroxetine safely.
Selective reporting in clinical trials in order to manipulate the outcome is a problem
in medical science and hard to trace without access to internal company documents. In
2004, through litigation, around 10,000 pages of study 329 became public. Jureidine et al.
(2008) examined the documents and found that the researchers overrated the efficacy and
underestimated the adverse events of the drug.[144]
In 2013, a group of scientists called out for disclosure of unpublished trials. They
called their initiative Restoring Invisible and Abandoned Trials (RIAT). Study 329 was
one of the trials deemed fit for re-analysis. When the RIAT researchers asked GSK to
correct their version of study 329, GSK responded that the study “accurately reflects the
honestly-held views of the clinical investigators authors”, and the GSK did “not agree
that the article is false, fraudulent or misleading.”[145] The RIAT crew re-analyzed the data
using the documents that were publicly available. After pressure was applied, GSK made
the de-identified individual case reports forms available. GSK posted around 77,000
pages on a website, which could only be accessed by one person through a remote
desktop facility. This made it almost impossible to analyze the data.
The conclusion of the RIAT investigation was that there was no beneficial effect from
paroxetine or imipramine and that there were significantly adverse events with both
drugs. Le Noury et al. (2015) described how the data in this study were manipulated to
arrive at a positive result:[145]
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1. Use of idiosyncratic coding system. Suicidal behavior for instance, was coded
as “emotional lability.”
2. Failure to transcribe all adverse events from the clinical records to the adverse
database. Reviewing the case report forms revealed many non-recorded
adverse events.
3. Filtering data on adverse events through statistical techniques. As Gøtzsche
phrased his analysis of study 329: “The statistical alchemy created four
statistically significant effects after splitting the data in various ways, and
many variations were tried before the data confessed to the torture.”[19]
4. Restriction reporting of events that only occurred above a given frequency in
any one group. Adverse events that occurred less than 5% of the patients were
not reported.
5. Coding events under different headings for different patients (dilution). If an
adverse event occurs with a frequency above 5%, it might be coded in
different ways to lower the frequency below 5%.
6. Grouping of adverse events. When benign adverse events that occur across all
the treatment arms are grouped with less benign, the differences in dangerous
side effects across the treatment arms becomes less clear.
7. No consideration of severity. If all side effects are treated equal, it makes
severe side effects looks less severe.
8. Coding of relatedness to study medication. In several cases, blinding of the
coding had been broken before the relatedness of the treatment and adverse
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effect were established. One investigator, who was aware the patient was on
placebo, contributed a suicidal event “definitely related to the treatment,”
while of 11 patients who suffered serious adverse event, in only one case the
adverse event (a headache) was contributed to the treatment with paroxetine.
9. Masking effects of concomitant drugs. This affects the difference between the
active drug and placebo, creating bias towards the treatment medication.
10. Ignoring effects of drug withdrawal. There was a taper phase of 7-17 days, but
these data were not analyzed. Given that antidepressants cause dependence,
there most likely was an increased rate of dangerous adverse events in
withdrawal.

An investigation, performed by the British Medicine and Health Care Products
Regulatory Agency (MHRA), concluded that the GSK documents “represented robust
evidence of a causal association between an SSRI and suicidal behavior.”[146] Study 329
was fraudulent, because it was known from the internal unpublished study documents that
at least eight children developed suicidality on paroxetine with only one child that
became suicidal while on placebo.[19] Up until today, the journal (JAACAP) has yet to
retract study 329.
In 2011, the United States Department of Justice filed a suit under the False Claims
Act. The claim included the JAACAP article about study 329. GSK pleaded guilty and
paid a $3 billion settlement, including a criminal fine of $1 billion. The Criminal Plea
Agreement stated:
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“GSK unlawfully promoted Paxil [paroxetine] for treating depression in patients
under age 18, even though the FDA has never approved it for pediatric use. The
United States alleges that, among other things, GSK participated in preparing,
publishing and distributing a misleading medical journal article that misreported that
a clinical trial of Paxil demonstrated efficacy in the treatment of depression in patients
under age 18, when the study failed to demonstrate efficacy. At the same time, the
United States alleges, GSK did not make available data from two other studies in
which Paxil also failed to demonstrate efficacy in treating depression in patients
under 18.”[147]
That the strategy of GSK has not changed over the years is clear from a documentary
broadcasted in July 2017 by the BBC about the Aurora Theater shooting. Despite the
Criminal Plea Agreement, GSK made the statement in the documentary which is shown
in Figure 1.6.
The result of the reanalysis of study 329 is in line with the findings in other studies
where trial summaries and journal articles were compared. In 2014, Maund et al. from the
Nordic Cochrane Centre discovered large amounts of data on severe adverse events in
clinical trials on duloxetine treatment for major depressive disorder that were absent in
the journal articles.[148] Hughes et al. found the same in their 2014 research into 142
studies on antidepressants and antipsychotic drugs.[149] The majority of the deaths
(94/151) and suicides (8/15), which were recorded in the summaries, were left out of the
journal articles. For instance, of the nine suicides in olanzapine trials, only one was
acknowledged in the journal papers.
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Figure 1.6: A Still from the BBC Documentary “Prescription for Murder”, July 2017
Another example of fraud is the work of Dr. Joseph Biederman, Professor of
Psychiatry at Harvard Medical School and Chief of Pediatric Psychopharmacology at
Harvard’s Massachusetts General Hospital. He promised Johnson & Johnson positive
results before the start of clinical trials on risperidone to treat children with bipolar
disorder. He was paid $700,000 as funding for a research center. From 2000 through
2007, he received $1.6 million from Johnson & Johnson, of which only a fraction was
disclosed to Harvard. In 2011, he was subsequently punished by the Harvard Medical
School and Massachusetts General Hospital.[150] Due to the work of Biederman, children
as young as two years old were diagnosed as bipolar and put on combinations of
antipsychotic drugs, not approved by the FDA for that use and not approved for children
under ten years old.[141] In addition, there was no research done on the long-term effects of
these medications on children.
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Fraud is not restricted to studies funded by pharmaceutical companies. The National
Institute of Mental Health (NIMH) funded a study (STAR*D) costing $35 million,
involving patients from clinical practices. The subjects started out on citalopram
(manufactured by Lundbeck) as the sole medication. Later, additional medication was
allowed with a follow-up of one year after recovery. There was no placebo group. When
the study was finished, the NIMH announced that “about 70% of those who would not
withdraw from the study became symptom free.”[19] The overall cumulative remission rate
was 67%. When independent researchers re-analyzed the data, a different picture
emerged. Many “remitted” patients still suffered symptoms of major depression.
Hundreds of patients were admitted to the study that did not fit the criteria and who,
according to the study protocol, should have been excluded. Those were patients with
mild symptoms of depression or who lacked a baseline Hamilton score. According to
Pigott, only 108 of the 4,041 patients went into remission and stayed well in the followup period.[151] Even this number is most likely inflated. Those 108 patients are probably
the ones who should have been excluded based on the intake criteria. It is possible that
the investigators provided extra good care to the study patients, leading to higher success
rates than in the normal day-to-day practice. Still, the study was presented as leading to
an approximately 70% recovery among depressed patients and “far more effective” than
placebo.[152] This conclusion is even more remarkable given that no placebo group was
included.
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Pigott (2011) stated that in the 5 years that he studied STAR*D, he
“identified one scientific error after another.…which all had the effectiveness of the
antidepressant drug look better than it actually was, and together these errors led to
published reports that totally mislead readers about the actual results. As such, this is
a story of scientific fraud funded by the National Institute of Mental Health at a cost
of $35 million.”[151]
Ten STAR*D authors had financial ties to Foster, Lundbeck’s US partner. In 2011,
Pigott filed a complaint that Foster’s principal investigator was bribed to manipulate the
results to the advance of citalopram, leading to that medication being the only
antidepressant at the start of the study, falsifying and overstating the drug’s
effectiveness.[19]
The financial interests in pharmaceuticals are immense. In 2002, the profit of the 10
drug companies in the Fortune 500 were more than the profit of the other 490 other
businesses combined ($35.9 versus $33.7 billion).[153] As Marcia Angell described it in
2004:[153]
“Over the past two decades the pharmaceutical industry has moved very far from its
original high purpose of discovering and producing useful new drugs. Now primarily
a marketing machine to sell drugs of dubious benefit, this industry uses its wealth and
power to co-opt every institution that might stand in its way, including the USA
Congress, the FDA, academic medical centers, and the medical profession itself.
(Most of its marketing efforts are focused on influencing doctors, since they must
write the prescriptions).”
Therefore, it might be that trials, in which no association is found between the medication
and thoughts and acts of violence, are more indicative of being inadequate rather than
being evidence of benefit.
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There is clearly an issue with psychoactive medication and the occurrence of
violence. If one wants to deny causality, then what is the cause of the behavioral
problems? It cannot be the “underlying disease,” given that healthy volunteers can exhibit
the exact same symptoms. It must be something connected to the medication, that being
the factor that all these patients and volunteers have in common. Given the number of
people that have suffered this side effect, it must be something easily detectable. Yet,
after all these years and all the research, no sound argument has been presented to explain
these acts of violence. Denial, in the face of the abundance of evidence available to
establish causality, is what Bradford Hill (1965) called “a vague contention of an
armchair critic. You can’t prove it, there may be such a feature.”[119] Maybe the most
obvious explanation is indeed the correct one. Using the scientific methods available to
establish causality surely point in that direction.
In many cases, it all starts with a minor incident or psycho-social problems.
Medication seems a quick and easy solution. Neither the prescriber nor the patient seems
aware of the risks. Whether the emergence of violence in any form or shape is caused by
the medication or consequence of an underlying psychiatric illness is basically of no
importance. If this medication has the effect of opening Pandora’s box, it should not be
allowed on the market. The treatment in those cases is worse than the ailment.
In conclusion, there is sufficient scientific evidence that supports an association
between psychoactive prescription drugs and activation events, aggression and violence,
as side effects. It is no proof however, that such is the case in individual cases. That
depends on the circumstances. Psychoactive medication can be a factor in the occurrence
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of violence, yet other factors should be taken into account as well. The criteria as
formulated by Bradford Hill (1965), and Edwards (1992) could be applied to that effect.
The crucial question in these cases is not if the medications caused the violence, but
whether the violence would have happened without the drugs.

Diagnostic and Statistical Manual of Mental Disorders
About a hundred years ago, depression was considered a self-limiting disorder. Emil
Kraeplin followed 450 patients with depression. From those, 60% suffered a one-time
depression and 13% had recurrent episodes. In New York between 1090 and 1920, a
group of 2,700 patients with depression were admitted. More than 50% had one episode,
and 17% suffered three or more attacks.[154] Today, an untreated depression lasts for about
three months.[19]
After the introduction of antidepressants, the number of patients taking medication
increased. For the USA, the following numbers apply: from 1988 to 2008, money spend
on antidepressants quadrupled; a study from 2002 reported the use of antidepressants of
11% in women and 5% of men; the number of people on antidepressants increased 62%
between 1997 and 2004; in 2008, 11% of people over 12 years were on
antidepressants.[155-157] In the UK, the number of prescriptions increased from about nine
million in 1991 to over 20 million by 2000.[155] In Canada, the people on SSRIs alone
increased between 2005 and 2009 by 44%.[156, 157] Not only did more people take
antidepressants, many stayed on it for years. In the USA, of the people who are on
antidepressants, over 60% have used it for more than two years, 14% of them for 10 years
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or more.[157] It is remarkable that, with the availability of a “cure” through medication, the
number of people suffering from the illness the medication is prescribed for, increases. It
could be that more people are diagnosed with depression, or access to health care has
improved. But another explanation could be what is called “diagnostic inflation.”[156]
In 1952, the American Psychiatric Association (APA) published the first DSM, with
descriptions of diagnostic categories, as a manual for clinical use. It was a small, spiralbound, 130 pages’ handbook, but the current edition, DSM-5, consists of 947 pages. It is
considered the “Bible” of psychiatry, and it is widely used by physicians. The DSM has a
large public impact ranging from health care, to insurance claims, to jurisprudence.[141, 158]
The experiment by Dr. David Rosenhan in the 1970s, laid bare the shortcomings of
the diagnostic system. James Davies, in his 2013 book, “Cracked: Why Psychiatry is
Doing More Harm Than Good”, recounted what happened:[158] A group of eight
academics conducted a dramatic experiment, months in preparation. As part of the
experiment, they individually presented themselves at different psychiatric hospitals
dotted around the United States. Each academic told the psychiatrist on duty they were
hearing a voice in their head that said the words “empty”, “hollow” or “thud.” That was
the only lie they would tell; otherwise, from that point on they would behave and respond
completely normally. All of them were admitted into their respective hospitals. And all
were diagnosed with serious mental disorders and given powerful antipsychotic pills. All
the while they acted completely normally. The experimenters thought they would be in
for a couple of days and then be discharged, but they were wrong. Most were held for
weeks, and some in excess of two months. They could not convince the doctors they were
93

sane. And telling the doctors about the experiment only compounded the problem. It
quickly became clear that the only way out was to agree that they were insane and then
pretend to be better.
Once the leader of the experiment, Dr. David Rosenhan, got out and reported what
happened, there was an uproar in the psychiatric establishment. Rosenhan and his
colleagues were accused of deceit. One major hospital challenged Rosenhan to send some
more fake patients to them, guaranteeing they would spot them this time. Rosenhan
agreed, and after a month the hospital proudly announced to the national media that they
had discovered 41 fakes. Rosenhan then revealed that he had send no one to the hospital
at all.
The remarkable aspect of this experiment is that several real patients did spot the fake
ones. Davies also mentioned research in which the same group of patients was presented
to different psychiatrists. Almost half of the patients would get a different diagnosis.
Other studies showed that the chance of being diagnosed as schizophrenic is twice as
high in the United States or Russia, compared to Britain and Europe.[158]
The APA decided to start over with a completely new version of the DSM, number
III. The aim was to better define disorders and develop checklists to improve reliability of
the diagnoses. There are only a few mental disorders that have a clear biological origin,
e.g., Alzheimer, Parkinson, Huntington, epilepsy, delirium, which belong to the realm of
neurology. There is no biological markers for psychiatric disorders.[141] Dr. Theodore
Millon, one of the leaders on the taskforce for the DSM III, said the following about their
work:
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"There was very little systemic research, and much of the research that existed was
really hodgepodge - scattered, inconsistent, and ambiguous. I think the majority of us
recognized that the amount of good, solid science upon which we were making our
decisions, was pretty modest.”[158]
Renee Garfinkel, a psychologist who participated in two DSM advisory committees,
gave Davies an example of the level of scientific reliability of these decisions:
“There was a discussion about whether a particular behavior should be classed as a
symptom of a particular disorder. As the conversation went on, one taskforce member
suddenly piped up. “Oh no, no, we can’t include that behavior as a symptom, because
I do that!” And so, it was decided that that behavior would not be included….”[158]
From the DSM-III on, instead of researching and expanding the scientific evidence to
validate mental illness, new disorders were invented at a great rate. The information
below shows the development of autism, from a childhood illness to a series of disorders,
now called a “spectrum,” which includes adults.[159]

•

DSM-I (1952): Schizophrenic Reaction, Childhood Type. In this first mention of
autism, it’s described only in children, as a symptom of a psychotic reaction.

•

DSM-II (1968): Schizophrenia, Childhood Type; Schizoid Personality. Now a
symptom of two conditions but still just in children.

•

DSM-III (1980; revised 1987): Infantile Autism. Autism gets its own
classification, but still only in children. The 1987 revision finally extends it to
adults.
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•

DSM-IV (1994; revised 2000): Autistic Disorder. As in the DSM-III revision,
DSM-IV defines autism through six specific symptoms, including impairment of
social interactions.

•

DSM-5 (rough draft released 2010): Autism Spectrum Disorder. Now an umbrella
term for a whole category of conditions, including autistic disorder, Asperger’s
syndrome, and more.

Another example is Depressive Disorder. In the DSM-III, bereavement over the loss
of a beloved person was considered a disorder when it was still present after a year. In the
DSM-IV, the time to mourn is reduced to two months and in the DSM-5, to two weeks. If
bereavement lasts more than two weeks, the person is supposedly suffering a mental
illness.[158]
Alan Frances was the chair of the task force to update the DSM-IV version. His goal
was that changes to the DSM should be evidenced based and “not influenced by my
personal whims or anyone else’s.”[156] As it turned out, his high standards could not be
met due to the lack of scientific data to back up the proposed changes regarding
diagnosing and treating patients. According to Frances (2013), DSM-IV led to three false
epidemics in children’s mental health: autism, attention deficit, and childhood bipolar
disorder. DSM-IV was not able “to contain the rampant diagnostic inflation that was
already expanding the boundary of psychiatry far beyond its competence.”[156] There is a
connection between the DSM and the amount of psychoactive medication prescribed and
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used. Frances feared the diagnostic inflation was leading to a society of “pill poppers.”
Out of every five US adults, at least one was on prescription psychoactive drugs.[156]
When the DSM-5 was prepared, Frances publicly warned that the new disorders that
were constructed would lead to tens of millions of new “patients.” Under the DSM-5,
these basically normal people would be declared suffering from mental illness, and many
would be medicated without reason with the chance of dangerous side effects. Frances
was convinced the pharmaceutical industry would come up with ways to increase their
profits from this new wave of so-called disorders. Disease mongering, is what Frances
called it.[156]
Disease-mongering is evident when considering “shyness.” It was labeled a
psychiatric disorder (“social phobia”) in the DSM-III, but its frequency was rare. By
1994, in the DSM-IV, it was described as an extremely common disease and called
“social anxiety disorder.” In 1999, GSK received FDA approval and promoted paroxetine
for treatment of this “severe medical condition”, see Figure 1.7. The product producer
stated about this strategy: “Every marketer’s dream is to find an unidentified or unknown
market and develop it. That’s what we were able to do with social anxiety disorder.”[141,
160]

The lack of scientific foundation is one aspect that diminishes the credibility of the
DSM, the other is the influence of the pharmaceutical companies on the contents. For the
DSM-IV, no financial disclosure was required. After being criticized over the nondisclosure, the APA instituted a mandatory disclosure policy.
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Figure 1.7: Advertisements for Paroxetine in the American Journal of Psychiatry,
October 1999
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Cosgrove et al. (2012) analyzed the financial ties with the pharmaceutical companies
of the members of the different panels and taskforces for the DSM-IV and DSM-5.[161]
Three quarters of the working groups allowed their members to have financial ties with
manufacturers. Both in the DSM-IV and DSM-5, the most financial conflict of interest
occurred in those working groups aiming at first-line intervention. Of the panel for Mood
Disorders, 67% (N=12) had ties with the companies that produced the medication to treat
the disorder. Of the panel for Psychotic Disorders and the Sleep/Wake Disorders (which
include “Restless Leg Syndrome”), the numbers were respectively 83% (N=12) and
100% (N=7). For three reasons, these do not reflect the correct number of members with
financial conflict of interest.[161]

1. The APA did not require the members to disclose membership of speaker’s
bureaus. These bureaus hire speakers to give a presentation on certain
pharmaceutical products. None of the DSM panel members declared such a
membership. An internet search by Cosgrove identified 15% of panel
members who had disclosed speaker’s bureaus participation elsewhere.
2. Unrestricted research grants were excluded from disclosure by the APA.
3. Under the APA policy, individuals do not have to disclose the amount of
money received from the pharmaceutical companies.[161]

Figure 1.8 shows the comparison between the members of the different task forces and
working groups of the DSM-IV and DSM-5. [161]
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As Frances put it in “saving normal”, “If everyone has the ill, then all must take the
pill.”[156] The indications for psychoactive medication have expanded from mental illness
to normal psycho-social problems, to medical problems like urine incontinence, ever
younger children, ever older people, and rampant off-label use. There is, however, no
scientific basis for this expansion. The DSM is mainly driven by the needs of the
pharmaceutical companies, at the costs of the “patients,” the young ones and the old ones
being the most vulnerable. The younger they start these drugs, the bigger the chances
they will stay on them for life.[156] The national trend in psychoactive medication is
towards polypharmacy. Between 1996 and 1997, 42.6% of visits ended with a
prescription for two or more drugs. Between 2005 and 2006, that increased to 59.8%.
Three or more prescriptions increased from 16.9% to 33.2%, many without any
scientific substantiation.[162] These developments make it more than likely that many
people are on medications they don’t need, that are not beneficial, that are addictive, and
that can have extremely dangerous side effects.[19, 156, 163]
In 1994, Shepherd put the question about the future of psychoactive medication like
this: “Whether the psychopharmacological revolution, like so many upheavals, will
devour its own children remains to be seen.”[14] The development of the usage of
psychoactive medication since 1950, the number of different drugs, the increase in
indications, the lack of transparency in the clinical studies, the corruption in every level
of the regulating bodies, the unscientific approach and state of denial by large parts of the
psychiatric community, the willingness of patients to try to solve their problems though
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medication and the willingness of physicians to describe them disregarding the dangerous
side effects, indicate that the children of the revolution have indeed been crushed.

Figure 1.8: Financial Conflict of Interest as Disclosed by Members of Task Groups and
Working Groups of DSM-IV and DSM-5 (Taken from Cosgrove, 2012)

Cytochrome P450
Cytochrome P450s are the most important enzymes involved in phase I drug
metabolism in humans. Most drugs are deactivated by CYP450 enzymes to facilitate
removing them from the body (drug clearance). Some medication (prodrugs) need to be
converted into a pharmacological active form by CYP450s. The drug metabolizing P450s
generally belong to the first three gene families (CYP1-3). P450 families with higher
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numbers are usually involved in the metabolism of endogenous compounds, e.g., fatty
acids, sterols/steroids, etc.[164]
Part of determining if there is an association between a drug and a side effect is the
classification of the side effect. If the side effect is related to the pharmacological
properties of the drug, the role and function of the metabolizing enzymes can be
investigated on a genetic level. Out et al. (2014) differentiated between type A- and type
B-side effects. Criteria for type-A side effects include:[165]

1. A clear temporal relation between starting the drugs and the appearance of
side effects.
2. A rechallenge test.
3. The side effect is often identified in major drugs studies before registration
and is noted in the product information.
4. The frequency is relatively high (>1%).

For a side effect to be considered a type-B, four different indicators were proposed:

1. Temporal relation is more uncertain.
2. The frequency is low.
3. The side effect is noted after the drug became available.
4. The side effect cannot be reproduced in other patients.
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Aggression and violence fit the criteria for Type-A side effects. The temporal relation
has been established in studies and in individual case histories, and the same applies to
the rechallenge test.[107, 125] That those side effects were known before registration is clear
from the in-house reports, and they are noted in the product through a Black Box
warning.[72, 90] The frequency approaches 1% and is probably underestimated.[59]
Decreased metabolism of a drug, or an increased production of toxic metabolites can
cause the occurrence of type-A side effects. Out et al. acknowledged the possibility of
genetic factors influencing the rate of metabolism of drugs. [165]
It has been suggested before that, when psychoactive medication is used, genetic
factors could play a role in the occurrence of side effects.[77, 79, 94, 134, 137, 166] Garrod
hypothesized in 1931 that biochemical differences between individuals could cause
unpredicted reactions to drugs, but it was not until 1959 that the term “pharmacogenetics”
was proposed.[167] Hall noticed in 1981 that “true” paradoxical reactions appeared abruptly
or gradually in patients in whom such reactions were not to be expected and that were out
of character. He hypothesized that they were brought about by some unknown
biochemical interaction between the medication and the human body.[75] DeSwarte (1986)
explained unpredictable adverse drug reactions to genetic differences which became
noticeable after administration of a specific medication.[168] A study investigating the
potency of benzodiazepine was done on a couple of healthy, male identical twins. On
three consecutive tests, one twin received midazolam 2 times 5 mg, 12 mg, and 10 mg of
diazepam intravenously, which resulted in restlessness with an identical movement
pattern of his arms on all three occasions. His brother reacted with the same movements
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on 5 mg midazolam.[129] The authors, Short et al. (1987), posed the question of a genetic
phenomenon.
Interest in pharmacogenetics increased when it became evident that there were
genetic variation in the metabolism of debrisoquine, an antihypertensive drug, and that
the liver enzyme cytochrome 2D6 (CYP2D6) was involved.[167] By the beginning of the
1990s, the importance of the cytochrome P450 (CYP450) enzymes in the oxidation of
medication was well established.[169] Especially CYP2D6 was increasingly studied and
mapped for polymorphisms and their effect on the metabolic rate of drugs. The saturation
of CYP2D6 at therapeutic dose by certain drugs like imipramine, as well as the inhibition
of the function of CYP2D6 by other drugs (drug-drug interactions), were reported by
Brosen (1990).[169]
At the turn of the century, many more polymorphisms for CYP450 genes had been
discovered, and the population can now be screened for several metabolic types, see
Table 1.6, which can serve as a guideline with regards to the effect of a metabolic type on
the medication prescribed.[170]
Lane (1998) connected drug-induced akathisia and extrapyramidal symptoms (EPS)
with “possibly” deficient CYP450 status. He noted a link between reduced CYP450
enzyme function, SSRIs and EPS. He mentioned that the dopamine neuronal response
may be affected by reduced CYP2D6 activity. He stipulated that it was not clear what the
role of CYP2D6 in the brain is.[79] Research by Armstrong (1997), and Andreassen (1997)
indicated that both poor and intermediate metabolizers at CYP2D6 may be prone to
antipsychotic drug-induced movement disorders, including tardive dyskinesia.[171, 172]
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Table 1.6: Metabolic Activity by Metabolic Type (Mayo, 2005)
Metabolic
Type

Active Therapeutic Agent
Parent Drug
Metabolite
• Normal metabolism
• Normal metabolism
• Optimal therapeutic
• Optimal therapeutic
EM
benefit at normal drug
benefit at normal drug
dosages
dosages
• Decreased drug
• Decreased drug
metabolism
metabolism, may result in
inadequate transformation
• Vulnerable to metabolic
of parent drug into active
inhibition due to drug
metabolite
IM
interactions and other factors
• May experience
• Susceptible to toxic
reduced therapeutic benefit
accumulation of parent drug
at normal drug dosages
and side effects at normal
drug dosages
• Limited or no drug
• Severely deficient or
metabolism
completely unable to
transform parent drug into
• Parent drug often
active metabolite
PM
accumulates to toxic levels
• Little or no therapeutic
• At high risk for serious
effect
adverse drug events at
normal drug dosages
• Rapid drug metabolism
• Conversion of parent
drug to metabolite occurs
• Circulating level of
much more quickly than
parent drug rapidly
normal
decreased below therapeutic
threshold
• The circulating
UM
metabolite is rapidly
• Little or no therapeutic
increased, often well above
benefit at normal drug
therapeutic levels
dosages
• Toxicity and side
effects may develop at
normal drug dosages
EM: Extensive-, IM: Intermediate-, PM: Poor-, UM: Ultra-Rapid Metabolizer

Given the chances and the severity of the side effects of psychoactive medication, it
could be of great importance if there were some way of predicting which patients are at
risk of adverse drug events. Enzymes, produced through the cytochrome P450 system,
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metabolize most psychoactive medication. Certain allelic variants for CYP450 genes
cause deviation in the rate at which these medications are metabolized. Most of these
alternate alleles produce enzymes with reduced metabolic capability, although some are
(super)fast metabolizers. Therefore, variant alleles can lead to toxic levels and adverse
drug reactions or subtherapeutic levels and non-treatment responses.
Piatkov et al. (2009) compared the number of P450 polymorphisms in a general
population to akathisia patients and illicit drug users in Australia. They reported a
significantly higher frequency of multiple reduced or loss of function alleles in akathisia
subjects and illegal drug users compared with the sample of Western Sydney clinical
patients.[173] In 2011, Lucire and Crotty followed up on the research of Piatkov by
publishing their paper on akathisia-related homicides associated with CYP450 genes
generating enzymes with reduced or loss of function.[174] In 2017, Eikelenboom et al.
published a paper with three, probably medication-induced, homicides in which drugdrug and drug-drug-gene interactions were investigated. The decreased metabolism of the
psychoactive medication prescribed to these subjects were the likely cause of the
catastrophic events.[135]
If, through further research, it can be substantiated that CYP450 testing can provide
information about the risk of aggression and violence when taking prescribed
psychoactive medication, such testing has the possibility of limiting the occurrence of
these side effects. The goal of the research outlined here is to investigate whether there is
an association between the use of psychoactive prescription medication and certain P450

106

variant alleles on the one hand and acts of violence, both directed inward (e.g., suicide)
and outward (e.g., homicide) on the other.

Disclaimer: This chapter is intended as a review of literature and information
pertaining to the topics of drug/medication and their usage, drug/medication side effects,
and the pharmaceutical industry. As such, this review contains facts and information from
peer reviewed publications as well as opinions and interpretations, some of which were
gleaned from non-peer reviewed sources. The views/opinions contained herein are not
necessarily the views of the author of this chapter.
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Chapter Two: CYP450, History and Current Role in Drug Metabolism

In the Beginning
Cytochrome P450 (CYP450) genes, presumably go back to before life, as we know it,
existed on earth. Supposedly, at least three and a half billion years ago, an ancestral P450
gene was involved in metabolizing substances like nitrogen in fermentation pathways of
bacteria. This happened under anaerobic conditions.[175, 176] It is likely that after the earth
atmosphere developed aerobic conditions, cytochrome P450s protected the first life forms
from oxygen toxicity.
Evolution occurs by several genetic processes. Gene duplication is a likely cause of
diversity among a species.[175] When a gene is duplicated, it provides raw genetic material
which can be used to create new functional genes.[177] During this process, DNA can, for
instance, be reshuffled, DNA chains can be spliced at inappropriate places, there can be
unequal crossing over, and genes can be shared. This might enable a species to adapt to a
changing environment. The first wave of genetic changes, dated around one and a half
billion years ago, probably lead to the CYP450s that contributed to a stable cell
membrane in eukaryote cells. They supposedly regulated the biosynthesis and
degradations of substances inside the organisms. As they diversified and began to work
with more substances, CYP450s engaged in using foreign chemicals as an energy source.
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This occurred around nine hundred million years ago. After about another 500 million
years, CYP450s had evolved into proteins that were able to protect organisms from
toxicity by metabolizing xenobiotics, substances that entered an organism from the
outside world.[175, 178] The CYP450 family expanded further, and the evolution of plant
CYP450s seemed to be connected to the development of animal CYP450s. One
evolutionary pathway aimed at keeping herbivores from eating them by developing
poisonous substances, the other in developing CYP450s able to metabolize these
dangerous products.[175] From there, it was a relatively small step to the CYP450s we
know today.
In the 1940s, cell biologists who were working on techniques to extract functional
cells from liver tissue, discovered a subcellular fraction and called it “microsomes.”[179] It
contained fragmented vesicles of the endoplasmic reticulum. In 1955, proteins containing
pigmentation that rendered them a certain chrome (from the Greek “chrómio”) or color,
were studied. Klingenberg (1955) discovered a carbon monoxide-binding pigment in
microsomes.[179] With the pigment reduced and bound to carbon monoxide, and if light
were passed though the solution, it produced a spectral absorbance peak at a wavelength
of 450 nm, hence the name P450, with P standing for pigment. Omura proposed the term
“cytochrome P450”, a colored pigment in a cell, in 1962.[179, 180] Basically, the name is
incorrect. True cytochromes are heme-containing electron transporters, essential for the
oxidative metabolism to generate adenosine triphosphate (ATP). Although CYP450s
transport electrons as well, they are enzymes, mainly involved in the oxidative
degeneration of substrates like drugs and xenobiotics.[180]
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Padmanabhhan (2014) describes the process of oxidative degeneration:[181]

1. Substrate binds to the enzyme, near to the heme iron in the ferric form.
2. Substrate binding displaces water from the heme iron.
3. The heme is reduced to its ferrous form via an electron transferred from
another enzyme, CYP450 reductase.
4. Oxygen binds to the heme iron.
5. A second electron is transferred to the bound oxygen.
6. An unstable peroxy intermediate forms.
7. A water molecule is released, generating compound I, which is a reactive iron
oxo (or ferryl) radical that extracts a proton and electron from the substrate.
8. An iron hydroxide complex is formed (known as compound II).
9. Compound II rapidly recombines with the substrate, yielding the hydroxylated
product.

After fully cycling through the oxidative reaction, there is a net input of one oxygen
molecule, one substrate molecule, two protons and two electrons resulting in the net
release of a hydroxylated product and one water molecule, see Figure 2.1.
In the decades after the discovery of the first CYP450, dozens more enzymes
involved in the metabolism of endogenous and xenobiotic substrates were identified.
Today, that is still an ongoing process. To match these developments, the Committee on
Standardized Nomenclature of P450 Genes was formed in 1987. A flexible system was
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put in place based on the degree to which genes had similar amino acid sequences and
evolutionary kinship.[182] It started with eight mammalian gene families and five
subfamilies. Today, 57 functional genes and about 58 pseudogenes have been identified
in humans, divided into 18 families and 44 subfamilies.[183] The general term CYP is used
to indicate a gene coding for and involved in the production of CYP450s enzymes. The
CYP450 family name is designated by an Arabic number, the subfamily with a letter, and
the individual gene with another Arabic number, as are the alleles (mostly two), preceded
by a * [star], see Figure 2.2. Both the gene and the enzyme it generates have the same
name, but the gene has an Italic font.

Figure 2.1: The Cytochrome P450 Catalytic Cycle (Taken from Ghosh, 2016)

The Human Cytochrome P450 (CYP) Allele Nomenclature Database, formerly hosted
at http://www.cypalleles.ki.se/, has been relocated to the “Pharmacogene Variation
Consortium”.[184]
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Figure 2.2: Nomenclature CYP450

Drug Metabolism
The CYP450 enzymes play important roles in human metabolism: detoxification of
foreign chemicals (families 1-3), and participating in endogenous functions like the
metabolism of sterols, steroids fatty acids and bile acids (families 4-51).[185] The focus of
this chapter will be on the families 1, 2, and 3, as about a dozen enzymes in these families
are the ones taking care of expelling the majority of drugs.[183]

There are three phases in drug metabolism:
1. Phase I aims to modify the substrate (the medication in question) in such a way
that it become available for enzymes from phase II. CYP450s react with a
substrate by introducing a functional group, e.g., -OH, -COOH, -SH, -O-, or NH-,
into the substrate (“oxidation”), which then can be used by phase II enzymes for
binding. Phase I products are more water-soluble, and therefore more excretable.
What is needed for this reaction are a P450 enzyme, oxygen, nicotinamide
dinucleotide phosphate (NADPH), and, for the redox reaction, a flavoprotein
called NADPH-CYP450 reductase, see above under step 3.[181, 186] In the majority
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of the cases, this reaction deactivates the drug, although some prodrugs need this
step to be converted into the pharmacological active component.[164, 187]
2. In phase II, the product from phase I is bound (conjugated) to another - not P450 enzyme. These transferases enzymes increase the water-solubility significantly,
which facilitate the excretion in the bile and/or urine, which lead to further
detoxification.[181, 188]
3. In phase III, the metabolites are excreted from the cells to the gut lumen by
transporters, P-glycoprotein (P-gp), which can be divided in uptake and efflux
transporters.[186, 188]

These three phases determine the effects of a drug in the body, whether it is the
therapeutic response or the probability of side effects. Genetic variants of these enzymes
and transporters can have an effect on the functionality of these substances, and hence the
clinical outcome.[186] The most important drug metabolizing enzymes are CYP1A2
(8.9%), CYP2B6 (7.2%), CYP2C8 (4.7%), CYP2C9 (12.8%), CYP2C19 (6.8%),
CYP2D6 (20%) and CYP3A4/5 (30.2%). These add up to about 90% of phase I
metabolism of clinically used drugs.[181, 183, 185] Other authors estimate the contribution of
these CYP450s to be around 75% of total drug metabolism.[187]
CYP450s are found in all organs and tissues, mostly in the cell’s endoplasmic
reticulum and sometimes in the mitochondria. Regarding drug metabolism, the liver and
the intestines are the most important organs: the liver because of the contribution in
metabolism, the gut due to the sheer quantity of CYP3A4.[164, 181] However, in some
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organs beside the liver and the intestine, specific CYPs have a higher degree of
expression. Research by Nishimura (2003) and Preisner (2013) found a heterogeneous
distribution of CYPs in several organs. Expression levels in specific organs are indicated
relative to the mean expression in all organs. In the kidneys, a four-fold increase in
CYP2B6 was detected, a five-fold increase of CYP2C8 in the lungs and in the stomach,
while a two-fold lower expression was noted for CYP2C9 and CYP2D6 in the spleen.
CYP1A2, CYP2C19 and CYP2D6 have a high expression in the pituitary gland, while
the highest expression of CYP2C9 is located in the cerebellum.[187, 189]

CYP450 Families 1 to 3
CYP1A2:
This enzyme is almost exclusively found in the liver. It makes up from 6% to 15% of
the total major CYP450s. It is involved in the metabolism of around 4% to 40% of
commonly prescribed drugs. Per individual, the amount of expression can vary up to 40
fold.[164, 190] The number of single nucleotide polymorphisms (SNPs) for CYP1A2 is 41,
with five additional SNPs where the haplotype has not yet been established.[164, 184] The
enzyme can be induced, leading to increased metabolism of its substrate, by consuming
cabbage, char-grilled meats and grapefruit juice. Vegetables like carrots and celery have
the opposite effect. They inhibit CYP1A2 enzyme activity. Cigarette smoking is a strong
inducer of CYP1A2. Research showed decreased levels of olanzapine and clozapine in
people that smoke. It might be advisable to decrease dosage of CYP1A2 substrates in
people that quit smoking but increase the dose in people that start smoking.[190] Substrates
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for CYP1A2 are acetaminophen, caffeine, clozapine, olanzapine, clomipramine,
duloxetine and imipramine.[164, 190]
CYP2B6:
CYP2B6 has been detected in the liver, the lungs, the kidneys and the intestines. It
has been rather underestimated in the past because it was thought to be of little
importance in humans.[190] Its part in the CYP450 system is between 1% and 10%, with a
contribution of around 7% in drug metabolism.[183] It is highly polymorphic, with 63 SNPs
and six additional SNPs, yet to be determined.[164] Inter-individual expression can vary 20
to 250 fold.[181] Anticonvulsants are among the inducers of CYP2B6, while inhibitors
include some selective serotonin reuptake inhibitors (SSRIs) e.g., paroxetine and
sertraline. The list of substrates for this enzyme is growing and includes the
antidepressant bupropion, ketamine and methadone.[190]
CYP2C8:
Sites of expression of CYP2C8 are the liver, lungs, stomach, kidney, adrenal gland,
brain, uterus, mammary gland, ovary, duodenum and cardiovascular tissue.[164] CYP2C8
makes up about 7% of total CYP450s in the liver and metabolizes approximately 5% of
prescription medication. The PharmVar website notes 14 allelic variants, with no
outstanding SNPs. The amount of inter-individual expression varies from two to nine
fold.[181] Inducers are rifampicin and barbiturates. Paroxetine is an inhibitor of
CYP2C8.[191] All-trans retinoic acid (Tretinoin, used against acne), is a substrate for
CYP2C8.[164, 191] Montelukast and ibuprofen are both inhibitors and substrates.[164]
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CYP2C9:
CYP2C9 is primarily expressed in the liver, but in minor amounts. It is also expressed
in kidney, adrenal gland, testes, prostate, ovaries and duodenum.[192] It contributes to
about 20% in liver CYP450s. It is responsible for the metabolization of approximately
15% of commonly prescribed drugs. At the moment, 65 alleles have been registered, with
8 SNPs not yet classified.[164] The amount of individual expression varies from three to 27
fold.[181] Inhibitors of CYP2C9 are the SSRIs fluoxetine, fluvoxamine and sertraline, with
fluoxetine and sertraline also being substrates.[190, 192] Amiodarone is an inhibitor, and
inhibition can last for weeks after the medication is stopped. Barbiturates are both
substrates and inducers. Other substrates are several non-steroidal, anti-inflammatory
drugs (NSAIDs) and anticonvulsants.[190, 192]
CYP2C19:
This enzyme is only expressed in the liver, and accounts for less than 5% of total
CYP450s.[164] It’s contribution to drug metabolism is between 5% and 13%.[181] At least 48
SNPs have been identified, with 20 variants not yet haplotyped.[164] Inter-individual
expression can vary up to 21 to 28 fold.[181] Inhibitors include fluoxetine, fluvoxamine,
moclobemide, paroxetine, and several anticonvulsants. Inducers are phenobarbital, and
St. John’s wort.[192] Substrates are several antidepressants, barbiturates and
benzodiazepine.[193] Of special interest is omeprazole, which simultaneously acts as a
substrate, inhibitor and inducer.[191]
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CYP2D6:
CYP2D6 is almost exclusively expressed in the liver, with low levels of expression in
the lungs and the intestinal wall.[164, 190] It’s contribution to total body CYP450 is between
2% to 5%, while it metabolizes between 15% to 25% of drugs.[181, 190] It is the most
researched enzyme, with at least 165 allelic variants.[164] However, almost 90% of
genotypes are caused by five variants.[190] Inter-individual expression can vary up to 1000
fold.[181] Among the inhibitors are several antidepressants, antipsychotics, MDMA,
bupropion, goldenseal and quinidine. There are no inducers on record for CYP2D6,
which is quite uncommon for a CYP450.[190] There are many substances metabolized by
this enzyme, which include the “old” tricyclic and the “new” SSRIs antidepressants.
Antipsychotics and the opioid analgesics are also substrates, as are cardiovascular drugs
like metoprolol.[193]
CYP3A4 and CYP3A5:
CYP3A4 and CYP3A5 are significantly homologous in their sequences (85%).[164, 181]
CYP3A4 enzyme makes up about 25 to 30% of liver P450s, and, in the small intestine,
this is even higher. It is also expressed in the lungs, stomach, colon and weakly in the
adrenal gland. In addition to these tissues, CYP3A5 is identified in in the prostate and
pituitary.[164] CYP3A5 represents only 2% of liver CYP450s.[181] CYP3A5 is expressed
significantly in the bowel. Consequently, CYP3A4/5 play a major role in the first part or
presystemic metabolism of orally administered drugs. Any substrate of CYP3A4/5 taken
by mouth will be reduced in availability significantly before it will reach the intestinal
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absorptive cells (enterocytes), after which the hepatocytes will reduces the
bioavailability even more.[190]
CYP3A4 is responsible for an estimated 50% to 70% of drug metabolism.[190] It is
considered the “workhorse” and the “backup system” for the CYP450 family. When other
CYP450s are unable to fulfil their metabolic duties, CY3A4 tends to take over as much as
possible.[190, 193] Currently, 43 alleles have been identified for CYP3A4, with four
additional SNPs waiting for designation. For CYP3A5, these numbers are respectively 26
and six.[164] Inter-individual expression for CYP3A4 can vary between four to 400 fold,
but, for CYP3A5, this number is not reported. CYP3A4/5 share almost identical substrate
specificity, but differ somewhat in their metabolic rate.[181] There is a long list of
inhibitors, inducers and substrates. Inhibitors include some SSRIs, antipsychotics,
antibiotics, and grapefruit juice. Inducers are anticonvulsants, protease inhibitors and St.
John’s worth. Among the substrates are antidepressants like the SSRIs, tricyclic
antidepressants, antipsychotics, benzodiazepines, opioids, anticonvulsants, antihistamines
and many other prescription medications.[190, 193] Figure 2.3 shows the number of variants
alleles per CYP450.
Ji et.al. (2016) examined 5 genes (CYP2C9, CYP2C19, CYP2D6, SLCO1B1, and
VKORC1) in 1013 subjects for the percentage of patients with variant alleles which have
metabolic consequences, see Figure 2.4. SLCO1B1 is solute carrier organic anion
transporter family member 1B1, which is involved in metabolizing simvastatin and
VKORC1 is vitamin K oxide reductase complex, which is involved in metabolizing
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blood-clotting medication. Of the subjects, 99% had at least one variant and 3% had
variant alleles in all 5 genes.

Figure 2.3: The Number of Variant Alleles per CYP450

Figure 2.4: Percentage of Patients with Variant Alleles which have Metabolic
Consequences (Taken from Ji, 2016)
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Genotyping versus Phenotyping
By performing CYP450 genetic testing, the general population can be divided into
poor, intermediate, or extensive (normal or “wild-type”) metabolizers, see Table 2.1.[185]
There is an additional category of (ultra)-rapid metabolizers for individuals who possess
the variant CYP2C19*17, or the CYP2D6*53 allele associated with increased activity[185,
194]

; individuals who have a duplication of functional CYP2D6 genes; and individuals who

smoke and carry the CYP1A2*1F allele.[195, 196]
The designation of the phenotypes “extensive, intermediate and poor” is somewhat
misleading. “Extensive” is considered the normal, the most frequently found in the
population, so it should be called “normal”. “Intermediate” metabolizers have at least one
defective allele which produces no enzyme, or two partially defective alleles, producing
small quantities or enzymes with reduced metabolic capability. They should be called
“poor” metabolizers. The “poor” metabolizers are, in fact, “non-metabolizers”. Some
authors have introduced a fifth category, the rapid metabolizers, individuals with one
active and one increased active allele.[197]
The impact of the genotype on the phenotype can be estimated by using a probe drug,
whose metabolism is dependent on just one CYP450. By measuring the unchanged drug
and its metabolite, the metabolic ratio can be established. Sparteine, an antiarrhythmic
drug, is solely metabolized by CYP2D6. Figure 2.5 shows the urinary metabolic ratio
(MRs) in a German population (n=308) in relation to the genotype.[183] Ultrarapid
metabolizers have at least one extra allele and are able to metabolize sparteine at an
increased rate, resulting in a low metabolic ratio (about 0.1). Poor metabolizers on the
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other hand have two null alleles, and are hardly able to metabolize sparteine, resulting in
a high metabolic ratio (about 100). Intermediate metabolizers, with one defective allele or
two partially defective alleles, have a metabolic ratio between one and 10. Extensive
metabolizers, with two functional alleles, reach a metabolic rate between 0.1 and one.
Table 2.1: Drug Metabolizing P450 Phenotypes and P450 Variant Alleles (Taken from
Ingelman-Sundberg, 2010)
Phenotype

Genetic basis

(Ultra-)rapid
metabolizer
(UM)

More than 2 active
gene copies on the
same allele, or
increased
expression of a
single gene

Extensive
metabolizer
(EM)

2 functional alleles

Intermediate
metabolizer
(IM)

Poor
metabolizer
(PM)

1 defective allele
or 2 partially
defective alleles

2 defective alleles

Clinical
consequences

Examples of alleles
causing the phenotype

Lack of response of
the parent drug
Increased adverse
drug reactions
(ADRs) due to
increased metabolite
or active drug
production

Ordinary response

Increased
concentration of
parent drug
Decreased
metabolite
formation
Higher levels of the
parent drug
Increased risk for
ADRs
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CYP2C19*17
CYP2D6*1/*2 x N
(gene duplication /
multi-duplication)

CYP2C9*1
CYP2C19*1
CYP2D6*1

CYP2C9*2
CYP2D6*10
CYP2D6*41

CYP2C9*3
CYP2C19*2
CYP2C19*3
CYP2D6*4
CYP2D6*5

From Figure 2.5, it becomes clear that, for sparteine, most people are extensive
metabolizers. Table 2.2 shows the results of a study by Hocum et al., published in 2016,
regarding the prevalence of phenotypes among more than 22,000 individuals, tested for
genotypes.[196] For CYP2D6, almost half of the population possessed a phenotype that
could have repercussions on the rate of metabolism of certain medications. For CYP2C9,
that was almost 35%; for CYP2C19, over 50%; and for CYP3A4/5, about 34%. Poor
metabolizers at CYP3A5 are designated nonexpressers and have two inactive genes.
As guidelines for medication dosage are based on the metabolic rate of an extensive
metabolizer, prescribers should be aware of the fact that a significant number of patients
do not fall into that category.

Figure 2.5: Urinary Metabolic Ratio (MRs) for Sparteine in a German Population (n=308)
in Relation to the Genotype (Taken from Zanger, 2013)
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Table 2.2: Frequency Distribution of Tested Phenotypes (Taken from Hocum, 2016)
CYP Isozyme and Phenotype
CYP2C9 (n = 22,649)
Normal metabolizer
Intermediate metabolizer
Poor metabolizer
CYP2C19 (n = 22,725)
Normal metabolizer
Ultrarapid metabolizer
Intermediate metabolizer

Prevalence (%)
67.5
29.1
3.4
42.1
29.5
25.8

Poor metabolizer
CYP2D6 (n = 22,225)
Normal metabolizer
Intermediate metabolizer
Poor metabolizer
Ultrarapid metabolizer
CYP3A4 (n = 14,615)
Normal metabolizer
Intermediate metabolizer
CYP3A5 (n = 14,596)
Nonexpresser
Intermediate expresser
Expresser

2.6
52.8
37.7
6.8
2.7
92.4
7.6
72.3
20.5
7.2

CYP450 and Ethnicity
The metabolic rate of xenobiotics varies with race/ethnicity. In the research group of
Hocum et al. (2016), results per CYP450 weren’t differentiated by ancestral background.
Their population included 68.7% Caucasians, 18% Hispanics, 11.4% African-Americans,
1.5% Asians and 0.4% Ashkenazi Jews.[196]
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Zou (2009) compared numbers for CYP2D6 phenotypes inside and outside the USA,
that were differentiated by racial background.[198] Compared to the numbers for poor
metabolizers (PM) in the population of Hocum et al. (6.8%), Africans have a frequency
up to 19%, see Table 2.3. For ultrarapid metabolizers (UM) the number for Hocum et al.
is 2.7%, Zou reports significantly higher numbers for Mediterranean, Black Ethiopians,
and Saudi Arabians. Intermediate metabolizers (IM) make up 37.7% in the Hocum study,
while the percentage for this phenotype with Zou is much lower for Caucasians, and a
much higher number of Asians have one *10 allele. According to Kircheiner (2004), the
allele frequency for heterozygote carriers of the *10 allele in Asians is about 50%, while
the poor metabolizer type is only rarely found in this population (<1%).[199]
The fact that ethnicity is a factor in an individual’s genotype is an important clinical
consideration. According to Muroi (2014), a study by Kiyotani et al. showed, that women
with a CYP2D6*1/*10 genotype had a 4-fold higher rate of recurrence of breast cancer
after adjuvant tamoxifen therapy compared to women with a CYP2D6*1/*1 genotype.
For women with a CYP2D6*10/*10 genotype, the recurrence rate was almost 17-fold
higher.[200] Tamoxifen is a prodrug and needs to be metabolize into an active component.
In women with a CYP2D6*10 allele, the dose needs to be increased. Another example is
the need for lower doses of antipsychotics in Asian IM patients compared with Caucasian
EMs, as these drugs are extensively metabolized by CYP2D6.[199] When prescribing
tamoxifen or antipsychotics to Asian patients physicians should consider the fact that up
to more than half this population is an IM for CYP2D6.
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Table 2.3: Frequency Distribution of CYP2D6 Phenotypes (Compiled from Zou,
2009)
CYP2D6
Phenotypes

Demography

Percentage

CYP2D6 PM

Caucasians
Asians
Indians
Africans
African-Americans
Hispanics

8 - 10%
0 – 1.2%
1.8 – 4.8%
0 – 19%
1.9 – 7.3%
2.2 – 6.6%

CYP2D6 UM

European Whites
American Caucasian
American Blacks
Mediterranean
Black Ethiopians
Saudi Arabians

0.8 – 3.6%
4.3%
4.9%
7 – 10%
16%
20%

CYP2D6 IM

Caucasians
Asians

2%
35 - 55%

Polymorphisms at the Allele Level
Table 2.4 is a compilation of information from papers by Zanger et al. (2013) and
Preisner et al. (2013).[183, 187] It describes the effect of polymorphisms at the allele level
and the frequencies. Polymorphisms vary in their influence on metabolism. In case of
smoking, the *1F allele for CYP1A2 leads to a higher inducibility of the allele, more
enzyme will be produced, and metabolism of its substrate will increase. The effects of a
*1C allele will be the opposite. Increased or decreased activity leads to an enzyme
metabolizing its substrate faster or respectively slower than compared to a wild type
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allele. Decreased expression (e.g., *22 on CYP3A4) results in less enzyme being
transcribed/translated and hence less enzyme available to metabolize the substrate. If an
enzyme becomes unstable due to a polymorphism (e.g., CYP2D6*10), it means it cannot
retain its structural conformation and will be less effective in metabolizing its substrate.
Certain variant alleles can change the active site where a substrate is supposed to bind,
causing an altered substrate specificity (e.g., CYP2C9*3 and CYP2D6*17).[201] A null
allele (e.g., CYP2D6*3) will not produce any enzyme at all, turning individuals with 2
alleles per definition into poor metabolizers. On the other hand, if transcription is
increased as in CYP2C19*17 or if there is gene copy number variance as in CYP2D6, the
amount of enzyme available will be increased. An increased value for the maximum
metabolizing rate (Vmax) can occur at CYP2B6*7, leading to a higher metabolism
compared to the wild type.[202]
Figure 2.6 is a summary of the most important factors that influence seven CYP450s
in their activity to metabolize a substrate. Apart from variant alleles, sex and age also
determine the activity of an enzyme. Inflammation can cause a downregulation of
expression, as well as influence the activity of some CYP450s.[203] Liver disease
accompanied by cholestasis also affects expression, especially for CYP1A2.[204]
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Table 2.4: Frequency Distribution of Alleles and the Resulting Enzyme Effects
(Taken from Zanger, 2013, and Preisner, 2013)
Cytochrome
CYP1A2

CYP2B6

CYP2C8

Allele

Asian
(%)

*1F
*1C
*1D
*5
*2
*4
*6
*7
*22
*18
*2
*3
*4
*2

CYP2D6

CYP3A4

CYP3A5

*41
*Nxn
*17
*18
*2
*22
*3C
*3K /
*10
*6

16.0

1

33-43

18.0
2.04
20 -25
4.1
1.3
1.0
2.0
8.0

6-7

7.5

8.0
28-56

0.0

2.0
17.0
2.7

0.0

81.3
2.0

Enzyme effect
higher inducibility
decreased inducibility
increased activity
reduced enzyme expression
increased activity
1.66-fold higher activity
decreased expression
increased values for Vmax
increased expression
reduced enzyme expression
decreased activity
decreased activity
decreased activity
poor metabolizer

19.0 *1/*2
1.6 *2/*2
1.8 *2/*3
9.0

*3
*2
*3
*17
*3
*4
*5
*6
*7
*9
*10
*17

African
(%)

4.82
14.0
5.3
5.0
25.0
3.0
3.0

CYP2C9

CYP2C19

Caucasian
(%)
33.3

poor metabolizer / altered
substrate specificity
poor metabolizer / null allele
poor metabolizer / null allele
increased transcriptional activity
poor metabolizer / null allele
poor metabolizer / null allele
no enzyme / null allele
nonfunctional / null allele
poor metabolizer
poor metabolizer
decrease / unstable enzyme
decreased expression and activity
/ altered substrate specificity
decreased expression and activity
increased transcriptional activity
decrease activity
increased activity
decreased activity
decreased expression and activity
express insignificant levels
very low activity
none
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Figure 2.6: Percentage of Prescribed Medication per CYP450 involved. Major Influences
Are Printed in Bold. Upward Arrows: Increased Activity, Downward Arrows: Decreased
Activity. Controversial Influences Are in Parentheses (Figure adapted from Zanger,
2013)

Inhibition
Drug-gene interactions occur when a variant allele for a CYP450 gene influences the
rate of the metabolism of a designated substrate. This was described previously. Alleles
with a decreased function can lead to less active enzymes and thus accumulation of a
substrate. Another mechanism that can cause the accumulation of drugs is inhibition.
Biochemical inhibition is related to enzymatic activity and can be either competitive,
noncompetitive and/or reversible or irreversible.
Competitive inhibition (see Figure 2.7), occurs when the substrate (drug) and the
inhibitor are very similar in structure and have similar affinities for the same place, i.e.,
the CYP450 active site. Many drugs can be competitive with one CYP450, while they are
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non-competitive with others. If the inhibitor is present in low concentrations, increasing
the amount of the substrate can overcome the inhibitory effects.[205]

Figure 2.7: Competitive Inhibition (Taken from Ahern et al., 2018)

In non-competitive inhibition (see Figure 2.8), the inhibitor and substrate do not
compete for the same active site. There is another site involved, called the allosteric site,
which is distant from the active site. If the inhibitor binds, the active site is changed, and
the substrate is less likely to bind. Increasing the amount of the substrate has no effect on
the chances of the substrate to binding to the enzyme.[205]

Figure 2.8: Noncompetitive Inhibition (Taken from Ahern et al., 2018)

Uncompetitive inhibition (see Figure 2.9), is an unusual form of inhibition, where the
inhibitor binds after the enzyme/substrate complex has been formed, e.g., in reactions
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where there are two or more substrates available. This complex cannot release the
product as long as the inhibitor is bound.[205]

Figure 2.9: Uncompetitive Inhibition (Taken from Ahern et al., 2018)

Mechanism-based inhibition is a form of irreversible inhibition, also called suicide
inhibition. It basically follows the same steps as a competitive inhibitor, but the substrate
occupies the site for an extensive period of time and can react chemically with the
enzyme in such a way, that it cannot be removed. It basically destroys the active site.[205]
There are three moments in the catalytic cycle of P450s where inhibition can occur:
(1) when a substrate binds to the protein, (2) when oxygen binds after the first electron
transfer, and (3) the catalytic step in which the substrate is actually oxidized.[164]
Substrates that interfere in the catalytic cycle while a substrate binds to the protein (1)
are, in general, reversible competitive, or noncompetitive inhibitors. Those that act during
or after the oxygen transfer step (2 and 3) form mostly irreversible (“dead-end”)
complexes with the enzyme and are the mechanism-based (or suicide) inactivators.[164] In
general, inhibition is not the root cause of the toxicity, not even when the enzyme
involved is destroyed. The toxicity arises when the accumulation of the substrate causes
dangerous side effects.[206]
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Drug-Drug Interactions
Other mechanisms that can interfere with drug metabolism are drug-drug interactions,
which are divided into seven basic patterns.[190, 191, 193]

Pattern 1: Inhibitor-substrate interaction
When an inhibitor is added to a substrate, this will likely result in an increase in
substrate levels and a prolonged stay in the body, compared to monotherapy. This
will increase the chances of side effects and toxicity.
Example: paroxetine is added to nortriptyline. Nortriptyline is a CYP2D6
substrate, and paroxetine is a CYP2D6 inhibitor. Paroxetine reduces the
metabolism of nortriptyline, leading to increased blood levels.
Pattern 2: Inducer-substrate interaction
Presence of an inducer will increase the metabolism of the substrate, leading to
lower blood levels than anticipated. This leads to loss of efficacy of the substrate.
In case of prodrugs, an increased turnover could lead to accumulation of a toxic
metabolite.
Example: carbamazepine is added to haloperidol. Carbamazepine induces
CYP3A4, which has haloperidol as a substrate. This leads to a more efficient
metabolism of haloperidol, which decreases the blood level. On the other hand,
aripiprazole is a prodrug, metabolized by CYP3A4 into the active metabolite
dehydro-aripiprazole. Carbamazepine induces CYP3A4, which results in an
increase in dehydro-aripiprazole and higher blood levels of this metabolite.
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Pattern 3: Substrate-substrate interaction
If two or more substrates are combined, inhibition due to competition can occur.
The drugs will stay longer in the body compared to a situation in which these they
were administered separately.
Example: paroxetine and quetiapine are combined. They both are metabolized by
CYP2D6. Levels of both drugs might increase.
Pattern 4: Inducer-inducer interaction
When two substrates induce the same CYP450 that metabolizes them, their rate of
metabolism is increased leading to decreased efficacy. In case of prodrugs, the
concern is toxicity.
Example: carbamazepine and ritonavir are administered simultaneously. They
both are metabolized by CYP3A4, which they both induce, leading to lower blood
levels than anticipated.
Pattern 5: Inhibitor-inhibitor interaction
When two substrates inhibit the same CYP450 that metabolizes them, their rate of
metabolism is decreased, leading to increased chances of side effects.
Example: paroxetine and ranitidine are administered simultaneously. They both
are metabolized by CYP2D6, which they both inhibit, leading to higher blood
levels than anticipated.
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Pattern 6: Reversal of inhibition
When an inhibitor and a substrate have been combined and the inhibitor is
discontinued, the enzyme will resume the normal, higher rate of metabolism, due
to more enzyme being available leading to a decrease of substrate blood levels.
Example 1: paroxetine is added to nortriptyline. Nortriptyline is a CYP2D6
substrate and paroxetine is a CYP2D6 inhibitor. When paroxetine is stopped,
CYP2D6 will metabolize nortriptyline at its normal rate, leading to decreased
blood levels. In the case of a prodrug another scenario applies. When a CYP450
inhibits the metabolism of a prodrug while being combined with another
substrate, the parent drug accumulates in the body as long as the two are
combined. When the inhibition is ended, the prodrug will be metabolized at a
normal rate, but due to the accumulation this could lead to overdose and toxicity.
Example 2: sertraline is combined with tramadol. Tramadol is a prodrug that is
metabolized by CYP2D6 and CYP3A4, which it inhibits as well. Sertraline is
metabolized by the same CYPs, which it also inhibits. When combined over a
period of time, the tramadol accumulates. If the sertraline is stopped, the
inhibition of the metabolism of tramadol will cease, leading to a significant
increase in the active metabolite desmetramadol, which is a potent opioid. This
can lead to serious side effects e.g., death by overdose.
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Pattern 7: Reversal of induction
When an inducer and a substrate have been combined and the inducer is
discontinued, the enzyme will resume the normal, lower rate of metabolism due to
less available enzyme, leading to an increase of substrate blood levels.
Example: a smoker uses clozapine. Smoking induces CYP1A2, for which
clozapine is a substrate. If this person stops smoking, so is the induction of
CYP1A2, leading to less available enzyme, a slower metabolism of clozapine and
higher blood levels, increasing chances of side effects.

Drug-Drug and Drug-Drug-Gene Interactions
Drug-drug interactions (DDI) can become more pronounced if there are variant
alleles involved, leading to drug-drug interactions superimposed on drug-gene
interactions (DDGI). Figures 2.10 - 2.13 illustrate the interactions that occur in the case
of several drugs combined with variant alleles.[197] In Figure 2.10, there is a steady state
between the amount of drug taken and the amount being metabolized.[197]
Comedication (the purple triangle), acts as an inhibitor, leading to a drug-drug
interaction (DDI), and increasing exposure to the substrate (Figure 2.11).
If alleles for a CYP450 gene are null or have a reduced function, the enzyme will not
work properly, leading to a drug-gene interaction (DGI) and exposure to the substrate
increases, see Figure 2.12. Although the mechanism is different, the effect of a DDI is
comparable to that in case of a DGI.[197]
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Figure 2.10: Normal Drug Metabolism and Exposure (Taken from Verbeurgt, 2014)

Figure 2.11: Increased Exposure Due to an Inhibitor (DDI) (Taken from Verbeurgt,
2014)
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Figure 2.12: Increased Exposure Due to a Loss-of-Function Allele (DGI) (Taken from
Verbeurgt, 2014)

A drug-drug interaction superimposed on a drug-gene interaction (DDGI) will lead to
severely increased exposure to the substrate, as is visible in Figure 2.13.

Figure 2.13: Severely Increased Exposure Due to a DDI in Combination with a DGI
(Taken from Verbeurgt, 2014)
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Verbeurgt et al. (2014) analyzed data from 1143 patients regarding DDIs, DGIs and
DDGIs. They were genotyped for CYP2D6, CYP2C19 and CYP2C9. The medication
these subjects used was known. The number of drugs patients were prescribed ranged
from one to 44. The mean number was 8.4 (± 5.7) with a median of seven drugs. Of these
patients, 31% had a DDI, 12% had a DGI, and in 12% DDGIs were identified. Nearly
half of the cases showed a potentially significant interaction. The authors emphasize that
moderate interactions can have clinically severe consequences. The medication most
involved in major interactions were b1-receptor blockers, e.g., metoprolol,
antidepressants, antiplatelets, opioid analgesics, and anti-inflammatory agents.[197] The
Verbeurgt study only tested three CYPs. It is to be expected that, with increased testing
of other CYP450s, e.g., CYP1A2, CYP2B6, CYP2C8, and CYP3A4, increasing number of
DDIs, DGIs and DDGIs will be detected.

The Importance of CYP450 Testing
An adverse drug event (ADE), is defined as an untoward clinical event caused by a
drug, and an adverse drug reaction (ADR) is an ADE at a normal drug dose. ADRs are a
major medical concern. Lazarou et al. (1998) performed a meta-analysis of 39
prospective studies performed in the United States, covering ADRs reported over a 32year period. They estimated the number of ADRs in hospital patients in 1994 alone at
4,986,000 (95% CI: 3,976,000 - 5,995,000) of which 106,000 (95% CI: 76,000 2,711,000) were fatal.[207]
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Many ADRs are caused by DDIs (see the previous paragraph). There are two
categories: pharmacodynamic DDIs and pharmacokinetic DDIs. Pharmacodynamic
interactions occur when one drug influences another drug’s effects on the body. This can
be an increased effect, a counter effect or a synergistic effect. Pharmacokinetic DDIs
occur when one drug modulates the absorption, distribution, metabolism or excretion of
the other drug. This affects the concentration of one drug or both. CYP450 enzymes
regulate the biotransformation of drugs, hence they can be a major cause of
pharmacokinetic DDIs.[197] DDIs and DGIs are similar in their effect on metabolism. In
studies with the platelet-aggregation inhibitor cilostazol for instance, poor metabolizers
for CYP2C19 (DGI) have the same drug titer as subjects who also received omeprazole,
which is a CYP2C19 inhibitor (DDI).[208, 209] DGIs and DDIs that occur via these
pathways can have such clinical consequences that changes in dosing or alternative drugs
are necessary.[210]
In 2013, Conrado et al. investigated how often clinically important DDIs and their
comparable DGIs, known from the literature, were mentioned in the FDA approved
product information labels available for prescribing physicians. They selected inhibitors
for CYP2C9, CYP2D6 and CYP2C19. Over 30% of DDI described in the literature were
not mentioned in the labels.[210] Of the 45 drugs which had known DDIs, analogous DGIs
were not mentioned in 27% of the labels. Dose recommendations were only provided in
24% for PMs. There were no recommendations for IMs at all. In Table 2.5, two examples
are taken from the study by Conrado et al. It shows the limitation with regards to the
information in the product labels. Haloperidol is a CYP2D6 substrate with a DDI when
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co-administered with paroxetine. In the product label, the DDI is mentioned, but it lacks
information on the management of the interactions, nor does it recognize the obvious
DGI.[210] The same applies to tamoxifen, where neither the DDI or the DGI are noted.
CYP450 testing is not regularly done, so any information regarding DGIs is not
available for those patients. Medication can be metabolized by different CYPs, which
means that DDIs can vary and be anticipated, contrary to DGIs. Recommendations for
DGIs are not necessarily the same as those for DDI’s, because DDIs can be prevented by
using alternative medications or dose adaptations. That would not be a solution in cases
of DGIs for which the genotype of the patient must be known.[210]

Table 2.5: DDIs and DGIs Between CYP2D6, Haloperidol and Tamoxifen with
Paroxetine, Literature and FDA Label (Taken from Conrado, 2013)

To get an indication about how well genetic testing can identify subjects with a slow
or fast metabolism, Lötsch et al. (2009) compared CYP2D6 genotyping with CYP2D6
phenotyping in 57 healthy Caucasians on a single oral dose of either 30 mg
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dextromethorphan hydrobromide or 50 mg codeine, which is a prodrug. The subjects
(7/8) who metabolized codeine into morphine at a slow rate and were more likely to have
a reduced response to the analgesic effects of codeine, were identified correctly by both
CYP2D6 genotyping or CYP2D6 phenotyping. However, the subjects with a high
turnover of codeine, and hence at risk for opioid toxicity, were only identified in 50% of
the cases as carriers of gene duplication by CYP2D6 genotyping and 5/8 (62.5%) of the
subjects were identified as phenotypically ultrarapid metabolizers. That number increased
to 7/8 when CYP2D6 genotyping and CYP2D6 phenotyping were combined.[211] Slow
metabolizers for codeine can easily be detected by either genotyping or phenotyping, the
ultrarapids need both. However, there can be concerns on how reliable the information is
when determined by one probe drug with regards to another drug. Can that information
just be extrapolated? Metabolic activity is substrate dependent with a variability in the
degree of activity from one substrate to another (substrate selectivity).[212] This
emphasizes the need for combining genotyping with phenotyping.
The majority of psychiatric drugs are metabolized by highly polymorphic CYP450s.
According to Preisner et al. (2013), over 4,000 psychiatric patients were genotyped for
CYP2D6 and CYP2C19 in three state hospitals in Kentucky. The results indicated the
importance of personalized medicine given that more than one in ten patients would not
respond to a standard dose and were at risk for developing unwarranted toxicity.[187] It is
assumed that CYP2D6 poor metabolizers have less tolerance for drugs like
antidepressants and antipsychotics. In addition to lower dosage of these medications,
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titrating the amount based on the patients response, could be of benefit for those patients
identified as slow or fast metabolizers.[210]
Not only patients who are poor metabolizers run the risk of ADRs. Intermediate
metabolizers may also encounter problems in metabolizing certain substrates and
contribute to ADRs that could have been prevented had their genotype been known.[210, 213]
Subjects with one reduced- or loss-of- function allele might have significantly slower
metabolism as well and be sensitive to substrates for those CYPs. These patients run the
risk of increased drug concentrations above the normal therapeutic doses, with the risks
of serious adverse events.[210]

Phenoconversion
When prescribing medication, both the possibilities of DDI and DGI need to be taken
into account. However, genotyping has what Shah called “an Achilles’ heel”:
phenoconversion.[214] When an individual has a PM genotype, it is highly likely that this
person also has a PM phenotype. Yet, a non-PM genotype does imply a non-PM
phenotype.[212] This is where phenoconversion comes in. It is distinct from a DDI or a
DGI. It occurs when a DGI or DDI slows down metabolism of an EM or an IM to such a
degree that the person follows the metabolic rate of a poor metabolizer.[197, 214, 215] The
extent of this phenomenon depends on the potency of the inhibitor. This will continue for
as long as this co-medication is taken or as long as a drug has an inhibiting effect, which
can persist for weeks after it is stopped.[190] Inflammatory diseases, HIV-infection, cancer
and liver disease can also cause phenoconversion.[212]
141

Preskorn et al. (2013) studied 865 patients on venlafaxine for phenoconversion for
CYP2D6, defined as a desmethylvenlafaxine to venlafaxine ratio smaller than one.[215]
Venlafaxine is both substrate and inhibitor of CYP2D6, which metabolized venlafaxine
into desmethylvenlafaxine. The ratio of desmethylvenlafaxine to venlafaxine provides an
indication of the phenotype. They compared patients using concomitant CYP2D6
substrates or inhibitors with those who did not. If patients did not use other medication
beside venlafaxine and their phenotype changed from EM into PM, this would be solely
due to the inhibiting effect of venlafaxine. In this group, from the 548 genotypic
extensive metabolizers, 77 (14%) converted to a poor metabolizer type. None of the
genotypic ultrarapid metabolizers seroconverted. From the 200 extensive metabolizers
who used co-medication, 82 (41%) changed from EM into PM. From the 10 genotypic
ultrarapid metabolizers, 1 (10%) phenoconverted. The 210 patients who phenoconverted
used a mean number of co-medications of 4.04 compared to the 690 nonconverters, who
used an average of 2.71 co-medications. If these patients had been genotyped and the
polypharmacy had not been taken into account, genotyping would have given an incorrect
indication with respect to the metabolic capacity of CYP2D6 in almost half the
population of extensive metabolizers.

Complicating Factors in Determining Phenotype
1. Many studies that investigate the relation between a drug and a metabolizing
enzyme are restricted to one gene and do not take other genes into account.[212]
This produces a skewed analysis of the complex interactions between the
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enzymes and the substrate. Many drugs for instance are metabolized by
different CYP450 enzymes.
2. Inter-individual expression of the CYP450 genes can vary up to a 1000fold.[181]
3. In addition to CYP450 genes, other genetic factors have an effect on drug
response, like variations in receptor or transporter genes.[212]
4. The metabolic activity of an enzyme can vary with the different substrates.[200]
CYP2D6*17 is considered an allele with a decreased function.[184] Yet, the
enzymes in patients with this genotype show different activities with regard to
substrates like dextromethorphan, risperidone, codeine and haloperidol.[212]
CYP2D6*2 is designated to encode an EM.[184] Muroi et al. (2014) performed
an in vitro study of 49 CYP2D6 variants and the drug tamoxifen. The
metabolic activity varied among the different alleles. CYP2D6*2, in
particular, showed the pattern of an IM instead of an EM, and the authors
proposed a reclassification for this genotype for tamoxifen.[200]
5. In addition to substrate selectivity, there is the phenomenon of altered
sensitivity to inhibition which is drug specific. This has been shown for
CYP2C9*1 and CYP2C9*3 by a multitude of inhibitors and five substrate
probes. The difference in inhibition was not only noted between the two
isoforms, but also between the different substrate probes.[212]
6. CYP450 enzymes are promiscuous. Many are able to bind with several
substrates or catalyze reactions for substrates other than their primary one.[216,
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This behavior of certain P450s should be considered, as they lead to

diversion from major pathways to minor pathways, especially in the case of
DDIs, combined with reduced or loss-of-function polymorphisms.
7. No inducers for CYP2D6 have been recorded.[190] However, a study by Ryu et
al. (2016) showed that pregnancy enhanced the metabolism of metoprolol in
IMs and EMs, compared to three months postpartum. That induction of
CYP2D6 is a possibility is further substantiated by an increase of the
metabolism of CYP2D6 substrates like clonidine, dextromethorphan,
fluoxetine, and nortriptyline during pregnancy.[218] An increase in CYP2D6
activity during pregnancy may be clinically relevant for mother and child.
8. The heterogeneity in activity of drug metabolizing enzymes in different
organs, such as that reported for CYP2D6 in the liver and the brain, is another
complicating factor in determining a phenotype.[187, 212]

Epigenetics
A new area of research that tries to explain the inter-individual variation of gene
expression, is the field of epigenetics. Gene expression within an individual can vary over
time, and monozygotic twins can have different phenotypes.[186] Epigenetics tries to
explain these differences, as it studies changes in gene expression that are not due to
changes in the DNA sequences.
Gene expression is influenced by DNA methylation, histone modification, and
through noncoding RNAs.
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1. DNA methylation involves adding a methyl group to the DNA molecule. It
silences the DNA to RNA transcription, which will lead to a decrease in the
gene expression.
2. Histone modifications play a role in the regulation of gene expression in two
ways.
a. Histone H3 acetylation is associated with increasing transcription.
b. Histone deacetylation can lead to repression of transcription.
c.

Short strands of noncoding RNAs called microRNAs (miRNAs), may
silence gene expression posttranscriptionally.[219, 220]

It is not clear how these epigenetic modifications come about. Because they are so
widely involved in gene regulation, the hypothesis is that epigenetics is an executor rather
than an initiator. As Peng describes it: “epigenetic modifications are the “code”, but there
must be “pens” that write down the “code” and “writers” that hold the “pens.”[186] These
modifications are not proactive, but responsive. In general, epigenetic regulations are a
response to changes of environment, diet, physiological or pathological conditions.
Studying how epigenetic modifications influence drug-metabolizing enzymes could
increase the understanding of drug-drug interactions.[186]

Conclusions
At the end of the day, the wide variations in drug metabolism, be it response or the
development of toxicity and side effects, are only partially caused by genetic factors. As
far as phenotyping goes, about 10% to 30% is due to genetic polymorphisms of the drug145

metabolizing enzymes.[186, 219] Genotyping is a powerful tool to determine the metabolic
rate, but there are complicating issues, e.g., substrate specificity, promiscuity,
unreliability of the probe used for phenotesting, phenoconversion, heterogeneity of
CYP450 enzyme activity in different organs, and altered sensitivity to inhibition. A single
genotype can only partially explain the observed variability in drug metabolism. Other
genetic factors that affect drug response or increase the chances of toxicity, for example
transporter and receptor status or HLA-mediated immune effects, will not be caught by
CYP genotyping or phenotyping.
Determining the metabolic rate is not an exact science. It creates a false sense of
security to extrapolate from studies to individual patients. The metabolic rate of a P450 is
easier to estimate in vitro than it is in vivo. We can acquire an indication of how certain
CYP450s will behave and how they will interact with substrates, inducers and inhibitors,
but we cannot quantify how fast that rate will actually be in a living patient. There are
cases where drug use has serious consequences. It may carry the risk for insufficient
response or toxicity, especially when drugs with a narrow therapeutic window are
involved. In those cases, the best way to estimate the possible metabolic rate is by
combining genotyping, phenotyping, and therapeutic drug monitoring, in addition to
carefully observing and listening to the patient.
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Chapter Three: The Relevance of Cytochrome P450 Polymorphism in Forensic
Medicine and Akathisia-related Violence and Suicide

Introduction
Many drugs that cross the blood-brain barrier and a quarter of the medicines in
general use are metabolized by the highly polymorphic cytochrome P450 system.[221]
Blood levels of prescribed medicines can be pushed towards toxicity because of
genetically determined metabolizing capacity, high doses, and interactions with coprescribed CYP450 inhibitors and synergies. Genetics of the cytochrome P450 (CYP450)
system are the otherwise invisible factor that can correlate with catastrophic behavioral
disturbances. A forensic investigation combined with medication history, reports from
observers, clinical records and a blood sample or a non-invasive swab from the living or
dead can help elucidate the proximate, pharmacogenetic cause of death, suicide or
violence. This determination can absolve persons charged with homicide (or abort the
investigation), affect insurance pay-outs for suicide, provide an defense of involuntary
intoxication for the perpetrator of violence, and should protect a living person from
getting more drugs with the same metabolic pathways as those that caused the problem.
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Medication-Induced Akathisia Violence, Suicide and Homicide
That antidepressants cause some people to commit suicide has been known since the
advent of the tricyclic antidepressants in the late 1950s.[222] In the early 1980s, Shear
(1983), then Schulte (1985) described cases of violence, homicide and suicide associated
with akathisia, (from the Greek “akathízein” for "can’t sit down"), in some people taking
antipsychotic medications.[52, 96] Since the late 1980s, “new generation” antidepressants
have been prescribed for stressful life situations, but their adverse effects and clinical trial
data and have not been fully disclosed.[125] Akathisia is a dangerous adverse effect of
antidepressants, antipsychotics and some other drugs that cross the blood-brain barrier.
Unlike delusion-driven homicide and depression-driven suicide, akathisia-related
violence and suicidality can abate when medication is decreased, changed or slowly or
abruptly stopped. Suicidality and violence tend to get worse if the dose is not tapered
slowly. In 1990, Teicher reported on cases of new and persistent suicidality on fluoxetine,
the first of a series of serotonin-boosting antidepressants, marketed as “new generation
antidepressants” SSRIs and SNRIs.[130] These new drugs carry a relative risk of suicide
and akathisia violence several times that of older tri- or tetracyclic antidepressants,
known as TCAs.[223] In 2003, Healy accessed company archives on court orders, inspected
the clinical trials presented for their licensing, as well as epidemiological and follow-up
studies, all containing evidence of SSRI-induced suicide.[131] This research contributed to
the document: “United States Food and Drug Administration (FDA) Public Health
Advisory: Worsening Depression and Suicidality in Patients Being Treated With
Antidepressant” (March 22, 2004).[72] This text was mandated into product information
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for all antidepressants and further warned health care providers and caregivers to monitor
daily for anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity,
akathisia (severe restlessness), hypomania, and mania in persons treated for psychiatric
and non-psychiatric conditions with antidepressants.[72] Fergusson et al. (2005) found
suicide rates were double to treble those on placebo in 183 antidepressant trials.[106] After
reviewing 373 antidepressant clinical trials on information provided by the drug
companies, the FDA conceded however that they did cause suicide. In that review, the
FDA relied on the drug companies’ own information and also persisted with the systemic
error they made before Healy’s review of early trials: FDA reviewers continued to code
suicides that occurred in the run in-washout period and in withdrawal as “placebo
suicides”. In 2006, Stone et al. found that more suicides had occurred in some of these
trials and had not been reported at all and that half of them had been incorrectly coded as
occurring on placebo.[224] In 2007, a Black Box suicide warning about increased
suicidality (the highest form of alert) was extended to persons up to the age of 24.[225]
Hostility is called “aggression” and “homicidal ideation” in some labels. “Emotional
lability” is used when a subject is withdrawn from a trial because of suicidal ideation.
RxISK.org manages a website documenting over 6,000 press reports of massacres,
homicides, suicides, school and college shootings, which date back to 1966, involving
both old and new antidepressants and stimulants prescribed for attention deficit
hyperactivity disorder. Some legal defenses are described.[226] Recent findings show a
significant association between SSRIs and violent crime for individuals 15-24 years
old.[227] Acute neuroleptic- (and SSRI-) induced akathisia (code 333.99) appeared in 1994
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in the Diagnostic and Statistical Manual of Mental Disorders of the American Psychiatric
Association (DSM IV) along with its fluctuating associated features: restlessness, suicide
attempts, aggression, symptoms of toxic psychosis and behavioral dyscontrol.[138] DSM-5
(2013) has acknowledged acute and tardive medication-induced akathisia, but the
constellation of catastrophic associated features no longer appears, nor does withdrawal
akathisia nor delayed post-withdrawal akathisia.[139] Restlessness, aggression in thought
and deed, suicidality, death wish, behavioral dyscontrol, confusion, delirium, cognitive
impairment, changing variable moods and presentations can be manifestations of
neurotoxicity.
Documents obtained in 1986 in a product liability suit against Eli Lilly revealed that
the FDA had repeatedly warned that fluoxetine has a stimulant profile similar to
amphetamines.[45] In 1998, Roger Lane (from Pfizer’s laboratories) confirmed that
antidepressant manufacturers were aware that SSRI-induced akathisia and suicide cases
were related, inter alia, to cytochrome P450 metabolizer status, as well as drug-drug
interactions, slowing metabolism and prolonging half-life.[79] In 2003, Breggin reported
patients taking SSRIs who deteriorated into mania, agitated depression and violence.[64]
Before the FDA’s concession, general causation of suicide and homicide by
antidepressants had been established in a series of Daubert Hearings in American
courts.[228] Expert evidence was compliant with Rule 702 of the Federal Rules of
Evidence. Healy suggested it was automatism: “…a transient, non-recurrent mental
malfunction caused by an external factor, whether physical or psychological, that the
mind of an ordinary person would be unlikely to have withstood and that produces an
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incapacity to control his or her acts.”[229] Automatism refers to behavior consequent on
chemical lobotomy disrupting the connection between the frontal lobe and motor
behavior.
Moore et al. (2010) studied 1,527 cases of violence reported for 31 drugs. They
concluded, “Acts of violence towards others were a genuine and serious adverse drug
event associated with a relatively small group of drugs.”[43] Varenicline, a drug for
smoking cessation, was followed by antidepressants, with fluoxetine and paroxetine
having the highest ranking. Violence associated with venlafaxine and desvenlafaxine, a
drug and its first metabolite, make that pair the most implicated in violence, which can
manifest as suicide and/or in others, as homicide. In the drugs companies’ own trials
presented for their licensing, “new generation” or “atypical” antipsychotics were found to
carry double the risk of suicide on antidepressants.[230]

Drug Metabolizing Enzymes of the Cytochrome P450 Family
The cytochrome P450 family of enzymes metabolizes up to 80 per cent of xenobiotics
and most drugs used in psychiatry.[201] Medicines interact with the cytochrome P450
system as substrates, inducers, inhibitors or any combination of the three.[183] Metabolism
is affected by extrinsic factors, doses, and co-prescribed medications as well as intrinsic
factors: nutrition, age, iron status, liver health, gender and comorbidity.[231]
The human population can be broadly divided by DNA testing into extensive, (those
being normal or “wild-type”), intermediate, and poor metabolizers for five major genes
involved in drug metabolism: CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4.
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There is an additional category of ultra-rapid metabolizers (UM) for CYP1A2, for
CYP2C19 due to the *17 allele, and for CYP2D6 due to gene duplication of alleles that
code for extensive metabolizing. DNA testing can be done from blood or buccal swab.
Changes in the sequence of amino acids in the genes result in variant alleles that produce
drug-metabolizing enzymes (DMEs) that differ in metabolic ability. Poor metabolizers
(PMs) tend to have adverse drug reactions quickly, but intermediate metabolizers (IMs)
in whom there is a slower and unrecognized build-up of a drug or its metabolites are also
at risk. Ultra-rapid metabolizers (UMs) for CYP2D6 have been found to be at increased
risk of death by suicide and intoxication, particularly if taking prodrugs, e.g., opioids,
which need CYP2D6 to convert them into the effective analgesic, e.g., morphine.[232, 233]
With ultra-rapid metabolizers, levels of some antidepressants with short half-lives may
fluctuate in the blood over a single day with intolerable effects and may never reach
therapeutic levels. Fast metabolism poses a greater risk on withdrawal. Fast-changing
levels of psychotropic substances, up or down, can cause behavioral changes, as the
neurotransmitters in the brain react to reach some equilibrium. This phenomenon makes
starting and stopping medication the most dangerous times for suicide and violence, but
both can happen at any time, with stress, provocation, dose change, addition or
subtraction of a medication. These toxic responses to antidepressants may occur early or
later in treatment.
DNA testing can provide forensic examiners with a tool to investigate death caused
by medication.[207] In 2000, forensic pharmacogenetics was first used to explain the death
of a nine-year-old child treated with a combination of methylphenidate, codeine and
152

fluoxetine where the medical examiner reported fluoxetine toxicity. Finding that the child
was defective in CYP2D6 capability aborted a homicide investigation of the parents by
explaining the toxic level.[234] Lucire and Crotty (2011), reported ten akathisia homicides
(and some attempts) committed by people taking antidepressants, not for mental illness,
but for distress caused by their predicaments. These individuals also had diminishing
mutations in the CYP450 family of metabolizing enzymes and all were taking medicines
that further decreased metabolism by inhibition.[174]
DNA testing can be used to predict and avoid adverse drug reactions. The forensic
perspective involves working backwards from the event, explaining the adverse drug
reaction by reference to the subject’s genotype and the effects of co-prescribed
medications. In this paper, the clinical history, medication regime and genotypes of three
persons who committed homicide, has been documented. It is proposed that the three case
studies are instances of antidepressant-induced, akathisia-related homicide where
diminishing mutations in CYP450-encoding genes contributed to toxicity, along with
high doses, substantial drug burden, drug-drug interactions, drug-gene and drug-druggene-interactions, inhaler and alcohol use.

Materials and Methods
The subjects were interviewed, and medical files were studied to ascertain if mental
illness was evident before medication was given and to establish reasons for prescribing
or changing medications. Reports of events were evaluated and medication in use was
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correlated with what the subjects were thinking and feeling before and during the
homicides. University of Denver’s Institutional Review Board approval #910661.
Genetic testing was performed for CYP450 genes that metabolize the drugs in use:
CYP2D6, CYP2C9, CYP2C19 and, when available, for CYP1A2, CYP3A4 and CYP2B6.
DNA sampling was done by buccal swap. DNA isolation was performed by Independent
Forensic Services in Hulshorst, The Netherlands, using the QIAamp Investigator Kit
(Qiagen). Cytochrome P450 genotyping was performed by the Erasmus University
Medical Center, Rotterdam, The Netherlands. For CYP1A2, CYP2B6, CYP2C9,
CYP2C19 and CYP3A4/A5 by using the TaqManÒ Drug Metabolism Genotyping Assays
(ThermoFisher Scientific) and PCR-RFLP. Genotyping of CYP2D6 was performed using
AmpliChip Test (Roche Molecular Diagnostics), which is specific for CYP2D6 variants.
Information on CYP450 alleles, drug-gene, and drug-drug interactions was obtained from
online databases: PharmVar Consortium and Database,[184] The Transformer
Database,[237,238] and PharmGKB.[235]

Subject 1, USA
A 39-year-old woman, with no prior history of mental illness, suicidality or violence
had a difficult marriage and was prescribed zolpidem 10 mg at night for insomnia and
alprazolam for fear of flying. A year later, she had divorced, moved to a new house, a
parent had died, and she felt overwhelmed. Sertraline, 50 mg per day, was superimposed
on long-term zolpidem use. Her mental state deteriorated. She said she had no emotions
and felt like a “zombie.” She was switched to venlafaxine 150 mg per day. Throughout
154

her treatment, she had been restless and had slept only with zolpidem, waking after few
hours in an agitated state. At some point, she began believing that killing her husband and
herself was the right thing to do for her children. She stopped venlafaxine abruptly and,
on the following day, she ambushed her husband with a baseball bat, then stabbed him
many times. Intent on committing suicide, she overdosed on zolpidem, alprazolam and
alcohol, but survived and was charged with murder. Consulting the Transformer website,
the metabolic pathways of the drugs in use were collected, see Table 3.1.[191] Her P450
genotypes for the relevant enzymes are presented in Table 3.2.

Table 3.1: Drugs and Metabolic Pathways Used by Subject 1 (Data from Transformer)
CYP1A2 CYP2B6 CYP2D6 CYP2C9 CYP2C19 CYP3A4
zolpidem

Sub Inh

sertraline

Sub

Inh Sub

Sub Inh

Sub

Sub

Inh Sub

Sub Inh

Sub Inh

Sub Inh

Sub Inh

Inh

Sub Inh

Sub

Sub

Sub Inh

venlafaxine
desvenlafaxine
Sub: Substrate; Inh: Inhibitor

Sub

Discussion
Her genotypes, CYP2D6*5/*41, CYP2C9*1/*1 CYP2C19*2/*17 and CYP3A4*1/*22,
characterize her as a metabolizer with diminished capacity involving five out of eight
alleles tested across four genes (Table 3.2). The effect of long-term zolpidem would be to
further inhibit CYP1A2, CYP2D6, and CYP2C9, which would likely have increased her
blood levels of zolpidem, a drug associated with homicidal behavior, both on its own and
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in conjunction with SSRIs.[236] The addition of sertraline to zolpidem, i.e., adding a
substrate to an inhibitor (pattern 2 described by Armstrong et al.) would likely have
provoked an adverse drug reaction, emotional numbing and worsening depression.[237] She
would have had very little metabolizing capacity left for zolpidem and venlafaxine. Both
have similar, synergistic neurotoxic effects, and this may be as significant clinically as
the interaction. Venlafaxine is primarily metabolized by CYP2D6 and CYP3A4, and its
psychoactive metabolite, desvenlafaxine, is a substrate of CYP3A4. Some databases
suggest that CYP2C19 or CYP2D6 may play a part in metabolizing desvenlafaxine, but
this information remains uncertain.[191, 235]
In this person, the activity of CYP2D6, a high-affinity but low-capacity enzyme,
would have been greatly reduced, compromised by a diminished activity allele, *41, and
a gene deletion, *5. CYP3A4 was also genetically compromised. Its enzymatic activity
would have been further diminished due to inhibition by long-term sertraline use and
substrate competition (between desvenlafaxine, sertraline, and zolpidem). The reduction
of metabolic capacity for venlafaxine would be expected to prolong its half-life, likely
taking the level over the therapeutic window and into a level that was toxic for that
person, with possible input from variants in the genetics of transporters and receptors.
While CYP2C9 and CYP2C19 are said to play a minor role in the metabolism of
sertraline and zolpidem, all enzymes can be promiscuous and facilitate metabolism, albeit
less effectively, under those conditions.[214] Substrate competition for enzymes by all three
drugs made further demands on limited enzymatic capacity: CYP2C9 being inhibited by
both zolpidem and sertraline and CYP2C19 being inhibited by sertraline. Increasing
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toxicity could have resulted in delirium, making her simultaneously euphoric and
homicidal. Possibly experiencing drug toxicity, she stopped venlafaxine without tapering,
and the rapid fall in blood level coincided with her behavior. A similar case has been
described, involving imaginary altruism that caused a loving father in a paroxetineinduced state of euphoria combined with homicidal ideation to kill his child.[174]

Table 3.2: Genotypes and Expected Phenotypes for Subject 1
Genotype

In Vitro
Activity

CYP2D6*5/*41

*5 gene
deletion
*41
diminished

CYP3A4*1/*22

*1 normal
*22
diminished

CYP2C9*1/*1

normal

CYP2C19*2/*17

*2 inactive
*17
ultrarapid

Gene-Drug, Drug-Gene
and Drug-Drug Interactions
venlafaxine is both a substrate
and inhibitor of CYP2D6, which
is genetically compromised
desvenlafaxine, sertraline, and
zolpidem are substrates of
CYP3A4 and compete for the
enzyme, which is inhibited by
both sertraline and venlafaxine
zolpidem, sertraline, and
venlafaxine are substrates of
CYP2C9 and compete for the
enzyme, which is inhibited by
venlafaxine
zolpidem, sertraline, and
venlafaxine are substrates of
CYP2C19 and compete for the
enzyme, which is inhibited by
sertraline

Phenotype
further
diminished
activity,
possibly no
activity
further
diminished
activity by
inhibition and
competition
further
diminished
activity by
inhibition and
competition
further
diminished
activity by
inhibition and
competition

Based on the pharmacogenetic analysis, poor drug metabolism and drug-drug-gene
interactions could have caused a CYP450-based adverse drug reaction resulting in a
medication-induced homicide. Zolpidem inhibits its own metabolism as well as the
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metabolism of venlafaxine and sertraline, which, in turn, inhibit the metabolism of
zolpidem.[191] Adverse effects of venlafaxine include abnormal thinking,
abnormal/changed behavior, aggressive reaction, akathisia, amnesia, apathy, confusion,
delusions, dementia, depersonalization, emotional lability, euphoria, hallucinations,
hostility, homicidal ideation, illusion, impulse control difficulties, manic reaction,
paranoid reaction, psychosis, depression and illusion, suicidal ideation and attempt,
psychotic and worsening depression.[238] Adverse effects listed for zolpidem are
synergistic and include confusion, euphoria, insomnia, agitation, anxiety, decreased
cognition, difficulty concentrating, dysarthria, emotional lability, hallucination, illusion,
nervousness, speech disorder, abnormal thinking, aggressive reaction, delusion, dementia,
depersonalization, dysphasia, feeing strange, intoxicated feeling, manic reaction,
personality disorder and suicide attempts.[239]
Subject 1 took a plea bargain for second-degree murder and received a lengthy prison
sentence. The pharmacogenetic evidence was brought up during the sentence appeal. A
drug-screen for venlafaxine had been performed, but five days after her last dose. The
coroner’s laboratory, apparently unaware that drugs are not detectable after five halflives, reported that the absence of venlafaxine in her blood meant that she never used it.

Subject 2, Holland
A 33-year old woman with marriage problems became depressed and preoccupied
with death but had no delusions or hallucinations. She was hospitalized and treated for
anxiety and depression with sertraline and temazepam, and then quetiapine was added for
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persistent insomnia. On this combination, she experienced severe fatigue, experienced
weird thoughts that she recognized as such, remained gloomy, and failed to recover. She
improved when her husband was hospitalized with a psychiatric breakdown but
deteriorated again when he came home. She reported mood swings and panic attacks.
A year later, she was hospitalized and switched to venlafaxine 150 mg per day, which is
2-4 times the recommended starting dose. A couple of months later, the note, “this patient
does not belong in psychiatric care,” was recorded, and she was discharged. Venlafaxine
was reduced to 75 mg per day, and temazepam and quetiapine were ceased. After nine
months, she stopped venlafaxine without tapering but, two weeks later, she resumed her
prescribed dosage. Her behavior was described as “erratic” and “chaotic.” Without
warning, she suffocated her two-year-old son with a pillow, hanged him using the cord of
her bathrobe, put him in a box, woke her 7-year-old-daughter and told her that they all,
including herself, had to die. She drove a car, along with her daughter, into a canal. Her
daughter escaped and got help. Charged with murder and attempted murder, she had only
patchy recall of these events. Drugs and enzymes for this subject are given in Table 3.3.
A year later, the defense team requested genetic testing for CYP450 (Table 3.4).

Discussion
Her genotypes, CYP2D6*2/*2 and CYP2C19*1/*1 were normal, but CYP2C9*1/*3
and CYP3A4*3/*22 are those of an intermediate metabolizer for both CYP2C9 and
CYP3A4 (Table 3.4). Her toxic problems started with the first prescription of
serotonergic antidepressants, sertraline, temazepam, and then quetiapine (a drug marketed
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as an antidepressant/antimanic/antipsychotic and also as a sleeping pill) for situational
depression.

Table 3.3: Drugs and Metabolic Pathways Used by Subject 2 (Data from Transformer)
CYP1A2 CYP2B6 CYP2D6 CYP2C9 CYP2C19 CYP3A4
sertraline

Sub

Inh Sub

quetiapine

Sub Inh

Sub Inh

Sub Inh

Sub Inh

Sub

Sub

Sub

Sub

Sub

Sub

Sub

Sub Inh

Sub Inh

temazepam

Sub

venlafaxine

Inh

Sub Inh

desvenlafaxine

Sub

Table 3.4: Genotypes and Expected Phenotypes for Subject 2
Genotype
CYP2D6*2/*2
CYP2C9*1/*3
CYP2C19*1/*1

CYP3A4*3/*22

In Vitro
Activity
*2 extensive

Gene-Drug, Drug-Gene
and Drug-Drug
Interactions
venlafaxine is a
substrate of CYP2D6,
which it also inhibits

Phenotype
diminished activity
by inhibition and
competition

*1 active
*3 inactive

venlafaxine is a
substrate of CYP2C9

diminished activity

normal

venlafaxine is a
substrate of CYP2C19

normal activity for
venlafaxine

*3 diminished
*22 diminished

desvenlafaxine and
venlafaxine are
substrates for CYP3A4
which is inhibited by
venlafaxine

further diminished
activity by inhibition
and competition,
possibly no activity

She failed to recover, and her doctor thought she was delusional, but the criterion of a
delusion, a fixed belief impervious to reason, was not met. Again, all three drugs
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interacted, and their listed side effects include abnormal thinking, aggression, akathisia,
amnesia, confusion, delirium, delusions, depression, emotional lability, euphoria,
hallucinations, manic reaction, paranoid reaction, morbid dreams and nightmares,
psychosis, suicidal ideation, attempts and suicide. Over time, sertraline most likely
inhibited and depleted her diminished CYP2C9, and sertraline and quetiapine inhibited
and depleted CYP2D6, leaving her with little or no enzyme capacity to metabolize her
medicines. She developed Adverse Effects of Medication NOS (DSM IV TR and DSM-5
995.2) necessitating hospitalization and medication change. Venlafaxine was introduced,
adding a drug that is both substrate and inhibitor of CYP2D6.
Further inhibition of CYP2D6 by venlafaxine over time would be expected to elevate
its blood levels, resulting in her decision to cease taking it. Sudden withdrawal caused
problems, and this was the reason she restarted it. CYP2D6 is a low-capacity enzyme,
which can be overwhelmed, converting even an extensive metabolizer into a poor
metabolizer. CYP3A4, on the other hand, is a high-capacity, low-affinity enzyme,
notoriously promiscuous and unpredictable, and it picks up metabolism when other
enzymes are not available.41 As with Subject 1, venlafaxine, by inhibiting CYP2D6,
inhibited its own metabolism. CYP3A4 was genetically compromised as well as
inhibited. Her metabolic capability was reduced. A toxicology screen performed on the
day of the homicide showed a toxic range in the blood with a total 2.29 mg/L, combining
venlafaxine: 0.59 mg/L and desvenlafaxine: 1.7 mg/L. The agreed therapeutic range at
that laboratory for the two drugs combined is between 0.2 and 0.75 mg/L, with toxic
effects starting at 1.0 mg/L.
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The phenomenon of dose-dependent inhibition of CYP2D6 increasing with drug
levels in the blood over time applies to other antidepressants. With daily doses, drug
levels may rise. By introducing inhibition of enzymes as well as competition for them,
polypharmacy increases the risk of catastrophic side effects. After Andrea Yates drowned
her six children in a bathtub while taking venlafaxine, mirtazapine and several other
substances, Wyeth, while denying causation, then added homicidal ideation to the list of
adverse effects on the product label for venlafaxine.[240-242]
Substance-induced homicidal ideation is biological and involuntary as are somatic
adverse reactions. When homicidal thinking is associated with mood elevation and
euphoria, it becomes homicidal mania. Involuntary, out-of-character, and uncontrollable
violent thoughts should not be taken as evidence of intent. Akathisia is sometimes
masked by akinesia, fatigue that “ropes you to the bed.” Patients stop taking medicines if
they experience their effects as intolerable, and unknowingly risk withdrawal effects,
which are often more severe. The post-withdrawal period is as dangerous as the initial
period for suicide and homicide.[238, 243-245] The combination of medication, fluctuating
restlessness, suicidality, aggression and toxic hallucinosis are pathognomonic of
akathisia. We cannot find any other diagnosis in any medical taxonomy that combines
suicidal and aggressive thoughts and behaviors with medication, nor any other that
recedes when the culprit medication has been stopped slowly.

162

Subject 3, Holland
A 42-year-old man, with no history of mental illness, suicidality or violence,
discovered that his wife was unfaithful, but they stayed together. He was prescribed
paroxetine 20 mg per day for his distress. He took it sporadically, when he felt that he
needed something for his nerves. Some months later, after drinking alcohol and taking 20
mg of paroxetine, he tried to strangle his wife with the sash of her bathrobe. She hit him,
and he stopped the attack, but he did not remember what he had done. His doctor failed to
recognize this as an akathisia event and added oxazepam 30 mg per day to be taken in
divided doses. Subject 3 gave the oxazepam to a person who also had marital problems,
saying he would take an “extra paroxetine tablet” if he felt depressed. Two weeks later,
he drank a dozen glasses of beer in a bar, took 40 mg of paroxetine and used his asthma
inhaler containing budesonide/formoterol. How long he had used that inhaler and how
many doses he used is not known. According to witnesses, he was neither drunk nor
aggressive when he left. On the way home, he saw the car of his now-estranged wife in
front of the house of his rival, and he called her on his cell phone. When she refused to
talk to him, according to his statement, his “lights went out.” He went home, picked up an
antique revolver and a hammer and returned to the house of his rival. He reported that he
could see them inside on the couch, which was impossible as the blinds were closed. He
then smashed the window with the hammer and climbed through it, cutting himself and
leaving blood. He said that he “felt nothing” and was “like a robot." He shot his wife and
rival, who both survived. He then drove to the house of the rival’s wife, whom he blamed
for coming between himself and his own wife. He forced entry into her house and shot
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her fatally. He reported feeling both hot and cold and shaking violently. He drove for
some hours before turning himself in to the authorities. No toxicology screen was
performed. He was charged with murder and two attempted murders, convicted and
sentenced to 24 years in jail.
On appeal, his lawyer raised the defense that paroxetine had caused this behavior.
Toxicology conducted on dried bloodstains detected paroxetine above the threshold of 10
ng/mL (blood), but the exact level could not be determined. The metabolic pathways of
the drugs in use are presented in Table 3.5. During the appeal, DNA testing for P450
genotypes was performed (Table 3.6).

Table 3.5: Drugs and Metabolic Pathways Used by Subject 3 (Data from Transformer)
CYP1A2

CYP2B6

Alcohol

Sub

Inh

Paroxetine
Budesonide
Formoterol

Inh

Inh

CYP2D6

CYP2C9

CYP2C19

Inh

Inh

Inh Sub

Inh

Inh

Sub

Sub

Sub
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CYP3A4
Ind Sub
Inha
Inh
Sub

Table 3.6: Genotypes and Expected Phenotypes for Subject 3
in Vitro
Activity

Gene-Drug, Drug-Gene
and Drug-Drug
Interactions

CYP2D6*2/*9

*2 active
*9 diminished

paroxetine is a substrate
of CYP2D6 and inhibits it
strongly; formoterol
competes for CYP2D6

CYP2B6*1/*6

*1 active
*6 diminished

paroxetine and alcohol
both inhibit CYP2B6

CYP2C9*1/*1

normal

paroxetine and alcohol
inhibit CYP2C9;
formoterol is a substrate

CYP2C19*6/*17

*6 no activity
*17 ultrarapid

paroxetine and alcohol
inhibit CYP2C9;
formoterol is a substrate

normal

paroxetine inhibits 3A4.
Low levels of alcohol
induce while high levels
inhibit CYP3A4.
Budesonide and alcohol
are substrates for
CYP3A4

Genotype

CYP3A4*1/*1

Phenotype
further
diminished
activity by
inhibition and
competition
further
diminished
activity by
inhibition
further
diminished
activity by
inhibition
further
diminished
activity by
inhibition
further
diminished
activity by
inhibition and
competition

Discussion
His genotypes, CYP2D6*2/*9, CYP2B6*1/*6, CYP2C9*1/*1 CYP2C19*6/*17
and CYP3A4*1/*1, characterize him as an intermediate metabolizer (IM) with diminished
capacity involving four out of ten alleles tested across five genes. Paroxetine is a potent
inhibitor of CYP2D6, and over time, converts 80 per cent of extensive metabolizers into
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poor metabolizers.[246] CYP2D6 was genetically compromised by the diminished activity
allele, *9. Paroxetine also inhibits CYP1A2, CYP2C19 and CYP3A4.
Possible competition between paroxetine and formoterol in his inhaler may slow
the rate at which either is metabolized. According to Jornil et al. (2010), CYP2D6 (high
affinity) and CYP3A4 (low affinity) are most likely the major contributors to paroxetine
metabolism. CYP1A2 could an important factor, whereas the importance of CYP2C19 is
probably limited.[247] Alcohol inhibits CYP2B6, CYP2C9, CYP2C19, and, given the
alcohol content of 12 beers, also CYP3A4. Alcohol is a substrate for CYP1A2. The
competition between paroxetine, alcohol and budesonide for CYP2D6 and CYP3A4 may
have increased toxicity. He was extensively evaluated, and no evidence of personality
disorder, psychiatric illness, aggression or impulsivity was found. Alcohol, on its own,
had not caused violent behavior in this individual before. In 2014, Menkes and
Herxheimer reported on a syndrome of pathological intoxication by alcohol in patients
being treated with SSRI antidepressants.[248] The hot and cold sensations and restless
driving all suggest acute serotonin toxicity and associated akathisia.

Overall Discussion
Three persons committed homicide, two of which intended to commit suicide. None
had been aggressive or mentally ill before getting medication. None had known that they
needed to take medication regularly or how to stop taking it safely. None improved on
medication, and no prescriber recognized their complaints as adverse drug reactions or
was aware of impending danger. Interviews elicited accounts of restlessness, akathisia,
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confusion, delirium, euphoria, extreme anxiety, obsessive preoccupation with aggression,
and incomplete recall of events. Weird impulses to kill were acted on without warning.
On recovery, all recognized their actions to be out of character, and their beliefs and
behaviors horrified them.
All were prescribed interacting medications, and one combined these with alcohol.
The drug-drug interactions further decreased their metabolizing capacity, increasing risk
for adverse drug reactions by prolonging half-life and raising levels. These cases
elucidate the necessary elements of an inquiry after a suicide attempt, a homicide, or a
violent crime. DNA testing can provide evidence for legal proceedings. Cytochrome
P450 genotyping can assist in the interpretation of toxicology.[249] The promise of
personalized medicine is that determination of a person’s metabolizing capacity before
drug treatment or after an adverse event will avoid catastrophic events in the future.
Pharmacogenetics paves the way for personalized justice.[250, 251]

Summary
A forensic investigation of the serious problem of akathisia-related violence requires
several elements: first, blood needs to be taken for a toxicology screen as soon as possible
after the event. Blood left at the crime scene may confirm medication use and sometimes
drug levels, but blood taken late does not exclude toxicity at the relevant time. Second,
pharmacogenetic testing should be performed for (at least) CYP1A2, CYP2C8, CYP2B6,
CYP2C9, CYP2C19, CYP2D6 and CYP3A4. The investigator needs to access reliable
information: the metabolic pathways of drugs in use, their interactions with genes and
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with each other. No one stores this knowledge about 2,000 drugs, so it is accessed
through charts and medical informatics programs. Familiarity with symptoms, signs and
behaviors associated with neuroleptic toxicity is needed to focus the history of experience
and behavior, which can be taken from a perpetrator, a family member, or an observer,
and can be assisted by clinical records. Establishing the behavioral aspects of akathisia,
the fluctuating restlessness, the behavioral toxicity prior to the event supports that
diagnosis. This restlessness is associated with thoughts of death, dying, and killing, and
such thoughts can be acted on without warning. Dysphoria, emotional distress that cannot
easily be articulated, ranges in intensity from mild discomfort to one of the most painful
mental states known to psychiatry, often described as torture - so bad that death is seen as
a welcome relief. An out-of-character unmotivated homicide or suicide by a person
taking medication might be chemically induced and involuntary. The capacity to use
frontal lobe functions and control behavior can be impaired by brain toxicity. A
“chemical lobotomy” could be the outcome.
CYP450 status is an important factor that differentiates those who can tolerate a drug
or combination of drugs from those who might not. Testing for cytochrome P450
identifies those at risk for such adverse drug reactions. As forensic medical and
toxicology professionals become aware of the biological causes of these catastrophic side
effects, they may bring justice to both perpetrators and to victims of akathisia-related
violence. The medicalization of common human distress has resulted in a very large
population getting medication that may do more harm than good by causing suicides,
homicides and the mental states that lead up to them.[123, 156]
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Chapter Four: Psychoactive Medication, Violence and Variant Alleles for
Cytochrome P450 Genes

Introduction
Medication-induced suicidality is well established in suicide epidemiology and
textbooks of psychiatry, contrary to violence and death by homicide caused by
psychoactive medication.[252] Homicide committed while in a state of akathisia (a
condition of severe restlessness associated with thoughts of violence, death and automatic
behavior) caused by adverse drug reaction,[65] is hardly known within the forensic medical
and psychiatric community.
Most psychoactive medication is metabolized by enzymes produced by the
cytochrome P450 family (CYP450 or P450). Certain allelic variants for CYP450 genes
cause deviation in the rate at which prescription medication is metabolized. Most of the
alternate alleles produce enzymes with reduced or no metabolic capability, although some
enzymes metabolize substrates fast to super-fast. Variant alleles can lead to toxic drug
levels and adverse drug reactions in some patients, or to subtherapeutic levels and nontreatment responses in others.[185] By genotyping the polymorphisms at certain P450 loci,
it could be possible to predict if an individual is susceptible for adverse drug reactions.
The goal of the research outlined herein, is to investigate the association between
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psychoactive prescription medication and P450 variant alleles on the one hand, and
violent behavior (assault, suicide, homicide) or an altered emotional state (AES), which is
considered a precursor to violent behavior, on the other.[113]
To do this, individuals who had demonstrated violent behavior (or an AES) were
compared to a control group who had no history of violence. The data obtained for both
groups included genotypes for the CYP450 genes that are involved in drug metabolism.
All prescription medication as well as other drugs that are known to be metabolized by
these enzymes were listed. Statistical comparisons were made between the violent and
nonviolent groups for a wide variety of different parameters in an effort to distinguish the
two groups. Comparisons between the groups were made for age, gender, the number of
variant alleles, the distribution of variant alleles on a per gene basis, the distribution of
P450 phenotypes for specific genes, the number of medications, the number of
antidepressants and other psychoactive medications, the number of drug-gene
interactions, the number of drug-drug interactions, and the number of drug-drug-gene
interactions. Within the violent group, comparisons were also made between the
assault/suicide/homicide subgroup and the altered emotional state subgroup.
This research can influence patient care, forensic science, and the justice system
in several ways. Patient care is involved, because CYP450 testing provides a physician
with knowledge about which medication is suitable for a patient: the right medication, for
the right patient at the right dose, the so called “personalized medicine”. If an association
between P450 variant alleles and medication-induced violence is established, patients at
risk for side effects, can be identified beforehand. Forensic science could be impacted
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because the determination of the cause, mechanism and manner of death as established by
a coroner or medical examiner, has far reaching implications. In an event of alleged
suicide, a P450/medication association could determine whether the medication taken
was a deliberate means to suicide, or that the death occurred as a result of P450 variant
alleles. In that case, manner of death should be ruled an accident. An association has a
bearing on the justice system because in cases of assault or homicide, it might provide an
accused with a defense of involuntary intoxication or temporary insanity.[250]

Methods
Four hypotheses were formulated:

1. Psychoactive medication is not correlated with violent behavior as an adverse
drug event in individuals taking those drugs.
The medication taken by 55 persons who have shown violent behavior or an
AES, was investigated. The literature was reviewed to determine if these
drugs are associated with violent behavior.
2. Individuals who exhibit acts of violence or an altered emotional state, do not
take more prescribed drugs.
Fifty-eight normal healthy volunteers were used as controls. To test this
hypothesis, the number of drugs used in the two groups was scored. The
hypothesis can be rejected if there are significantly more drugs prescribed in
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the violent compared to the nonviolent, control group. It would indicate that
polypharmacy is associated with such side effects.
3. Individuals who exhibit acts of violence or an altered emotional state, do not
have more variant alleles with respect to certain CYP450 genes.
Alleles at the following CYP450s were typed out: CYP1A2, CYP2B6,
CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4/5. The number of
variant alleles in the groups were determined. The hypothesis can be rejected
if there are significantly more variant alleles in the violent behavior compared
to the control group.
4. A reduced or an increased rate of metabolism, is not a factor that increases an
individual’s vulnerability for toxic effects of drugs.
Based on potential drug-drug (DDI), drug-gene (DGI), and drug-drug-gene
interactions (DDGI), phenoconversion from a normal metabolizer genotype to
an intermediate, poor or rapid phenotype can be established.[214] The
hypothesis can be rejected if there are significantly more interactions between
the drugs and the genes in the violent compared to the control group.

Because there is an essential difference between acts of violence and an altered
emotional state, those subgroups were studied separately. The results of several specific
cases are presented. Those analyses could illustrate how complex the interactions
between drugs and genes are. They can also offer insight in how pathways to toxicity
develop, and what the consequences of toxicity in actual cases looks like.
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Between January 2018 and January 2020, Independent Forensic Services (IFS)
provided de-identified case histories of individuals who have shown violent behavior or
an AES. Case histories were included from April 2013 until April 2019. This was done
under a data usage agreement approved by the University of Denver’s Institutional
Review Board (IRB #910661). The information included the prescription drugs that were
involved, and the relevant P450 genotypes of those individuals. Participants provided an
informed consent. If deceased, an appropriate relative signed a permission form. Persons
without a history of violence volunteered to participate in the control group. Funding was
provided by IFS and a grant from the University of Denver.
Inclusion Criteria:

1. Acts of violence or an altered emotional state.
2. Subjects were on psychoactive medication around the time of an incident or in
withdrawn from such medication, not exceeding a 2-month period since the
last use of medication.
3. Eighteen years or older.

IFS provided the CYP450 DNA testing. The following alleles were determined:

1. CYP1A2*1F, *1C, *1K, *1L
2. CYP2B6*4, *5, *6, *7, *8, *9, *13, *18, *19
3. CYP2C8*3
173

4. CYP2C9*2, *3
5. CYP2C19*2, *3, *17
6. CYP2D6*2, *3, *4, *5, *6, *7, *8, *9, *10, *12, *14, *29, *41, including copy
number variants
7. CYP3A4*1B, *1G, *2, *3, *4, *5, *6, *10, *12, *17, *18, *20, *20, *22
8. CYP3A5*1, *3

DNA sampling was done by either buccal swap or a venous blood sample. Depending
on the location of a subject, samples were taken by personnel of the facility where he or
she was incarcerated. If necessary, buccal swabs were taken by the subjects themselves,
with written instructions provided by IFS. CYP450 genotyping was done either in the IFS
laboratory (Hulshorst, the Netherlands), at the University of Rotterdam Erasmus Medical
Center (the Netherlands), or at the laboratory of OneOme (Minnesota, USA). IFS and the
Erasmus Medical Center performed the genotyping using the 7500 real-time PCR System
with TaqManÒ Drug Metabolism Genotyping Assays and Software. The Erasmus
Medical Center also used restriction fragment length polymorphism (RFLP), a gel-based
technique, and Oneome used LGC Biosearch BHQplus® assays, another PCR based
technique. The overall error rate for CYP450 genotyping is 1.44%. It has significantly
decreased over the years, and it depends on which locus is involved.[253] Information
regarding co-medication, drugs, and alcohol consumption etc., as far as available, was
collected by IFS from the subjects themselves or from their medical files.
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For this study, violence was defined according to the description used in the research
of Breggin (2003), Moore et al. (2010), and Bielefeldt (2016).[43, 64, 113] Included were
homicide, homicidal ideation, suicide, suicidal ideation, physical assault, and violencerelated symptoms, e.g., verbal abuse and/or threatening. The medical history of all
participants was screened for aggressive behavior, or behavior considered a precursor for
violent events. Examples of such behavior were emotional disturbances, e.g.,
depersonalization, disinhibition, lack of empathy (emotional blunting). Psychotic events
included abnormal feeling and thinking, nightmares, hallucinations, behavioral
dyscontrol, delirium, paranoia and mania. Jitteriness, anxiety, hyperactivity, racing
thoughts, and motor restlessness were also examples of activation events as precursor to
violent events. These symptoms were indicative of an altered emotional state.[113]
Regarding the determination about the likelihood whether a certain drug is associated
with violent behavior, the list of 350 medicines that are potentially dangerous as
compiled by RxISK.org served as a guideline.[254]
Andrea Gaedigk, a member of the Steering Committee at the Pharmacogene Variation
Consortium (PharmVar) which hosts The Human Cytochrome P450 (CYP) Allele
Nomenclature Database, communicated in a personal correspondence, that there have
been no systematic efforts in the past by any group to review activity of CYP1A2 allelic
variants. For that reason, CYP1A2 was dropped from this research. Due to the extensive
overlap between the DNA sequences of CYP3A4 and CYP3A5 and their almost identical
substrate specificity, CYP3A5 was also excluded. The remaining CYP450s to be included
were CYP2B6, CYP 2C8, CYP2C9, CYP2C19, CYP2D6 and CYP3A4. Each allele was
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scored as either normal, reduced, or loss, or increased function. The phenotype of the
combined alleles are scored according to the criteria set by Ingelman-Sundberg, see Table
4.1[185]

Table 4.1: Drug metabolizing P450 Phenotypes and Variant Alleles. (Taken from
Ingelman-Sundberg, 2010)
Phenotype

Genetic basis

Ultrarapid metabolizer
(UM)

More than 2 active gene
copies on the same allele,
or increased expression
of a single gene

Extensive metabolizer
(EM)

2 functional alleles

Intermediate metabolizer
(IM)

1 defective allele or 2
partially defective alleles

Poor metabolizer (PM)

2 defective alleles

On a per subject basis, the DDIs, DGIs and DDGIs according to Verbeurgt et al.
(2014), see Table 4.2, were established, using the website Transformer:[191, 197, 255]
For additional information and to detect difference in interpretation and in allele calls,
DDIs, DGIs, and DDGIs, the following databases were consulted:

1. Pharmacogenomics Knowledgebase.[235]
2. FDA.[256]
3. PharmVar Consortium and Database.[184]
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Table 4.2: Drug and Gene Interaction Types (Taken from Verbeurgt et al., 2014)
Type of
interaction

Definition

An interaction solely caused by drug response to a coadministered drug (both pharmacokinetic and
pharmacodynamic)
An interaction solely caused by drug response to CYP450
DGI
genetics
DDGI
An interaction that is cumulative of both DDI and DGI
DDI: Drug-drug interaction; DDGI: Drug-drug-gene interaction; DGI: Drug-gene
interaction.
DDI

The clinical impact of the interactions (major or moderate) was not taken into
account. Instead, the general guidelines, see Table 4.3, of the Transformer website were
applied.[191]
The pharmacological effect of the specific drugs, previously identified in both groups,
needed consideration. This was achieved by using the Transformer website, the
Pharmacogenomics Knowledgebase, the PharmVar Consortium Database and the product
labels posted on the website of the FDA.
For each subject a drug search in Transformer was performed. This provided
information of the CYP450s involved and the DGI and DDI’s, see the example in Table
4.4.[191]
In the case of the example, a subject has variant alleles (in red) on CYP2C19,
CYP2D6 and CYP3A4. Subsequently, the DGIs and DDIs were scored. Since one drug, in
itself, does not give a DDI, when there were two drugs involved, the DDI was counted as
one. When there were three drugs involved the DDIs were counted as two. The DDGI
was the total of the DGIs and the DDIs. The DDIs in the example are between sertraline
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and temazepam on CYP2B6, on CYP2C9 and CYP2C19, and between oxazepam,
sertraline and temazepam on CYP3A4. The example would score six DGIs (in red), five
DDI and 11 DDGIs. Since active metabolites are limited available in the Transformer
database, they are not considered in the analyses of the drug-drug interactions. This is a
simplified reproduction of the interactions in vivo.

Table 4.3: Drug-Drug Interactions in Transformer

Substrate-Substrate
Interaction

Inhibitor-Substrate
Interaction

Inducer-Substrate
Interaction
Inducer-Inducer
Interaction

Inhibitor-Inhibitor
Interaction

If more than one drug is metabolized by the same CYP, it is
possible that its metabolism is inhibited because of the
competition between the drugs. That means, it can be useful
to lower the dosage of the drugs in the drug-cocktail because
they remain longer in the organism than in monotherapy.
Combining drugs that have inhibitory effect and are substrates
of one particular CYP, should be compensated by lowering
the dosage. They rest longer in the organism than in
monotherapy. Not adapting the dosage bears the risk of even
more side effects.
Combining drugs that are inducers and substrates of one CYP
should be compensated by increasing the dosage because
metabolism is stimulated and faster than in monotherapy.
Therefore, the drugs are even earlier eliminated.
Combining two or more inducers of one CYP, should be
compensated by increasing the dosage to reach the normal
therapeutic effect because their metabolism is stimulated.
Therefore, the drugs are even earlier eliminated.
Combining two or more inhibitors of one CYP, should be
compensated by lowering the dosage of these drugs because
the metabolism is reduced, and the drugs remain longer in the
organism than in monotherapy. Not adapting the dosage bears
the risk of even more side effects.

Since virtually all the data are categorical in nature, statistical testing primarily
employed Chi-square statistics. When the number in any category was numerically below
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five, the Fisher’s exact test was performed, as is appropriate for data of this type.
Statistical significance was determined the statistical probability of 0.05 as a cutoff value.

Table 4.4: Example of Drug Search in Transformer
Oxazepam

Sertraline

Temazepam

Inh S

S

CYP2B6
CYP2C8

S

CYP2C9

S Inh

S

CYP2C19

S Inh

S

CYP2D6

Inh S

CYP3A4

S

S Inh

S

S: Substrate, Inh: Inhibition

Results
The violent group consisted of 55 individuals, their behavior ranged from an
altered emotional state (AES, 30 subjects), to assault, and attempted or completed suicide
and homicide (A/S/H, 25 subjects). Two subjects in the violent group committed suicide
during the research, another one died of an overdose morphine. The control group
(nonviolent) consisted of 58 volunteers from the locations where IFS performs its work,
both in the Netherlands and in the US. These were people without any clear mental health
issues or histories of violence. One person died of natural causes.
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There were 31 males and 24 females in the violent group and 28 males and 30
females in the nonviolent group. To test whether the distribution of gender in the groups
is significantly different, a Chi-square test of independence was performed. There was no
significantly difference between the number of males and female participants (Chi-square
statistic = 0.740, df = 1, P = 0.390) see Table 4.5.
Age range in the violent group was 22-71, with a mean of 46.8 years, and in the
nonviolent this was 18-75, with a mean of 46.9. The age distribution between the two
groups did not differ significantly. The number of CYP variant alleles for all 113 subjects
is presented in Table 4.6, and the distribution of variant alleles expressed as percentages
is shown in Figure 4.1.

Table 4.5: Chi-square Test of the Gender Composition of the Experimental and Control
Groups
Gender

Violent

Nonviolent

Male
Female

31
24

28
30

Chi-square Statistic
(Probability)
0.740 (0.390)

Table 4.6: Number and Percentages of Variant Alleles in All Subject
Frequency
5
17
31
37
14
9

Number of
Variant Alleles
1
2
3
4
5
6
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Percentage
4.4%
15.0%
27.3%
32.6%
12.3%
7.9%

Figure 4.1: Percentage of Subjects with Variant Alleles

The number of CYP450 variant alleles divided between the violent and the
nonviolent group is presented in Table 4.7 and the distribution of variant alleles
expressed as frequencies is shown in Figure 4.2. From these data, it is clear the number of
variant alleles does not follow a normal distribution.
Using the data in Table 4.7 as a set of frequency distributed data, several
descriptive statistics can be calculated. It appears that the violent group is skewed to the
left and the nonviolent group is skewed to the right. The distribution mean and skewness
(g1) for the violent group are 3.9 and -0.188 respectively, while the same parameters for
the nonviolent group are 3.3 and 0.273. Note: a symmetrical distribution yields a
skewness (g1) statistic of zero. Skewness is reflected in Figure 4.2 where the nonviolent
group appears to be more heavily weighted for low numbers of variant alleles and the
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violent group appears to be more heavily weighted for higher numbers of variant alleles,
although neither skewness value is statistically significant. A t-statistic cannot be used
here because there is no expectation that the underlying distribution of variant alleles is a
normal distribution. In addition, the number of variant alleles is a discrete variable, which
requires the Chi-square test of independence to test whether the distribution of variant
alleles in the groups is significantly different. The first two and the last two row
categories in this table had to be combined because of low cell numbers, see Table 4.8.
The Chi-square statistic for this test was significant (Chi-square statistic = 10.051, df = 3,
P = 0.018), and the conclusion is that groups (violent and nonviolent) and the numbers of

Percentage Within Group

variant alleles are not independent variables.

35
30

Frequency Distribution of Variant Alleles
Violent

Nonviolent

25
20
15
10
5
0
1

2

3

4

5

Number of Variant Alleles
Figure 4.2: Percentage of Subjects with 1-6 Variant Alleles
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Table 4.7: Number of Variant Alleles in the Violent Versus the Nonviolent Group
Number of
Variant Alleles

Violent

Nonviolent

1

2

3

2

4

13

3

14

17

4

18

19

5

11

3

6

6

3

Table 4.8: Chi-square Test of the Distribution of Variant Alleles
Number of
Variant Alleles
1 and 2
3
4
5 and 6

Violent

Nonviolent

6
14
18
17

16
17
19
6

Chi-square Statistic
(Probability)

10.051 (0.018)

To emphasize this difference, a Chi-square test was done with all cells with less
than five variant alleles being summed, and the cells with five and six being summed.
This is shown in Table 4.9. The test resulted in a Chi-square statistic of 7.364 (df = 1, P =
0.007), which is statistically significant. The violent group has significantly more
individuals with five or six variant alleles than the nonviolent group.
An odds ratio (OR) for the strength of the association between having five or six
variant alleles and the change of developing violent behavior can be calculated. An odds
ratio provides the chance that a certain outcome will happen when a specific condition is
present. This is compared to that outcome when that specific condition is not present,
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e.g., the chance of developing lung cancer while smoking compared to developing lung
cancer while not smoking. The odds ratio for the numbers as presented in Table 4.9 is
calculated as:

!" =

%&&' %( )*+'%, ℎ./0,1 5 %+ 6 /.+0.,4 .55*5*' 6*0,1 /0%5*,4
%&&' %( . )*+'%, ℎ./0,1 5*'' 4ℎ., 5 /.+0.,4 .55*5*' 6*0,1 /0%5*,4
=

17 9 52
884
=
= 3.88
38 9 6
228

Table 4.9: Chi-square Test of the Distribution of Variant Alleles
Number of
Variant Alleles
Less than 5
5 and 6

Violent

Nonviolent

38
17

52
6

Chi-square Statistic
(Probability)
7.364 (0.007)

The 95% confidence interval for this odds ratio is 1.40 - 10.76. This supports the
hypothesis that having five or six variant alleles affects the likelihood of violent behavior.
The number of variant alleles of the CYP450s were then analyzed on a per gene
bases, regardless whether the variant alleles were reduced, loss of function, or increased.
This is appropriate because, besides high to toxic levels, fluctuations in medication levels
in blood due to P450 activity (increase or decrease) can lead to dangerous side effects as
well. Chi-square 2 x 2 contingency tests were done for each gene and the results are
presented in Table 4.10. Only at CYP3A4 were there significantly more variant alleles in
the violent group (23) versus the nonviolent (14) (Chi-square statistic 4.007, df = 1, P =
0.045).
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A similar analysis was done by analyzing the different CYP450s according to the
metabolic capacity phenotype: EM, IM, PM or (U)RM. The phenotype is determined by
taking the actual function of an allele into account. To distinguish the phenotypes in this
research, the variant alleles that are still considered to have extensive metabolizing
capacity, and therefore, have the same phenotype as wildtype alleles, need to be separated
from the alleles with other, altered function. Following the allele designation by
PharmVar, the distribution of phenotypes among the two groups was compared.[15] This
analysis was only done for two genes, CYP2D6 and CYP3A4, since these were the only
two genes for which the numbers changed substantially over what is shown in Table 4.10.
The results are presented in Table 4.11. The data for CYP2D6 were analyzed
using Chi-square, while the data for CYP3A4 employed the Fisher’s exact test due to the
low cell numbers involved.
There was no significant difference in phenotype between the violent and the
nonviolent group regarding CYP2D6. Only with CYP3A4 were there significantly more
subjects categorized as non-EM in the violent group (12) versus the nonviolent group (4)
(Fisher’s exact probability = 0.031). This supports the idea that there is an association
between having a CYP3A4 non-EM phenotype and violent behavior.
One additional analysis involved CYP2C19*17, which is an allele that results in
an (ultra)-rapid metabolizing P450 isoform (RM or URM). Chi-square analysis was used
to determine if there was a significant difference between the violent and nonviolent
groups with respect to the number of *17 alleles. The results are shown in Table 4.12.
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There was no significant difference between violent and nonviolent groups with respect
to (U)RM phenotype for CYP2C19 (Chi-square statistic = 1.026, df = 1, P = 0.311).

Table 4.10: Chi-square Tests of the Distribution of Variant Alleles on a Per Gene Basis
Number of
Variant Alleles

Violent

0
1 or 2
0
1 or 2
0
1 or 2
0
1 or 2
0
1 or 2
0
1 or 2
*Significant at the 5% Level

Nonviolent

Results for CYP2B6
24
24
31
34
Results for CYP2C8
45
48
10
10
Results for CYP2C9
34
44
21
14
Results for CYP2C19
21
26
34
32
Results for CYP2D6
6
7
49
51
Results for CYP3A4
32
44
23
14
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Chi-square Statistic
(Probability)

0.059 (0.808)

0.017 (0.896)

2.604 (0.107)

0.513 (0.474)

0.037 (0.847)

4.007 (0.045)*

Table 4.11: Chi-square Tests of the Distribution of Phenotypes on a Per Gene Basis
Phenotypes
EM
Non-EM
EM

Violent

Nonviolent

Results for CYP2D6
27
22
28
36
Results for CYP3A4
43
54

Chi-square Statistic
(Probability)

1.432 (0.232)

Fisher’s Exact
Probability (0.031)*
EM: Extensive metabolizer, Non-EM: Non-Extensive Metabolizer
*Significant at the 5% Level
Non-EM

12

4

Table 4.12: Chi-square Test of the Distribution of Phenotypes for CYP2C19
Phenotypes

Violent

Nonviolent

URM
Non-URM

18
37

14
44

Chi-square Statistic
(Probability)
1.026 (0.311)

The violent and nonviolent groups were then analyzed with respect to the number
of prescription medications, including the important active metabolites. The number of
medications is presented in Table 4.13 and the distribution of the prescription drugs
expressed as frequencies is shown in Figure 4.3.
With respect to the number of medications regardless of group, it can be
concluded that almost 70% of the subjects take three or more medications. The mean use
of medications in the violent group was 4.4 (standard deviation = 2.77, Range = 1-13,
95% CI = 3.7-5.1) and 1.3 (standard deviation = 2.56, Range = 0-11, 95% CI = 0.7-2.0)
in the nonviolent group.
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Table 4.13: Number of Medications in the Violent Versus the Nonviolent Group
Number of
Medications
0

Violent

Nonviolent

0

38

Results for Medication Taken

Total (%)

1

9

3

16%

2

4

7

15%

3

11

3

19%

4

10

0

13%

5

4

2

8%

6

7

1

11%

7

3

1

5%

8

1

1

3%

9

3

0

4%

10

1

1

3%

11

1

1

3%

12

0

0

0%

13

1

0

1%

The median number of medications prescribed for the violent group was four, for
the nonviolent this was two. The midpoint of these two numbers is three. Using this
number, the data for both groups were separated into two or less medications and three or
more medications and a Chi-square contingency test was performed to determine if the
number of medications was independent of groups (violent and nonviolent). The data and
the statistical results are presented in Table 4.14. The Chi-square statistic was highly
significant (Chi-square = 39.722, df = 1, P = 2.93E-10). This supports the contention that
there is an association between the number of medications taken and violence.
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Prescription Medications Expressed as Frequencies

Percentage Within Group

70
60
50

Violent

Nonviolent

40
30
20
10
0
0

1

2

3

4

5

6

7

8

9

10 11 12 13

Number of Medications
Figure 4.3: Comparison of Groups with Respect to the Number of Prescription
Medications

Table 4.14: Chi-square Test of the Distribution of the Number of Medications
Number of
Medications
Less than 3
3 or more

Violent

Nonviolent

13
42

48
10

Chi-square Statistic
(Probability)
39.723 (2.93E-10)

The analysis was then focused specifically on the use of antidepressants within
the violent and nonviolent groups. As can be seen in Table 4.15, there were statistically
more anti-depressants used in the violent group (Chi-square = 37.364, df = 1, P = 9.80E10) and this result is highly significant. The conclusion is that taking antidepressants
affects the likelihood of violent behavior.
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Table 4.15: Chi-square Test of the Use of Antidepressants
Violent

Nonviolent

Antidepressants

35

5

No Antidepressants

20

53

Chi-square Statistic
(Probability)
37.364 (9.80E-10)

Further detail regarding the use of psychoactive medication was acquired by
calculating the number of subjects on additional psychoactive prescription medication
e.g., antipsychotics, hypnotics (sleep medication) or mood stabilizers. In the violent
group, all subjects were on medication. In the nonviolent group, 38 subjects did not take
any medication, leaving 20 subjects that did take prescription medication. In the violent
group, five subjects were on antipsychotics, 21 used hypnotics and eight were prescribed
a mood stabilizer. This makes a total of 34 subjects on psychoactive medication, apart
from antidepressants. In the nonviolent group, there were only two subjects on hypnotics.
As can be seen in Table 4.16, there was significantly more psychoactive medication used
in the violent group (Fisher’s Exact Probability = 6.09E-05).

Table 4.16: Fisher’s Exact Probability Test of the Use of Psychoactive Medication
Violent

Nonviolent

Psychoactive Medication

34

2

No Psychoactive Medication

21

18

Fisher’s Exact Probability

Fisher’s Exact Probability
(6.09E-05)

The next step was to investigate a possible association between drug-drug, druggene and drug-drug-gene interactions and violent behavior. The drug-gene interactions
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were defined according to Verbeurgt et al. (see Table 4.2 in this paper). To keep the
research manageable, the clinical impact of the interactions (major or moderate) was not
taken into account, which is what was done by Verbeurgt et al. Instead, the general
guidelines of the Transformer website were followed.[191]
The number of drug-gene interactions (DGIs) is presented in Table 4.17 and the
distribution of drug-gene interactions expressed as frequencies is shown in Figure 4.4.
The mean number of DGIs in the violent group was 2.5 (±1.42) and in the nonviolent
group 2.5 (±1.92). The range in both groups was 0 - 7.

Table 4.17: Number of Drug-Gene Interactions in the Violent Versus the Nonviolent
Group
Number of
Drug-Gene
Interactions
1

Violent

Nonviolent

15

6

2

18

7

3

11

2

4

4

0

5

4

1

6

1

0

7

1

2

The median in both groups is two. This number was taken to divide the violent
and the nonviolent groups into two subgroups, one with two or less DGIs, and one with
more than two DGIs. A Chi-square test to determine if the distribution of DGIs between
the violent and the nonviolent group was comparable, showed no significant difference,
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(Chi-square = 0.773, df = 1, P = 0.395), see Table 4.18. The data indicate that the number

Percentage Within Group

of drug-gene interactions is independent of groups.

Frequency of Drug-Gene Interactions

50
40

Violent

30

Nonviolent

20
10
0

1

2
3
4
5
6
Number of Drug-Gene Interactions

7

Figure 4.4: DGIs in the Violent versus the Nonviolent Group

Table 4.18: Chi-square Test of the Distribution of Drug-Gene Interactions
Number of DrugGene Interactions

Violent

Nonviolent

1-2

33

13

3-7

21

5

Chi-square Statistic
(Probability)
0.773 (0.395)

The same steps were applied to drug-drug interactions (DDIs) and drug-drug-gene
interactions (DDGIs). The number of drug-drug interactions for each group is presented
in Table 4.19 and the distribution of DDIs as frequencies is shown in Figure 4.5. The
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mean number of DDIs in the violent group was 6.3 (+5.68) and in the nonviolent group
4.0 (+3.26). The range in the violent group was 0-21 and in the nonviolent 0-12.

Table 4.19: Number of Drug-Drug Interactions in the Violent Versus the Nonviolent
Group
Number of DrugGene Interactions
1-2

Violent

Nonviolent

13

4

3-5

11

4

6-8

6

2

9-11

3

0

12-14

3

1

15-17

3

0

18-21

2

0

Percentage Within Group

Frequency of Drug-Drug Interactions
40
35
30
25
20
15
10
5
0

Violent

1-2

3-5

6-8

9-11

Nonviolent

12-14

15-17

18-21

Number of Drug-Drug Interactions
Figure 4.5: DDIs in the Violent Group versus the Nonviolent Group
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The median in the violent group was four, and in the nonviolent group, the
median was three. The last number was taken to divide the violent and the nonviolent
groups into two subgroups, one with three or less DDIs and one with more than three
DDIs. A Chi-square test was performed to determine if the distribution of DDIs between
the violent and nonviolent groups was comparable (Chi-square = 0.602, df = 1, P =
0.438). The results showed that the distribution is independent of groups, see Table 4.20.

Table 4.20: Chi-square Test of the Distribution of Drug-Drug Interactions
Number of DrugDrug Interactions

Violent

Nonviolent

1-3

17

6

4-21

24

5

Chi-square Statistic
(Probability)

0.602 (0.438)

The number of drug-drug-gene interactions is presented in Table 4.21, and the
distribution of variant alleles expressed as frequencies is shown in Figure 4.6. The mean
number of DDGIs in the violent group was 7.3 (+6.38) and in the nonviolent group 7.3
(+5.33). The range in the violent group was 0-25 and in the nonviolent 0-17.
The median in the violent group was three, and in the nonviolent group, the
median was four. The last number was taken to divide the violent and the nonviolent
groups into two subgroups, one with four or less DDGIs and one with more than four
DDGIs. A Chi-square test to determine if the distribution of drug-drug-gene interactions
between the violent and the nonviolent group was comparable showed that the

194

distribution was independent of groups (Chi-square = 0.365, df = 1, P = 0.546; see Table
4.22).

Table 4.21: Number of Drug-Drug-Gene Interactions in the Violent Versus the
Nonviolent Group
Number of Drug-DrugGene Interactions
1-3

Violent

Nonviolent

21

3

4-7

15

5

8-11

8

0

12-15

4

2

16-19

1

1

20-23

3

0

24-25

2

0

Percentage Within Group

Frequency of Drug-Drug-Gene Interactions
50
45
40
35
30
25
20
15
10
5
0

Violent

1-3

4-7

8-11

Nonviolent

12-15

16-19

20-23

24-25

Number of Drug-Drug-Gene Interactions
Figure 4.6: DDGIs in the Violent Group versus the Nonviolent Group
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Table 4.22: Chi-square Test of the Distribution of Drug-Drug-Gene Interactions
Number of Drug-DrugGene Interactions

Violent

Nonviolent

1-4

25

4

5-21

29

7

Chi-square Statistic
(Probability)
0.365 (0.546)

Table 4.23 presents a summary of the most important results regarding the violent
versus the nonviolent group.
There were two distinct sorts of behaviors in the violent group: subjects who
suffered an altered emotional state (abbreviated AES, e.g., derealization,
depersonalization, delusional thoughts, aggressive impulses, suicidal ideation, depression,
agitation, akathisia, movement disorder etc.), and those who exhibited real violent
behavior (abbreviated A/S/H, e.g., assault/suicide/homicide, attempted suicide and
homicide are included). There were noticeably more men than women in the A/S/H
subgroup (18 versus seven) compared to the AES subgroup (13 versus 17). To test
whether the distribution of gender in the more violent subgroup was significantly
different compared to the less violent subgroup, a Chi-square test of independence was
performed. The Chi-square statistic = 4.56, df = 1, P = 0.03, see Table 4.24. This supports
the idea that, as far as these two subgroups are concerned, gender and violent behavior
are not independent.
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Table 4.23: Summary of Results

Gender

Violent

Nonviolent

Male: 31 Female: 24

Male: 28 Female: 30

Less than 5 variant alleles
38
5 or 6 variant alleles
17
Distribution is not independent, Probability = 0.007

52
6

0 Variant alleles for CYP3A4
32
1-2 Variant alleles for CYP3A4
23
Distribution is not independent, Probability = 0.045

44
14

EM for CYP 3A4

43

54

Non-EM for CYP 3A4
12
4
Distribution is not independent, Probability = 0.031
Mean number of medications +
4.35
1.34
95% CI
95% CI: 3.6-5.9
95% CI: 0.68-2
SD + Range
2.83, 0-13
2.56, 0-11
Less than 3 medications
13
48
3 or more medications
42
10
Distribution is not independent, Probability = 2.93E-10
Antidepressants
35
5
No Antidepressants
20
53
Distribution is not independent, Probability = 9.80E-10
Psychoactive medication
34
2
No Psychoactive medication
21
18
Distribution is not independent, Probability = 6.09E-05
Mean number of DGI
SD, Range

2.5
1.4, 0-7

2.5
1.92, 0-7

Mean number of DDI
SD, Range

6.3
5.68, 0-21

4.0
3.26, 0-12

Mean number of DDGI
SD, Range

7.3
6.38, 0-25

7.3
5.33, 0-17
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Table 4.24: Chi-square Test of the Gender Composition of the A/S/H and AES
Subgroups
Gender

A/S/H

AES

Male

18

13

Female

7

17

Chi-square Statistic
(Probability)
4.56 (0.03)

The number of CYP450 variant alleles, divided between the A/S/H and the AES
subgroups, is presented in Table 4.25, and the distribution of variant alleles expressed as
frequencies is shown in Figure 4.7. From these data, it does not appear that the number of
variant alleles follows a normal distribution.

Table 4.25: Number of Variant Alleles in the A/S/H and the AES Subgroup
Number of
Variant Alleles
1

A/S/H

AES

1

1

2

3

1

3

8

6

4

5

13

5

5

6

6

3

3

To test whether the distribution of variant alleles in the A/S/H and AES subgroups
is significantly different, a Chi-square test of independence was performed, see Table
4.26.
The median in the A/S/H group is three, in the AES four. The lowest number three,
was taken to divide the A/S/H and AES groups into two subgroups, one with three or less
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variant alleles and one with more than three variant alleles. There is no significant
difference between the A/S/H and the AES subgroups regarding the number of variant
alleles (Chi-square statistic = 2.681, df = 1, P = 0.10, see Table 4.26), although the AES

Percentage Within Subgroup

subgroup includes more individuals with four or more variant alleles.
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40

Frequency Distribution of Variant Alleles Among
A/S/H and AES Subgroups

A/S/H

AES

30
20
10
0
1

2

3

4

5

6

Number of Variant Alleles
Figure 4.7: Percentage of Subjects with 1-6 Variant Alleles
Table 4.26: Chi-square of the Distribution of Variant Alleles
Number of Variant
Alleles
Less than 4 variant
alleles
4-6 variant alleles

A/S/H

AES

12

8

13

22

Chi-square Statistic
(Probability)

2.681 (0.101)

The A/S/H and AES subgroups were then analyzed with respect to the number of
prescription medications, including the important active metabolites. The number of
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medications is presented in Table 4.27 and the distribution of the prescription drugs
expressed as frequencies is shown in Figure 4.8.
The median in the A/S/H group was four, in the AES it was three. The last
number was used to divide the A/S/H and the AES subgroups into two groups, one with
two or less medications and one with three or more medications. A Chi-square test to
determine if the distribution of the number of medications between the A/S/H subgroup
and the AES subgroup was comparable, showed no statistically significant difference
(Chi-square = 0.003, df = 1, P = 0. 953, see Table 4.28).

Table 4.27: Number of Medications in the A/S/H Versus the AES Subgroups
Number of
Medications
0

A/S/H

AES

0

1

1

2

7

2

4

0

3

3

7

4

5

5

5

2

2

6

4

3

7

2

1

8

0

1

9

1

1

10

0

1

11

1

1

12

0

0

13

1

0
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Table 4.28: Chi-square of the Distribution of the Number of Medications
Number of
Chi-square Statistic
A/S/H
AES
Medications
(Probability)
Less than 3

6

7

3 or more

19

23

0.003 (0.953)

As is the case with the violent and the nonviolent groups, there is a significant
difference between the A/S/H and the AES subgroups regarding the use of
antidepressants (Chi-square statistic = 5.303, df = 1, P = 0.021, see Table 4.29). As can
be seen, there are more A/H/S individuals using antidepressants than expected, based on
random chance. Calculations were then performed with respect to the number of
psychoactive prescription medication e.g., antipsychotics, hypnotics (sleep medication) or
mood stabilizers, as was done in comparing the violent versus the nonviolent group.
In addition to antidepressants, three subjects in the A/S/H/ group were on
antipsychotic medication, 13 were on hypnotics and three were prescribed a mood
stabilizer. For the AES group those numbers were respectively two, eight and five. The
Chi-square test to determine if the distribution of psychoactive medication between the
two subgroups was comparable, showed a significant difference (Chi-square = 3.905, df
= 1, P = 0.048, see Table 4.30).

Table 4.29: Chi-square Test of the Use of Antidepressants
A/H/S

AES

Antidepressants

20

15

No Antidepressants

5

15
201

Chi-square Statistic
(Probability)
5.303 (0.021)

Percentage Within Subgroup

Frequency Distribution of Prescription Medications
25
20
A/S/H

15

AES

10
5
0
0

1

2

3

4
5
6
7
8
Number of Medications

9

10

11

12

13

Figure 4.8: Comparison of the Number of Prescription Medications Among
Subgroups

Table 4.30: Psychoactive Medication Usage in the A/S/H and AES Subgroups
A/S/H

AES

Psychoactive Medication

19

15

No Psychoactive Medication

6

15

Chi-square Statistic
(Probability)
3.905 (0.0481)

The number of drug-gene interactions in the A/S/H and AES subgroups is
presented in Table 4.31 and the distribution of DGIs expressed as frequencies is shown in
Figure 4.9. The mean number of DGI in the A/S/H subgroup was 2.84 (+1.65, range 1-7,)
and in the AES subgroup 2.1 (+ 1.13, range 0-5).
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Table 4.31: Number of Drug-Gene Interactions in the A/S/H Versus the AES Subgroup
Number of DrugGene Interactions

A/S/H

AES

1

6

9

2

6

12

3

6

5

4

3

1

5

2

2

6

1

0

7

1

0

Percentage Within Subgroup

Frequency Distribution of Drug-Gene Interactions
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Number of Drug-Gene Interactions
Figure 4.9: DGIs in the A/S/H and the AES Subgroups

The median in the A/S/H subgroup was three, and, in the AES subgroup, the
median was two. The last number was taken to divide the A/S/H and the AES subgroups
into two groups, one with two or less DGIs and one with more than two DGIs. A Chi203

square test to determine if the distribution of DGIs between the A/S/H and the AES
groups was comparable, showed no significant difference, although it was close to being
statistically significant (Chi-square = 3.367, df = 1, P = 0.067, see Table 4.32).
The number of DDIs in the A/S/H and AES subgroups is presented in Table 4.33
and the distribution of DDIs expressed as frequencies is shown in Figure 4.10. The mean
number of DDI in the A/S/H subgroup was 7.7 (±6.5, range 0-21, 95% CI: 4.8 - 10.7) and
in the AES subgroup 2.8 (±1.28, range 0-17, 95% CI: 2.2 - 3.4).

Table 4.32: Chi-square Test of the Distribution of Drug-Gene Interactions
Number of DrugGene Interactions

A/S/H

AES

1-2

12

21

3-7

13

8

Chi-square Statistic
(Probability)
3.367 (0.067)

Table 4.33: Number of Drug-Drug Interactions in the A/S/H Versus the AES Subgroups
Number of DrugDrug Interactions
1-2

A/S/H

AES

6

7

3-5

3

8

6-8

5

1

9-11

1

2

12-14

2

1

15-17

2

1

18-21

2

0

The median in the A/S/H subgroup was six, and, in the AES subgroup, the median
was four. The average between the two, five, was taken to divide the A/S/H and the AES
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subgroups into two groups, one with two or less DDIs and one with more than two DDIs.
A Chi-square test was performed to determine if the number of DDIs was independent of
groups (A/S/H or AES). The data and the statistical results are presented in Table 4.34.
The Chi-square statistic was significant (Chi-square = 4.36, df = 1, P = 0.037). This
supports the contention that there is an association between the number of DDIs and
subgroups. From the data in Table 34, it appears that there are more subjects in the A/S/H
subgroup with 6-21 drug-drug interactions than would be expected on the basis of
random chance.
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Figure 4.10: DDIs in the A/S/H and the AES Subgroups
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18-21

Table 4.34: Chi-square Test of the Distribution of Drug-Drug Interactions
Number of DrugDrug Interactions

A/S/H

AES

1-5

9

15

6-21

12

5

Chi-square Statistic
(Probability)
4.36 (0.037)

The number of DDGIs in the A/S/H and AES subgroups is presented in Table
4.35, and the distribution of DDGIs among subgroups expressed as frequencies is shown
in Figure 4.11. The mean number of DDGIs in the A/S/H subgroup was 9.3 (+7.55) and
in the AES subgroup 5.5 (+4.61). The range in the A/S/H subgroup was one to 25 and in
the AES subgroup the range was one to 21.

Table 4.35: Number of Drug-Drug-Gene Interactions in the A/S/H and AES Subgroups
Number of Drug-DrugGene Interactions

A/S/H

AES

1-3

8

13

4-7

6

9

8-11

3

5

12-15

3

1

16-19

1

0

20-23

2

1

24-25

2

0

The median in the A/S/H subgroup is five, in the AES four. The last number was
taken to divide the A/S/H and the AES subgroups into two groups, one with four or less
DDGIs and one with more than four DDGIs, see Table 4.35. A Chi-square test to
determine if the distribution of DDGIs between the A/S/H and the AES subgroup was
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comparable, showed no significant difference, (Chi-square statistic = 0.365, df = 1, P =
0.159, see Table 4.36).
Table 4.37 presents a summary of the results of the three different possibilities
regarding drug and gene interaction for the A/S/H and AES subgroups. This table is
similar to Table 4.23 except that it focuses on the two subgroups within the violent group
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Figure 4.11: DDGIs in the A/S/H and the AES Subgroups
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Table 4.36: Chi-square Test of the Distribution of Drug-Drug-Gene Interactions
Number of Drug-DrugGene Interactions

A/S/H

AES

1-4

9

16

5-25

16

13

Chi-square Statistic
(Probability)
0.365 (0.159)

Table 4.37: Summary of the Results of the Drug and Gene Interactions for the A/S/H and
AES Subgroups
A/S/H

AES

Gender
Male: 18 Female: 7 Male: 13 Female: 17
Distribution is not independent, Probability = 0.03
Antidepressants
20
No Antidepressants
5
Distribution is not independent, Probability = 0.021

15
15

Psychoactive medication
19
No Psychoactive medication
6
Distribution is not independent, Probability = 0.048

15
15

1-2 Drug-Gene Interactions
12
3-7 Drug-Gene Interactions
13
Distribution is independent, but Probability = 0.067

21
8

1-5 Drug-Drug Interactions
9
6-21 Drug-Drug Interactions
12
Distribution is not independent, Probability = 0.037

15
5

Mean number of DGI
SD, Range

2.84
0.33, 1-7

2.07
0.21, 0-5

Mean number of DDI
SD, Range

6.48
1.32, 0-21

3.20
0.77, 0-17

Mean number of DDGI
SD, Range

9.32
1.51, 1-25

5.30
0.85, 0-21
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Discussion
The goal of this research was to investigate a possible association between genetic
variants of CYP450 genes, psychoactive medication and acts of violence. There were
indications that such an association exists.[43] Violence is a known side effect of
psychoactive medication, as is recognized in the literature, and substantiated in chapter
one.[229] Psychoactive medication is mainly metabolized by enzymes generated by
CYP450 genes.[193] Reduced or non-functional alleles will have an effect on blood levels
of drugs, and can cause side effects e.g., acts of violence. Yet, causality is notoriously
hard to prove. Arguments for causality are based on knowledge acquired from everyday
practice, in combination with statistical results from basic research. Statistical results in
themselves do not prove causality either. Statistics are merely tools that support or rejects
hypotheses, formulated in an effort to understand problems or phenomena that are
encountered in the surrounding world.
Some of those phenomena involve people who, completely out of character, killed
themselves or loved ones, or children who committed school shootings, pilots who
crashed their planes, bus drivers who crashed their buses loaded with schoolchildren, an
adolescent girl who jumped out of an airplane without a parachute. What they had in
common was the use of psychoactive medication. An often-heard argument is that they
also had a mental illness in common. Surely, mental illness can be a confounding factor,
but there is good reason to believe that perfectly sane individuals on prescription
psychoactive medication can be driven to such acts.[19, 42, 45, 63, 73, 94] In those cases, another
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explanation was needed. Given the biological model of medication induced toxicity,
genetic variants - “killer genes” - as a root cause was worthwhile to explore.
Piatkov (2009), Lucire et al. (2011), Eikelenboom et al. (2016), and Ekhart et al.
(2017) have studied the number of variant alleles for CYP450 genes in relation to
violence and/or akathisia.[135, 173, 174, 257] The CYP450s studied in their research, were
CYP2D6, CYP2C9, and CYP2C19. In this research, additional genes CYP2B6, CYP2C8
and CYP3A4 were also studied. Piatkov concluded that violent psychosis in some patients
can be caused by genetic variations on CYP450 genes. Lucire et al. established an
association between antidepressant-induced akathisia and CYP450 genes with reduced
metabolic capacity, and Eikelenboom et al. described 3 patients with diminished
metabolic capacity who committed violent acts while on psychoactive medication. Ekhart
et al. were unable to detect a relationship between CYP2C19 and CYP2D6 and aggression
in 18 patients on SSRIs.
To get a more comprehensive picture of a subject’s metabolic capacities, it is
important to genotype more than three CYP450s. If one pathway is compromised due to
genetic variants, another CYP450 can take over, even if that is not the preferred pathway.
By being a high affinity-low specificity enzyme, CYP3A4 in particular performs by
picking up the slack when other enzymes are not performing as they should.[193] Also,
drug-drug interactions can change the expected metabolic pathways, as can drug-druggene interactions.[255] Due to the substantial interindividual differences in expression,[181]
and hence the metabolic rate per CYP450, it is impossible to quantify a subjects
metabolic capabilities. All the factors that determine the rate at which medication in a
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subject is being expelled, cannot be taken into account. To extrapolate from studies to
individual patients, or to determine the metabolic rate per isolated CYP450, can create a
false sense of security. The metabolic rate of a P450 is easier to estimate in vitro than it is
in vivo. Controlling an experiment in a test tube is easier than measuring a metabolic rate
in a living, complex subject where all kind of unknown effects influence the results. An
indication can be acquired as to how certain CYP450s will behave, and how they will
interact with substrates, inducers and inhibitors, but how fast that rate will actually be in a
living patient cannot be quantified. All in all, a wide approach in interpreting the possible
influences of the different aspects involved was taken in this research: the number of
variant alleles, the effect of inhibition or substrate competition, copy number variations.
In this research, these factors were considered without quantifying their part in the
metabolic process.
The first hypothesis was whether psychoactive medication is correlated with
violent acts and behavior as an adverse drug event. In chapter one, the evidence
substantiating a possible link was described. The conclusion of this literature study was
that there are sufficient arguments that supports an association between psychoactive
prescription drugs and activation events, aggression and violence.
The second hypothesis was whether people, who exhibit the previous describe
violent behavior, take more prescribed drugs than subjects in the nonviolent group. For
this question, the number of anti-depressants, antipsychotics, hypnotics (sleep
medication), and other drugs used, were scored. Active metabolites, as known from the
literature, and for as far as they were deemed important, were included.[258] An example of
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why active metabolites are a factor to be considered, was recently reported in the
toxicology report in the death of the granddaughter of Robert Kennedy. According to the
coroner she suffered acute toxicity due to a combination of methadone, diazepam,
nordiazepam (metabolite), fluoxetine, norfluoxetine (metabolite), and ethanol in her
system.[259] Prescribers need to consider that some medications have an active metabolite
that, in itself, is marketed as separate medication, e.g., venlafaxine which is also sold
under the brand name Effexor, and its metabolite desmethylvenlafaxine, sold under the
brand name Pristiq. Active metabolites put a strain on the metabolic resources, thus
increasing the risk of side effects.
In this research, the mean number of prescribed drugs in the violent and control
group (± the standard deviation) was respectively 4.4 ± 2.77 (Range = 0-13, 95% CI =
3.7-5.1) and 1.3 ± 2.56 (Range = 0-11, 95% CI = 0.7-2.0). The fact that the confidence
intervals didn’t overlap indicated that these two groups differ essentially with respect to
the number of medications taken. The use of three or more medications, no matter what
kind, affected the likelihood of violent behavior (Chi-square statistic 39.722, P = 2.93E10), which can be considered highly significant.
Not only did the subjects in the violent group used significantly more medication,
they also used significantly more anti-depressants (Chi-square statistic 37.364, P = 9.80E10). This was in line with current literature indicating that subjects with three or more
medications, with or without a depression as possible side effect (including
antidepressants), were significantly more likely to suffer depression compared to subjects
not taking such drugs (15% versus 4.7%).[213, 254, 260]
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It is well-known that the use of prescription medication increases with age. The
percentage of individuals on prescription medication over a 30 day period between 2015
and 2016, was published by the Centers for Disease Control and Prevention in May
2019.[261] Of the adults over aged 60, 85% used prescription drugs, see Figure 4.12.

Figure 4.12: Use of Prescription Medication by Age (Taken from Martin, 2019)

The mean age was approximately 47 years in both the violent and the control group,
and there was no significant different between mean age for the two groups. The most
commonly used medications in the CDC research group of 20-59 years old, were
antidepressants, see Figure 4.13. Although individuals 60 years and older use more
medication, they use less antidepressants than the generation that came after them (20-59
years old). It is probably no coincidence that the mean age of the violent group falls
within the age group that uses the most antidepressants. This finding supports a
correlation between the use of antidepressants and acts of violence and could explain why
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there is a significant difference between the violent and the nonviolent group with regards
to the use of antidepressants. In conclusion, these results indicate that polypharmacy in
general and the use of antidepressants in particular, is associated with violent behavior.

Figure 4.13: Use of the Most Commonly Prescription Medication over 30 Days by Age,
2015-2016 (Taken from Martin, 2019)
The third hypothesis involved whether individuals, who exhibit violent behavior,
have more genetic variants with respect to the tested CYP450 genes. A Chi-square test to
explore the distribution of variant alleles between the two samples was applied. The null
hypothesis was that the distribution of variant alleles was the same in both groups. This
test for the distribution of up to six variant alleles, yielded a Chi-square statistic of 10.051
with a P-value of 0.018. As can be seen in Table 4.8, the distribution of the variant alleles
differed significantly. The nonviolent group appeared to be more heavily weighted for
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low numbers of variant alleles and the violent group appeared to be more heavily
weighted for higher numbers of variant alleles. With a Chi-square statistic of 7.364 and a
P-value of 0.007, the violent group had significantly more individuals with five or six
variant alleles than the nonviolent group, see Table 4.9.
These results indicated that subjects in the nonviolent group were better equipped
to metabolize medication than subjects in the violent group. The odds ratio for having
five or six variant alleles and the chance of developing violent behavior was 3.9 (95% CI:
1.40 - 10.76). This meant that subjects having five or six variant alleles in total on the six
tested CYP450s, irrespective of the metabolic capacity of those variants, had a greater
likelihood of developing violent behavior compared to subjects who have less than five
variant alleles.
Of the 113 subjects in this study, 20% had five or six variant alleles. Ji et al.
(2016) found in their study of 1013 subjects from the Mayo Clinic, which were
genotyped on CYP2C19, CYP2C9, CYP2D6, SLCO1B1 (solute carrier organic anion
transporter family member 1B1) and VKORC1 (vitamin K oxide reductase complex),
concluded that 99% of their subjects had at least one actionable variant allele. 263] In the
113 subjects of this research, 100% had at least one variant allele. Since six genes were
tested, that result was to be expected. These results are consistent with those of Hocum et
al. (2016) who tested over 20,000 subjects on CYP2C19, CYP2C9, CYP2D6, CYP3A4
and CYP3A4. Only a minority had no actionable alleles for any of those CYP450
genes.[196]
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It was of interest to determine whether any of the CYP450s in this study involved
showed more genetic variants in the violent versus the nonviolent group. This was the
case with CYP3A4, where there were significantly more variant alleles in the violent
group (23) versus the nonviolent group (14), with a Chi-square statistic of 4.007 and a
probability of 0.045. CYP3A4 is responsible for an estimated 50% to 70% of drug
metabolism.[190] It is considered the “workhorse” and the “backup system” for the
CYP450 family.
To further investigate the hypothesis of the violent group having more genetic
variants and hence being more likely to engage in violent acts, the phenotypes resulting
from the variant alleles were studied. In this case, the functionality of the genetic variants
was considered. Again, only at CYP3A4 were significantly more subjects categorized as
non-EM (extensive metabolizer ≡ normal) in the violent group (12) versus the nonviolent
group (4), (Fisher’s Exact Probability = 0.031). At CYP3A4, there are only two
phenotypes, normal and intermediate metabolizers. Given that many commonly used
drugs are inhibitors, substrates or inducers of CYP3A4, this enzyme is more likely to be
subject to drug-drug and drug-gene interactions, see Table 4.38.[193]
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Table 4.38: Examples of CYP3A4 Substrates and Inhibitors (in Red) (Taken from
Sandson, 2002)

Antidepressants

Antipsychotics

Sedative-hypnotics

Other drugs

Amitriptyline

Aripiprazole

Clonazepam

Analgesics

Citalopram

Chlorpromazine

Diazepam

Buprenorphine

Fluoxetine

Clozapine

Nitrazepam

Codeine

Mirtazapine

Haloperidol

Alprazolam

Fentanyl

Paroxetine

Quetiapine

Buspirone

Methadone

Sertraline

Risperidone

Midazolam

Hydrocodone

Trazodone

Antiepileptics

Zolpidem

Tramadol

Venlafaxine

Carbamazepine

Zopiclon

Statins

Antibiotics

Valproic acid

Antimalarials

Atorvastatin

Ciprofloxacin

Antihistamines

Chloroquine

Pravastatin

Rifampin

Loratadine

Primaquine

Simvastatin

Azithromycin

Terfenadine

Antihypertensiva

Miscellaneous

Erythromycin
Antiparkinsonian
drugs
Bromocriptine

ß-Blockers

Amlodipine

Acetaminophen

Metoprolol

Nifedipine

Cisapride

Propranolol

Verapamil

Diclofenac

Antirejection drugs

AntiHIV

Antineoplastics

Itraconazole

Cyclosporine

Efavirenz

Busulfan

Ketoconazole

Tacrolimus

Nevirapine

Cyclophosphamide

Meloxicam

Steroids

Nelfinavir

Doxorubicin

Montelukast

Cortisol

Saquinavir

Paclitaxel

Ondansetron

Dexamethasone

Indinavir

Tamoxifen

Sibutramine

Estradiol

Ritonavir

Vincristine

Sildenafil

This is where phenoconversion comes into play. If a subject is an IM
(intermediate metabolizer), or even an EM, on CYP3A4, and he/she uses medication that
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inhibits this enzyme, the chances of this subject converting to a PM (poor metabolizer)
phenotype are substantial. Given the large part CYP3A4 plays in metabolizing drugs,
such phenoconversion could lead to dangerous side effects like acts of violence. None of
the other CYP450s showed any significant difference between the violent versus the
nonviolent group, either in the number of variant alleles or in the number of people with a
phenotype other than EM.
Combining medication, and especially three or more, can lead to drug-drug
interactions, which increases the risk of dangerous side effects.[260] Drug-drug interactions
interfere with the metabolic rate in a way comparable to drug-gene interactions. DDIs are
superimposed on DGIs, increasing the effects of the DGIs. If a subject’s metabolic rate is
compromised by substrates that inhibit the expulsion from that drug from the body, and
co-medication is inhibiting that process further, phenoconversion is much more likely. In
a situation where there are variant alleles, it depends on the levels of the different
substrates, and on the affinity of the different enzymes, which drug gets priority in being
metabolized. Another complicating factor is the kind of inhibition a substrate can perform
on an enzyme. In cases of competitive inhibition, increasing the amount of the substrate
can overcome the inhibitory effects. [205] In non-competitive inhibition, the inhibitor and
the substrate do not compete for the same active site. Increasing the amount of the
substrate has no effect on the chances of the substrate binding to the enzyme.
Uncompetitive inhibition is an unusual form of inhibition, where the inhibitor binds after
the enzyme/substrate complex has been formed. This complex cannot release the product
as long as the inhibitor is bound.[205] Then, there is mechanism-based inhibition, a form of
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irreversible inhibition, also called suicide inhibition. It basically follows the same steps as
a competitive inhibitor, but the substrate occupies the site for an extensive period of time
and can react chemically with the enzyme in such a way, that it cannot be removed and
basically destroys the active site.[205] In cases of polypharmacy, all the forms of inhibition
are possible. They are however impossible to predict, let alone quantify.
In this research, the interactions between the drugs and the genes were
investigated in the violent and the nonviolent groups. In the violent group, there was only
one subject who was on medication with no drug-gene interaction. In the nonviolent
group, 38 subjects did not use any prescription medication, which means the control
group was limited to 20 persons. Chi-square testing regarding the distribution of DG, DD,
and DDG interactions between the violent and the nonviolent group showed no
significant differences. This is most likely due to the small number of subjects in the
nonviolent group: 18 with DGIs, and 11 for both DDIs and DDGIs. Comparing the
violent and the nonviolent group, the fourth hypothesis could not be rejected.
Because there is an essential difference in people who have suffered from an
altered emotional state (AES) and those who commit acts of violence (assault/suicide/
homicide or A/S/H) after taking prescription drugs, these subgroups were studied further.
There were 25 subjects who committed an A/S/H and 30 who suffered an AES. In the
A/S/H group, there were 18 men and 7 women, in the less violent AES group those
numbers were 13 versus 17 (Chi-square statistic 4.556, P = 0.033). This is in line with
data indicating that men tend to be more aggressive than women.[262] The same trend was
seen in the comparison of male versus female when the violent and the nonviolent groups
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were compared. However, in that comparison, the difference was not statistically
significant.
There was no significant difference between the two subgroups regarding the
number of variant alleles, or the number of medications, but there was with respect to the
use of antidepressants. The subjects in the A/S/H subgroup used more antidepressants
compared to the AES subgroup (Chi-square statistic 5.303, P = 0.021). The same applied
to the use of psychoactive medication other than antidepressants (Chi-square = 3.905, P =
0.048).
With regards to the interaction between the genes and the drugs, the distribution of
the DGIs and the DDGIs were not significantly different (respectively P= 0.067 and P=
0.159). These numbers were close to being statistically significant, indicating that the
A/S/H group probably had more DD and DDG interactions, and that became significant
with the DDIs. There, the number of DDIs was statistically dependent on subgroup
(A/S/H vs. AES; Chi-square statistic 4.360, P = 0.036). This association between
combining medication and side effects, was not seen in the comparison between the
violent and the nonviolent group. Given that the number of subjects on medication in the
AES subgroup (30) is larger than the number of subjects on medication in the nonviolent
medication users (18), it is understandable that a different distribution of the number of
interactions between drugs and genes becomes more evident in the comparison between
the A/S/H and the AES group.
The data pointed at two different mechanisms that could lead to medicationinduced toxicity: either by way of lack of metabolic capacity through genetic variants, or
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by the enzyme system being overwhelmed by too much medication at the same time. The
cut-off point for number of variant alleles, seems to be four. No distinction was made
between the supposed amount of reduction or increase in function of an allele, the only
distinction was between wild type/normal function or not. For the likelihood of
developing violent behavior, increased function or decreased function did not make a
difference. Neither did the phenotyping for that matter. The only CYP450 which was
indicative for increased risk on violent behavior was CYP3A4, both in the number of
variant alleles and in the phenotyping, which is obviously related. The cut-off point for
number of medications was put at two, which is supported by the literature.[254, 260]
There seems to be a slippery slope in the risk for developing violent behavior. If
one has a limited number of variant alleles combined with a limited amount of
medication, the chances of acts of violence are also limited. This might explain why
millions of people take prescription drugs and less than 1% commit acts of violence.[43]
However, when either the variant alleles, or the amount of medication increase, one
might develop an altered emotional state. This should be taken as a warning sign. From
the medical histories, such emotional states are often considered as a sign that the
medication is not working correctly. A typical result is to add more or different
medication, elevating a patient to a level with increased risk of acts of violence.
Another area of concern are those patients with five or more variants alleles,
especially if those alleles lead to a classification of intermediate metabolizers. In this
research, 23 out of 113 (20%) had five or more variant alleles for the six CYP450s tested,
see Figure 4.1. In an effort to apply “personalized medicine”, physicians might type out
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some CYP450s. Often these tests are limited to two or three genes. However, this will not
provide enough information to know what drug-gene or what drug-drug interactions to
expect. Many guidelines do not address dose adjustments for IMs as they are considered
of no clinical importance, or because there are no data on the metabolic effects.[263] In this
research, 52 of 75 of the subjects (almost 70%) were on three or more medications, see
Table 4.13. Given the extensive practice of polypharmacy, these guidelines seem
insufficient. The combination of five or more variants alleles and more than two drugs,
bears a serious risk of acts of violence, especially when there are antidepressants or other
psychoactive medication involved. In the violent group, there were 15 subjects with the
combination of three or more drugs and five or six variant alleles, in the nonviolent
group, there were only two. In the violent group, there were 12 subjects on
antidepressants and five or six variants, in the nonviolent there were none.
There were five subjects in the A/S/H subgroup and one in the AES subgroup, who
did not fit those criteria, e.g., they had either four or less variant alleles or less than three
drugs. What they did have in common though was they were put on an increasing or
decreasing dose of drugs, which caused fluctuations in the drug levels in the blood.
Zackrisson et al. (2009), and Ahler et al. (2010) published their research on CYP2D6,
gene duplication and suicide. They hypothesized that subjects with an UM phenotype,
might metabolize their antidepressant medication too fast and not reach therapeutic
dosage.[233, 264] Another explanation could be that the rapid fluctuations in drug levels
causes suicidal acts. This is a known phenomenon, which is mentioned in the product
labels and in the literature.[252] The information on Cymbalta (duloxetine) states:
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“All patients being treated with antidepressants for any indication should be
monitored appropriately and observed closely for clinical worsening, suicidality, and
unusual changes in behavior, especially during the initial few months of a course of
drug therapy, or at times of dose changes, either increases or decreases.”[265]
Here, these six subjects are described in detail.
1. Subject one was on paroxetine 20 mg per day for seven years. He had three
variant alleles (CYP2D6*29 and CYP3A4*1G/*1G). These alleles are
associated with decreased metabolic activity. Due to legal circumstance, he
was forced to discontinue the medication. On day one he was told to reduce
the dose from 20 to10 mg per day. On day 15, he reported he was not doing
well, yet the prescribers decided to continue the tapering, and he was put on
10 mg paroxetine every other day. Due to increasing anxiety and sleep
problems, after another week the prescribers decided to go back to a dosage of
10 mg per day. Five days later he developed akathisia, beat his fiancé to death
with a fire extinguisher, shot and killed an off-duty law enforcement officer
with his own gun, and shot a bystander. He was tased and was shot three
times, and it still took several law enforcement officers to control him.
Witnesses described him as “a robot”, “an empty shell without a soul”, “his
face was without emotion, dead”. The paramedic who provided medical care
at the scene was baffled that the man was shot in the leg and the thorax and
showed no signs of pain.
Drug tapering should be extremely slow, with one mg per week along with
close observation of how a patient reacts. It can take six to 12 months, and in
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many cases people are not able to break the habit.[19] On paroxetine, going
from 20 to10 mg per day is way too fast. The longer a person has been on
psychoactive medication, the longer the tapering should take.[266, 267] Moreover,
paroxetine has a short half-life (21 hours) compared to other antidepressants.
Taking 10 mg every other day will lead to dangerous fluctuations in drug
levels which should be avoided.
2. Subject two was on paroxetine (40 mg per day) for eight months. He had four
variant alleles (CYP2B6*6, CYP2C19*17/*17, CYP2D6*41). He weaned
himself off paroxetine but kept the rest of his medications. A year later, he
started self-medicating with 40 mg paroxetine per day. He developed suicidal
ideation and agitation. Because his condition worsened, after eight days he
upped the dosage to 60 mg per day. He developed full blown akathisia. Fifteen
days later, he strangled his 11-year old son.
3. Subject three was on duloxetine and trazodone, he had three variant alleles (a
copy number variation with 2 inactive alleles and 1 active allele for CYP2D6,
and one allele *1G for CYP3A4). On day one, he was prescribed duloxetine,
30 mg per day. After for two weeks, this was increased to 60 mg per day. Due
to sleep problems and five weeks later, the duloxetine was acutely
discontinued and immediately replaced by trazodone, 50 mg per day. He
developed suicidal ideation. Because his condition worsened, he went to the
hospital 12 days later, where the dose trazodone was doubled. He developed
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full blown akathisia, and, four days later, he stabbed his wife, all but killing
her. A witness described him as having a “blank expression”.
4. Subject four was prescribed Adderall (amphetamine and dextroamphetamine),
10 mg twice per day on day one. He had two variant alleles, (CYP2C9*18,
CYP2D6*5). Within two days, he felt worse. He went to the hospital and was
administered acetaminophen, 500 mg, lorazepam 2 mg, prochlorperazine, 10
mg, midazolam, 2 mg and diphenhydramine, 2 x 25 mg. Within 15 minutes
after being discharged, his condition deteriorated, and he went back.
Subsequently, he was administered lorazepam, 2 mg, haloperidol, 2 x 1 mg,
and benztropine, 2 x 1 mg. On day 10, he was prescribed alprazolam 0.5 mg,
1-2 tablets as needed. On day 31, the dextroamphetamine was stopped and
substituted by lisdeamfetamine, 20 mg, 1 per day, increasing to 2 per day. He
was also prescribed oxycarbazepine, 150 mg, 1 per day, increasing until 4 per
day. When he was on the maximum dose of alprazolam and the maximum
dose of oxycarbazepine, combined with lisdeamfetamine, and being on
medication for approximately 62 days of, he attacked his pregnant partner.
5. Subject five was prescribed Vistaril (hydroxyzine), 50 mg per day and
Seroquel (quetiapine), 200 mg per day on day one. He had one variant allele
(CYP2D6*4). In the past, he was prescribed quetiapine at a dose of 50 mg per
day. His starting dose was four times higher than ever before. Approximately
20 days later he stabbed and killed his best friend.
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6. Subject six was put on morphine after a herniation operation. He had three
variant alleles (CYP2C9*3, CYP2C19*17, CYP2D6*41). He immediately
developed an altered emotional state, with delusions, agitation, memory
problems and tremors.

In summary, this research identified four risk factors for acts of violence or an altered
emotional state:

1. More than four variant alleles for the six tested CYP450s.
2. More than two drugs, especially when an antidepressant or other psychoactive
medication is prescribed.
3. Having an intermediate metabolizer (IM) phenotype at CYP3A4.
4. Fluctuations levels of psychoactive medication in the blood.

There is an association between prescription drugs, most notably antidepressants and
other psychoactive medication, having variant alleles for CYP2B6, CYP2C8, CYP2C9,
CYP2C19, CYP2D6 and CYP3A4, and the occurrence of an altered emotional state or acts
of violence. Based on these results, genotyping patients for these six CYP450s would
provide information as to who might be susceptible for adverse drug reactions, e.g., the
development of an altered emotional state or assault/suicide /homicide.
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Perspective on Potential Applicability to the Areas of Psychoactive Medication,
Mental Health and Violence/Suicide
The goal of the research was to investigate the association between psychoactive
prescription medication and P450 variant alleles on the one hand, and violent behavior
(assault, suicide, homicide) or an altered emotional state (AES), which is considered a
precursor to violent behavior, on the other. By identifying four risk factors for developing
acts of violence or an altered emotional state while on psychoactive medication, that goal
was accomplished. There are three areas where the results of this research can be applied:
patient care, forensic science and the justice system.
In the following paragraphs, patient care will be addressed through the increase in
polypharmacy and some critical remarks with regards to the guidelines of the Clinical
Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics
Working Group (DPWG). In addition, some instructions for prescribers are provided how
to decrease the chances of side effects by combining pharmacogenetic testing with the
use of a free website that focuses on identifying drug-gene and drug-drug interactions.
Forensic science and the justice system can benefit from these results by introducing
pharmacogenetic testing as part of substantiating a defense of involuntary intoxication
due to prescription drugs or establishing cause of death as an accident rather than a
suicide.
Within 20 years the start of the introduction of the SSRIs, there has been a 35-fold
increase of mentally disabled children in the US and world-wide. [268] The treatment with
ADHD medication and SSRIs has led to an explosion of bipolar disorder, which in its
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turn is often treated with antipsychotic medication.[268] Moore et al., (2010) estimated the
frequency of acts of violence towards others while using prescription psychoactive
medication, at about 0,25%.[43] Suicide and suicidal ideation were not included in their
research. Most side effects are reported by doctors and patients, they are not reported by
the pharmaceutical companies. However, only between one and 10% of side effects are
reported through the regular reporting systems.[42] It is safe to assume that the real number
of acts of violence is considerably higher.
A recent analysis by Olfson et al. (2019) among almost 140,000 mental health
care outpatients in the US between 2004 and 2015 showed that the absolute increase in
outpatient mental health care was due to an increase in individuals with less serious or no
psychological distress.[269] Individuals were questioned about their psychological stress,
which was then scored with the Kessler 6 scale (0 to 30; no psychological stress is scored
0 on the scale; less serious psychological stress is scored 1-12). Almost 64% of subjects
with serious psychological stress and almost 19% of those who suffered less serious or no
psychological distress used psychoactive medication.[269]
There is an increase in polypharmacy, e.g., combining antidepressants and
antipsychotic, even though there are about their efficacy.[162] According to Quato et al.
(2018), there have been reports on more than 200 medications associated with suicidal
ideation and depression.[260] The research group led by prof. Healy has identified 350
different prescription medication that can increase the risk of suicide by causing
depression, anxiety, agitation, akathisia, disinhibition and psychosis.[254] Normal emotions
in reaction to sad life events are labeled mental illness and they are subsequently treated
228

with psychoactive medication. Psychiatrists are over-diagnosing and over-medicating.[270]
Suicide in the United States is on the rise, with an increase of 24% between 1999 and
2014, see Figures 4.14, 4.15 and 4.16.[271]
Basically, it makes no difference whether people suffer from depression or
whether the depression is caused by the medication. Both groups are vulnerable to the
depression-causing effect of certain drugs. Physicians need to be aware that medication,
meant to improve a mental illness, can actually make it worse, especially when combined
with other medication.

Figure 4.14: Suicide death in the US per 100,000. Source: Center for Disease Control
and Prevention

Quato et al. (2018) performed a large study (26,192 adults) on the prevalence of
depression as a potential side effect of medication in the US between 2005-2014.
Subjects with three or more medications, with depression as possible side effect
(including antidepressants), were significantly more likely to suffer depression, compared
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to subjects not taking such drugs (15% versus 4.7%). That difference persisted when the
subjects on psychoactive medication were excluded. This is consistent with the reserpine
research from the 1950s and later, in which patients with hypertension were treated with
or without reserpine, a drug that has depression as a side effect.[10, 33, 73]

Figure 4.15: Suicide Rate in the US per 100,000 per race. Source: Center for Disease
Control and Prevention
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Figure 4.16: Cause of Death in Suicide in the US per 100,000. Source: Center for
Disease Control and Prevention

Even if people suffer from psychiatric illnesses, they still can develop the same
side effects as people without any psychiatric pathology. Their genetic variants will
function similar to mentally healthy patients. If anything, they might be more sensitive
for side effects from these drugs and especially in the case of variant alleles and
polypharmacy, the dosage should be lowered even more than in other patients.[137]
To decrease the number of people dying due to acts of violence, doctors and
patients need to acknowledge there is an association between psychoactive medication
and acts of violence. Despite the body of evidence, this association is still largely not
recognized. The US Preventive Services Task Force (USPSTF) proposed a screening
program for adults for depression. Yet, the typically used depression scales do not contain
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questions regarding prescribed medications that have depression as a possible side
effect.[260]
These adverse effects need to be discussed when both physicians and patients
consider psychoactive medication, for whatever indication. In the US, approximately
100,000 patients die each year due to prescription medication, even though no errors were
made. Another 100,000 die due to errors.[272] The European Commission estimated that
around 200,000 people die each year due to adverse events in Europe. The costs in
Europe are estimated at €79 billion (ca. 88 billion US dollars). Pharmacogenetic testing is
becoming cheaper every year and more and more insurance companies are paying for it.
Given that three or more drugs can put a patient at risk, pharmacogenetic testing should
become standard practice.

Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch
Pharmacogenetics Working Group (DPWG)
Gaedigk et al. (2008, 2013) have designed a scoring system for CYP2D6 alleles,
see Table 4.39.[273, 274] That scoring system has been accepted by both CPIC and the
DPWG.
Both consortia also set up guidelines for adjusting drug dose, based on
pharmacogenomic testing.[275] CPIC has reviewed 40 gene-drug pairs which led to 19
guidelines. The DPWG studied 86 gene-drug pairs and published 47 guidelines. [275] There
are some severe limitations to following these guidelines. Firstly, regarding the
translation from activity score to phenotype, there are differences between CPIC and the
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DPWG, as is evident in Table 4.40. Differences in designating phenotypes based on
genotype can lead to differences in dose recommendations.[212]

Table 4.39: Activity score (Taken from Gaedigk et al., 2008, 2013)
Activity
score (AS)

Allele 1

0
0,5

Null
Null

1

Null

1
1.5
2
2

Reduced
Reduced
Functional
Reduced x 2

>2

Functional

Allele 2
Null
Reduced
Functional
Reduced
Functional
Functional
Functional
Ultrarapid
(Functional xN)

Examples of
diplotypes

Phenotype
assignment

*3/*4, *5/*6
*5/*10, *4/*41

PM
IM

*1/*4x2, *2/*6

EM

*9/*41, *1/*10
*1/*17, *2/*29
*1/*2, *2/*2
*1/*41x2, *2/*10x2

EM
EM
EM
EM

*2x2/*35, *1x2/*2

UM

Table 4.40: Discordance between CPIC and DPWG
Gene

Genotype / activity score

CYP2C19

*1/*17

CYP2D6

AS 1.0

CYP2D6

AS 2.5

Classification *
CPIC: Rapid metabolizer
DPWG: Normal metabolizer
CPIC: Normal metabolizer
DPWG: Intermediate metabolizer
CPIC: Ultra-rapid metabolizer
DPWG: Normal metabolizer

Secondly, there are the actual differences in dose adjustments. With regards to
paroxetine, one of the most dangerous SSRIs according to Moore et al. (2010).[43] CPIC
advises to consider an alternative drug if the patient is a poor metabolizer, while the
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DPWG advises to start with the dose recommended by the manufacturer, see Table
4.41.[275]
Thirdly, the guidelines focus on one drug-one gene interaction. Swen et.al. (2011)
admit that such an approach is often limited.[263] Polypharmacy is on the rise, just as
pharmacogenetic testing. In this research, the mean use of medication in the violent group
was 4.4. In the research of Verbeurgt et al. (2014), the mean medication count of 501
subjects (nearly half of the data set) with serious interactions, was 11.[197] In the 2010
Guide to Psychiatric Drug Interactions, Preskorn and Flockhart published a figure,
depicting the increase in patients on three or more medications between 1974 and 1995 at
the National Institute of Mental Health, see Figure 4.17.[231]

Figure 4.17: Increasing Use of Polypharmacy in Psychiatric Patients Between 1974 1995 (Taken from Preskorn and Flockhart, 2009)
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In this research, the mean number of variant alleles in the violent group was 3.9.
Of the 1013 subjects tested by Ji et al. (2016), for five genes, only 10% had one
actionable variant allele, the rest had more than one.[276] In 14,578 subjects tested on five
CYP450s by Hocum et al. (2016) approximately 93% did not have a normal metabolizer
phenotype on all the five tested CYP450s.[196] The guidelines of CPIC and the DPWG will
not be helpful to patients with more than one drug combined with more than one genetic
CYP450 variant allele, which, given the research available, most likely will be the
majority of patients.
Additionally, the guidelines overestimate the metabolic capacity of IMs,
especially if a substrate is prescribed that inhibits the CYP450 that it depends on. For
instance, paroxetine is mainly metabolized by CYP2D6, which it also inhibits. Paroxetine
is a pan-inhibitor; besides CYP2D6, it inhibits CYP1A2, CYP2B6, CYP2C8, CYP2C9,
CYP2C19 and CYP3A4. Both CIPIC and the DPWG advise that, if paroxetine is
prescribed in the case an IM, to start with the dose as recommended by the
pharmaceutical company.
Figure 4.18 depicts the urinary metabolic ratio of a probe substrate, sparteine.[183]
As can be seen in this figure, there is an overlap between the subjects who can be
considered either EM or IM. Sparteine is mainly metabolized by CYP2D6, which has a
greater than 1000 fold interindividual variability in protein expression.[181, 185] Therefore, a
certain amount of subjects could be wrongly classified based on genotyping.
Genotypically EMs could be phenotypically IMs.[249] What could happen to an IM on
paroxetine is that, due to inhibition and phenoconversion, the patient becomes a PM over
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time.[214] Because paroxetine also inhibits CYP3A4, the backup system would also be
reduced as well. Toxicity would creep up on these patients, and, weeks to months later,
they could start experiencing side-effects that could lead to acts of violence. In the
guidelines, these risks are not considered, thus overestimating the metabolic capacity of
IMs.

Table 4.41: Difference in Guidelines Between CPIC and DPWG with Respect to
Paroxetine

Gene

Phenotype

Action
Therapeutic
Required Recommendations

IM

No

PM

Yes

UM

Yes

IM

No

DPWG PM

No

Drug

CIPIC

CYP2D6

Paroxetine

UM

Yes
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Initiate therapy with
recommended starting
dose.
1) Consider alternative
drug not predominantly
metabolized by CYP2D6.
2) If paroxetine use
warranted, consider a 50%
reduction of recommended
starting dose and titrate to
response.
Consider alternative drug
not predominantly
metabolized by CYP2D6.
Initiate therapy with
recommended starting
dose.
Initiate therapy with
recommended starting
dose.
Consider alternative drug
not metabolized by
CYP2D6.

A similar mechanism is in play with regards to women with breast cancer and a
reduced function allele, CYP2D6*10. These women are designated EM, but Kiyotani et
al., (2008) reported a 4-fold higher rate of cancer relapse in women on tamoxifen
treatment compared to women with a *1/*1 genotype.[277] According to the DPWG, these
women are not considered IMs and do not need dose adjustments.[263] Tamoxifen is a
prodrug and needs to be metabolized by CYP2D6 into its active metabolite. Women with
one *10 allele are less capable of doing that, which can unnecessarily decrease their life
expectancy.[210] These pharmacokinetic effects should be mentioned in the guidelines.
Ekhart et al. in their paper from 2017, exhibit the lack of awareness of how patients
with reduced function alleles can react.[257] They investigated 18 patients who reported
aggressive behavior while using SSRIs and had variant alleles for CYP2D6 and
CYP2C19. They did not find any PMs for either CYP450.

Figure 4.18: Urinary Metabolic Ratio (MRs) for Sparteine in a German Population
(n=308) in Relation to the Genotype (Taken from Zanger, 2013)
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According to the authors, that result provided no supporting evidence of a
“significant relationship between CYP2C19 and CYP2D6 polymorphisms, and aggression
in patients using SSRIs”.[257] As Eikelenboom and Fogleman (2018) pointed out in their
Letter to the Editor regarding this paper, a more likely explanation is that individuals,
who are receiving psychoactive drugs and are PMs, are the first to feel the adverse effects
of medication, and stop the medication when they feel increasingly worse instead of
better.[278]
The question can be raised as to why the authors of CPIC and DPWG failed to
clearly mention the limitation of the guidelines. The notion that enzymes are specific
catalysts which metabolize one substrate into one metabolite is not accurate. In fact,
many enzymes are, on many levels, promiscuous.[279, 280] In cases of polypharmacy, the
guidelines do not provide an accurate picture. The same applies to cases of variant alleles
for more than one CYP450. In those cases, the metabolic rates can differ significantly
from what is to be expected in a one drug - one gene situation. As levels of substrates or
metabolites rise, the specificity for certain substrates of enzymes changes. This can lead
to enzyme catalytic promiscuity, enzyme substrate promiscuity, and to a diversion from
the usual specificity to, sometimes hardly related, previously unprecedented reactions.[217,
281-283]

Inhibitor promiscuity can present another problem. The inhibitor promiscuous
activity of an enzyme can vary and CYP450s are inhibited by many substances. When
more than one drug is involved, overlapping preferences from the substrates involved
with different, unpredictable inhibitory interactions can occur, causing dangerous
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DDIs.[284] To be able to compare inhibitory promiscuity, Nath and Atkins (2008), devised
the promiscuity index, see Figure 4.19.[285] The closer the value to one, the higher the
promiscuity. They calculated the inhibitory promiscuity of CYP2C9, CYP2C19 and
CYP3A4. CYP2C9 was less promiscuous, and CYP2C19 and CYP3A4 were comparable
in their promiscuity, but obviously, all four of the CYPs were highly promiscuous. [285]

Figure 4.19: Promiscuity Index, GSTs = Glutathione S-transferases (Taken from Nath
and Atkins, 2008)

Using the same promiscuity index and 11,578 inhibitors instead of the 64 used by
Nath and Atkins, Cheng et al. (2011) calculated a rank order in five CYP450s, from less
inhibitory activity to more: 2D6 < 2C9 < 3A4 < 2C19 < 1A2. They illustrated the
difference between a selective and a promiscuous inhibitor in Figure 4.20.[286]
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Figure 4.20: Selective Versus Promiscuous Inhibition (Taken from Cheng et al.,
2011)

These different forms of promiscuity can lead to phenoconversion. When
reviewing drug-gene interactions is limited to one drug and one gene, promiscuity may be
overlooked and the effects of reduced metabolism and dangerous side effects may be
underestimated. Phenoconversion is a serious and difficult to predict phenomenon, due to
all the aspects involved. One of the aspects that is often overlooked, is the duration of
phenoconversion after the discontinuation of the inhibitor, see Table 4.42.[214]
In case of DGIs or DDIs where an inhibitor is discontinued and other medication
is added, the inhibition can take weeks to wear off. During that period, the inhibited
enzyme will metabolize at a slower rate, with drug levels in the blood that will be
increased. Once the enzyme is able again to metabolize a substrate at its normal rate, the
blood levels will decrease. If not anticipated, this mechanism can lead to toxicity or under
treatment. In the guidelines, this effect is not mentioned.
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Table 4.42: Duration of Inhibition after Discontinuation of the Inhibitor (Taken from
Shah et al., 2014)

Fluoxetine

Duration of Phenoconversion after
the Last Dose of Inhibitor
At least 3 days
to 21 days
63.2 ± 5.6 days

Paroxetine

20.3 ± 6.4 days

Sertraline

25.0 ± 11.0 days

Terbinafine

>4 weeks
4 weeks after 6 weeks of treatment
6 weeks after 18 weeks of treatment

Co-Medication
Quinidine

Paroxetine

Another problem in developing guidelines, is the limited research. Preskorn and
Flockhart (2018) calculated the possible combination of polypharmacy for up to five
drugs at 1015. That was based on the 2017 Physicians’ Desk Reference. Yet, in 2017 there
were approximately 1,000+ DDI studies performed.[280] Most of these studies focused on
the interaction between one drug and one other drug. The complexity of drug-drug and
drug-gene interactions cannot be solved with one-on-one research when there are so
many drugs involved. The only way to quantify a metabolic rate or a phenotype in a
patient, is by actually measuring it in real time. Anything else requires a certain amount
of speculation.
In their 2008 paper, Gaedigk et al. emphasized that whatever scoring system to
predict phenotype is used, other factors that determine the metabolic rate should be
considered as well.[273] Such factors can be renal function, co-morbidity e.g., liver disease,
co-medication etc. Within the complexity of polypharmacy, there are too many variables
to quantify how much a specific variant allele will be able to contribute to the metabolism
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of a certain substrate. Under laboratory circumstances, probe substrates like
dextromethorphan can be used to determine a urinary metabolic rate for several variant
alleles and score the activity.[274] But is that applicable to patient X, who’s CYP2D6*4
might differ significantly in activity compared to patient Y’s CYP2D6*4? Designating a
phenotype based on a liver extract and a probe substrate and applying that to an
individual patient, is at most an educated guess. The goal of this research was to see if
variant alleles in a broad sense can be used to identify people at risk. The six CYP450s
tested, are part of a system that is highly interactive and complex, and our current
knowledge has only scratched the surface. If a person has more than four allelic variants,
he/she is at risk. Even if it is not known what the efficacy of their affected alleles is, a
prescriber should be careful with his/her prescription pad. And therein lies the problem:
CYP450 genes and their interactions are generally not assayed.
An even bigger problem in applying the CPIC and DPWG guidelines, is whether
clinicians in general practice are comfortable with their knowledge of
pharmacogenomics.[287] Applying the guidelines assumes a certain level of understanding
which can be hard to acquire outside research or academia. Some pharmacists in hospitals
for instance, refuse physicians CYP450 testing on the basis that they don’t consider a
particular CYP450 to be clinically relevant. In cases of polypharmacy, such a refusal is
not advisable.
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Pharmacogenetic Testing in the General Practice
In 2001, Phillips et al. published a clinician’s checklist in the Journal of the
American Medical Association (JAMA) to reduce adverse drug reactions, see Table
4.43.[213] Although correct, it does not provide a guideline about how to collect the
information needed to choose the best medication. Almost two decades later, science has
involved in such a way that, for every prescriber, it is relatively easy to access the
available knowledge.
The results from this research could bridge the gap between academia and the day-today practice. A physician only needs to be aware that more than two drugs and more than
four variant alleles for CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4,
increases the risk of side effects. After patients get tested for those six CYP450s, the
prescribing physician should keeps those results next to the medication list. If a patient
has two or more drugs, those drugs should be investigated on the website of Transformer,
see Figure 4.21 and 4.22.[191] Most of the information on Transformer was compiled from
the original publications, available through Pubmed. Information was also gathered using
databases e.g., Drugbank and Fachinfo, where the Summary of Product Characteristics
(SPCs) can be found.[191]
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Table 4.43: A Clinician’s Checklist for Evaluating the Potential Role of
Pharmacogenomics in Reducing Adverse Drug Reactions (Taken from Phillips et al.,
2001)
A Clinician’s Checklist for Evaluating the Potential Role of Pharmacogenomics in
Reducing Adverse Drug Reactions (ADRs)
Check whether the drug is known to be metabolized by a polymorphic drugmetabolizing enzyme. Pay special attention to the prevalence of polymorphic alleles
of the relevant drug-metabolizing enzyme in the patient population being treated
since prevalence varies considerably among groups.
If genetic variability may be a significant problem:
• Consider alternative drugs that may not be subject to known polymorphic
drug-metabolizing enzymes.
• Advise the patient to carefully monitor adverse effects early in therapy.
• Be aware of compounded ADR problems when prescribing 2 or more drugs
concomitantly that interact with the same drug-metabolizing enzymes.
• In some circumstances (particularly when a patient has an ADR and no alternative
medication is available), genotyping can be considered to ascertain that
a defective drug-metabolizing enzyme is the likely cause for the observed ADR
and to permit an appropriate dosage reduction.
Figure 4.21 shows the search screen. As an example, enalapril and tasosartan have
been filled in under “Cocktail”. Figure 4.22 shows that both substrates are metabolized
by CYP3A4. That indicates drug-drug interactions. If a patient has a variant allele on
CYP3A4, drug-gene interactions occur. By clicking the blue end of the header,
alternatives and their metabolic pathways come up. A prescriber can then choose a drug
metabolized by a different CYP450 and thus prevent potential dangerous DGIs, DDIs and
DDGIs.
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Figure 4.21: Search Screen in Transformer

Figure 4.22: Search Results in Transformer
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Transformer is a free and easy to use website, with links to references on which
the advises are based.
Preskorn and Flockhart (2009) advise prescribers to create a personal formulary
with approximately 20 - 30 medications, with which physicians should be thoroughly
acquainted.[231] In combination with one time genetic CYP450 testing and online use of
databases like Transformer, it will not take much time to decide on a patient’s
medication, while at the same time, overmedication and dangerous interactions between
drugs and genes can be limited if not prevented.

Toxic Tort, Involuntary Intoxication and Toxicogenomics
If prescription drugs can cause criminal acts like violence through toxic side
effects, a defendant can put on a defense of involuntary intoxication. They can posit that
it was the exposure to the medication that caused the criminal behavior, hence the
defendant is not to blame.
In civil cases, the exposure to a chemical substance causing harm is called toxic tort.
For a toxic tort to be successful, the plaintiff has to prove two elements: exposure and
causation. The toxic substance must be able to cause the ailment (general causation) and
the toxic substance must have did indeed caused the ailment (specific causation).[288, 289]
More often than not, general causation is not the problem. For instance, it is common
knowledge that asbestos can cause mesothelioma, but how to prove that in a specific case
it was the asbestos and not the smoking that caused the cancer? What level of probability
is necessary to establish specific causation? Epidemiological studies which strongly
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support a causal relation between a substance and an alleged injury, are considered the
strongest evidence.[289, 290]
Courts vary in their demand of the level of probability. In the jurisprudence
regarding toxic tort, the judges have laid down some important arguments and decisions.
In the case Westberry v. Gislaved Gummi AB, 178 F.3d. 257 (1999), the defendant put
forward that the testimony from the expert for the defense was not admissible, due to the
lack of epidemiological studies, peer-reviewed publication, animal experiments, or
laboratory data to support a relation between the substance involved and the disease of
the plaintiff.[291] The court however, did not agree, and ruled the expert’s opinion based
upon a differential diagnosis admissible. A differential diagnosis (DD) was defined by the
court as a standard scientific technique in which the results of the physical examinations,
the medical history and clinical tests are reviewed together, and possible causes are listed.
Through a process of elimination, less likely causes are ruled out until, from the causes
that are left, the most likely one is chosen. As it was put in Glaser v. Thompson Med.
Co., 32 F.3d 969, 978 (6th Cir.1994): This technique "has widespread acceptance in the
medical community, has been subject to peer review, and does not frequently lead to
incorrect results."[292] The court in the Westberry case did not deem it necessary that all
potential causes needed to be ruled out.[290] The vast majority of the courts of appeals have
upheld that a reliable DD is in line with Rule 702, which regulate the standards under
which an expert can testify. In Benedi v. McNeil-P.P.C., Inc., 66 F.3d 1378, 1383-85 (4th
Cir.1995) for instance, a treating physician could testify about the cause of a plaintiffs
liver failure, even though no epidemiological data were available.[293] In the previously
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mentioned Westberry v. Gislaved Gummi case, the expert for the plaintiff was unable to
present scientific literature regarding the causality between the substance and the
illness.[291] Yet, the court accepted the Material Safety Data Sheet (MSDS) in which that
relation was noted, as such. The court also regarded a temporal relationship between
being exposed to a substance and the development of an illness, as evidence of
causation.[290] If that is the case, other standard methods of determining toxicological
effects are not necessary, per the transcript. Another important indication of causality
according to the court was the de-challenge - rechallenge effect: the symptoms subsided
when the substance was removed and returned when the substance was reintroduced, thus
indicating a temporal relationship.[290]
Toxicogenomics, a discipline that deals with gene and protein activity in relation
to exposure to toxic substances, will, in the near future, likely play an increasing
important role in establishing both general as well as specific causation.[288, 289] With
respect to general causation, toxicogenomic data might indicate that certain genetic
profiles in individuals may increase their chance for suffering injury due to a toxic
substance. Once exposed, changes in gene expression as a result of the exposure could
directly link the substance to the injury, thus indicating specific causation.[288, 289]
In criminal cases involving prescription medication, the drug is the toxic
substance. Piel (2015) reviewed appellate cases involving involuntary intoxication due to
prescription medication.[294] Table 4.44 shows 100 criminal case in which the medication
is classified by intoxicating substance.
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The Model Penal Code Section 2.08 (1985) mentions that, if a substance is
“pursuant to medical advice” and the intoxication is “pathological”, meaning “grossly
excessive in degree given the amount of the intoxicant, to which the actor does not know
he is susceptible”, the intoxication is an affirmative defense.[295] It also a condition that
“the actor at the time of his conduct lacks substantial capacity either to appreciate its
criminality [wrongfulness] or to conform his conduct to the requirements of law”. The
defendant must admit to the crime and the goal is to be excused from liability. For such a
defense to be successful, the burden of proof rest with the defense. They have to prove
that 1: the intoxication was involuntary, 2: the defendant was actually intoxicated at the
time of the criminal act, and 3: that the defendant was mentally insane. According to Piel
et el. (2015), it is difficult for defendants to meet all three requirements.[294]
Considering the results of this research, the following arguments can be made.
Regarding the first requirement: since the substances involved are prescribed by
physician and hence are “pursuant to medical advice”, it is covered by the Model Penal
Code. However, when a defendant combined the medication with other substances e.g.,
alcohol, or illegal substances, the chances of a court considering involuntary intoxication
greatly reduce.[294, 296]
Considering the second requirement: drug levels in the blood could be useful,
although low levels of psychoactive drugs could still cause severe side effects and acts of
violence.[76, 127] What also needs to be made clear to the court, is that withdrawal from
these drugs can present with the same symptoms and behavior as toxicity. Withdrawal
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can last for weeks to months, and when drug levels in blood are determined they will be
negative.[297]
Table 4.44: Cases by Intoxicating Substance (Taken from Piel, 2015)
Agent

Cases (n)

Sedative hypnotic/narcotic

45

Antidepressant

18

Stimulants
Steroids
Over the counter
Antipsychotic
Miscellaneous
Combined effects >1 class
Undefined psychotropic

6
3
2
1
9
9
7

From a medical point of view, these symptoms and behavior will still be
considered as results from toxicity. Withdrawal symptoms could be useful as proof that
an individual is suffering from a mental defect, since it can be considered medicationinduced brain damage.
Considering the third requirement: the mental condition of a defendant at the time
of the crime, should be consistent with the mental condition described in the 1843,
English M'Naghten case, which is the national accepted, standard rule in the US. As it
was noted in those days in the House of Lords:[298]
“That persons of otherwise sound mind, might be affected by morbid delusions: that
the prisoner was in that condition: that a person so labouring under a morbid
delusion, might have a moral perception of right and wrong, but that in the case of
the prisoner it was a delusion which carried him away beyond the power of his own
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control, and left him no such perception; and that he was not capable of exercising
any control over acts which had connexion with his delusion: that it was of the
nature of the disease with which the prisoner was affected, to go on gradually until
it had reached a climax, when it burst forth with irresistible intensity: that a man
might go on for years quietly, though at the same time under its influence, but
would all at once break out into the most extravagant and violent paroxysms”.
And:
“that to establish a defence on the ground of insanity, it must be clearly proved that,
at the time of the committing of the act, the party accused was labouring under such
a defect of reason, from disease of the mind, as not to know the nature and quality
of the act he was doing; or, if he did know it, that he did not know he was doing
what was wrong”.
In Colorado, the rules for insanity are described in Low, 732 O.2d at 628:
“The applicable test of insanity shall be, and the jury shall be so instructed: "A
person who is so diseased or defective in mind at the time of the commission of the
act as to be incapable of distinguishing right from wrong with respect to that act is
not accountable. But care should be taken not to confuse such mental disease or
defect with moral obliquity, mental depravity, or passion growing out of anger,
revenge, hatred, or other motives, and kindred evil conditions, for when the act is
induced by any of these causes the person is accountable to the law”.
The defendant in the Low case had been taken “Hold” cough drops, which contain
dextromethorphan hydrobromide. He developed a toxic psychosis with hallucinations,
delusion, and a distorted perception of reality. He then stabbed a friend. The psychiatrist
for the defense in that case, Dr. Lewis, examined him more than half a year later, at
which time he was completely sane. In the opinion of this psychiatrist, he was clearly
suffering of an "organic delusional syndrome" or "toxic psychosis" at the time of the
crime. Dr. Lewis testified:
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“There seems to be no doubt that the patient was legally insane at the time he committed
the act. At that point in time, he literally and concretely did not know the difference
between right and wrong and was unable to adhere to the right. This case comes as close
to duplicating "McNaughten" [sic] as any I have ever seen.”
The M’Naghten case is considered to be the first modern insanity standard.
This meant the defendant was not able to form intent, necessary to commit a crime.
The chief of the Department of Psychiatry and Forensic Psychiatry at the Colorado State
Hospital, Dr. Huffaker, testified at trial that “Dr. Lewis report was excellent and I concur
with it wholeheartedly. Dr. Huffaker agreed with the diagnosis of toxic psychosis and
concluded that the defendant was "temporarily insane" when he stabbed the victim. It is
important to emphasize that when somebody is suffering from a toxic psychosis, he does
not know right from wrong, and is not able to adhere to the law in the same way as such a
person would feel and behave when not psychotic. Psychosis has elements of automatic
behavior. Healy (2013) defines automatism as a temporary malfunction of the brain,
caused by physical or psychological circumstances which forces a person to behavior in
which he has no choice, and in which is his not able to control his acts.[229] This is
consistent with what is described in the M'Naghten case. It is similar to behavior people
exhibit when they sleepwalk or suffer from certain frontal syndromes, delirium or
epilepsy.[229] De Kogel et al. explained it in their 2015 paper, that when the frontal cortex
is disconnected from the rest of the brain, automatic behavior can occur. [299] In such a
state, an individual can interact with his environment, he can plan, he can perform
activities, but the frontal cortex is no longer able to control the behavior in a moral sense.
There is consciousness, but the person’s own identity and moral framework are beyond
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reach. The person is no longer aware of his position within his environment. A person in
a situation of automatic behavior cannot be expected to act consciously.[299] In such a
state, intent cannot be formed as an automatism leads to a total alienation of reason.
With regards to proving causation: in the Westberry case, the court accepted the
Material Safety Data Sheet (MSDS) in which the relation between the toxic agent and the
illness was noted, as evidence of causality. The MSDS is comparable to the FDA
approved product data sheets. Aggression, agitation, anxiety, confusional state,
depression, disorientation, homicidal ideation, akathisia, and suicidality, are all
mentioned in the product data sheets of most psychoactive medication, some even as
black box warnings. Through CYP450 testing, toxicogenomics can be applied to prove an
increased sensitivity for side effects in case of certain drug use. Piel (2015), describes a
case where an expert emphasized the role of hepatitis in relation to involuntary
intoxication.[294] The decreased drug metabolism caused by liver failure is comparable to
the effects of reduced to loss-of-function CYP450 alleles. The patient history can provide
a temporal relationship and/or indications of challenge-dechallenge-rechallenge effects,
and a DD can be formulated. Withdrawal and automatism can be explained to the jury.
Providing these elements in their context before the court and the jury, it should be
feasible to put up a successful defense of involuntary intoxication and temporary insanity
in cases of violence through toxic side effects caused by prescription drugs.
In cases of suicide, CYP450 testing should be performed to establish the
possibility that an individual died due to an impaired metabolic rate or drug-gene, drugdrug or drug-drug-gene interactions. If such could be the case, the manner of death
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should be ruled an accident due to involuntary intoxication instead of a suicide. This is of
importance with regards to life insurance, with insurance companies not willing to pay
out in case of suicide. For families, such a ruling could present a warning sign and
emphasizes the need to get CYP450 genotesting as well.

Limitations
In this study, the number of variant alleles were scored, indiscriminate of the amount
of loss or gain of function. To be more accurate, the metabolic rate and the phenotype in
cases of multiple variant alleles and polypharmacy should be measured in real life, at the
time the patient is actually on the medication. Since that is not yet possible, and most
variant alleles have reduced metabolic capability, the approach chosen is sufficient for the
goal of this study. Also, other factors that influence the metabolic rate, e.g., co-morbidity,
smoking, certain foods, were not incorporated, as that information was often not
available.
Drug levels in the blood at the time of the acts of violence or altered emotional
states would provide important information. Unfortunately, if blood has been drawn, it is
seldom checked for more than alcohol and illegal substances. However, drug levels are
not iron clad evidence, since the side effects, studied in this research, can happen at low
blood levels and, when patients are in withdraw, there would be no measurable drug
levels at all.[297]
The number of subjects in this study was limited (55 subjects and 58 controls).
Although sufficient for statistical purposes, a larger study would provide more concrete
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evidence. Getting access to people who have committed crimes is extremely difficult.
Gathering information on individuals that have committed suicide, is even harder.
However, Ekhart et al. (2017) based their conclusion that there was “no supporting
evidence for a significant relationship between CYP2C19 and CYP2D6 polymorphisms,
and aggression in patients using SSRIs” on 18 subjects.[257] Their conclusions were
disputed by Eikelenboom and Fogleman (2018) on several points, including their small
sample size. [279]
An often-heard argument is that an underlying psychiatric illness is responsible
and that patients did not take their prescribed drugs, or not in enough quantities. Some
subjects had received previous psychiatric treatment, which is not the same as suffering
from a psychiatric condition. Many subjects received psychoactive medication for nonpsychiatric conditions, e.g., sleep problems, grieving, exhaustion, stress, mild anxiety,
urine incontinence, premature ejaculation. On psychoactive medication, they developed
more or less severe psychiatric conditions, were diagnosed with major depressive
disorder, schizophrenia, bipolar, mania, borderline personality disorder etc., and were
completely cured after discontinuation of the prescribed medication. Such a change in
mental condition does not support a diagnosis of psychiatric illness. In addition, given the
goal of this research, i.e. identifying people vulnerable to side effects, pre-existing
psychiatric conditions does not exclude them from being at risk for the effect of variant
alleles or polypharmacy.
Recently, the FDA raised questions about pharmacogenomic testing for
antidepressants.[300] Last year, the American Psychiatric Association (APA) pushed back
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on pharmacogenomics testing claiming a lack of evidence. This was focused on the
predictability of which medication would work best with respect to antidepressants.
There are some interesting aspects to this action from the FDA and the APA. From
independent literature, the evidence that antidepressants work is, at best, meager.[60, 142, 301,
302]

They do not cure the depression; they dumb the emotions until the depression

subsides.[19, 87, 303] If antidepressants do not actually cure depression, it is logical that
pharmacogenomics testing, aimed at prediction therapeutic response, will not be helpful.
In this research, the goal was not to study therapeutic response, but to predict dangerous
side effects. The results strongly support pharmacogenomics testing. This raises the
question why the APA and the FDA do not put more emphasis on preventing harm.
Possibly because pharmacogenomic testing will most likely lead to less medication use.
Pharmaceutical companies have a long history of influencing both the FDA and
the APA. Since the 1990, opposition from the FDA has been dealt with through direct
pressure or through their contacts in Congress.[153] Time and again the FDA sided with the
interest of the pharmaceutical companies over that of the people. An example of that is
approving variations of old drugs that were no improvements over existing drugs, or
rejecting negative reports regarding drug safety. Accepting people with connections to
pharmaceutical companies on its advisory panels is a regular practice.[19, 141, 153] The
Diagnostic and Statistical Manual of Mental Disorders (DSM) is a publication from the
APA. Cosgrove et al. (2012) analyzed the financial ties with the pharmaceutical
companies of the members of the different panels and taskforces for the DSM-IV and
DSM-5.[161] Three quarters of the working groups allowed their members to have financial
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ties with manufacturers. Of the panel for Mood Disorders 67% (N=12) had ties with the
companies that produced the medication to treat the disorder. Of the panel for Psychotic
Disorders and the Sleep/Wake Disorders (which include “Restless Leg Syndrome”), the
numbers were respectively 83% (N=12) and 100% (N=7). The most financial conflict of
interest occurred in those working groups aiming at first-line intervention.[161]

Summary
This research was set up in an effort to shed light on the association between
psychoactive prescription medication, certain P450 variant alleles, and violent behavior
or an altered emotional states. The null hypotheses to be tested were:

1. Psychoactive medication is not correlated with violent acts and behavior as an
adverse drug event.
2. People who exhibit violent acts and behavior do not take more prescribed
drugs than subjects in the nonviolent group.
3. People who exhibit violent acts and behavior, do not have more variant alleles
for CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4.
4. Drug-gene, drug-drug, and drug-drug-gene interactions do not increase an
individual’s vulnerability for toxic effects of drugs.

Fifty-five subjects with violent behavior were compared to 58 healthy controls with
regards to characteristics relating to the four hypotheses. In addition, the violent group
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was divided up into 30 subjects with an altered emotional state and 25 subjects who
committed assault/suicide/homicide, and these subgroups were subsequently compared.
Through literature study, genetic testing and statistic calculations, the first three
hypotheses could be rejected. The fourth hypothesis, the interactions between drugs and
genes, could not be rejected due to the results in the sample of violent versus nonviolent
subjects. There was an indication that the assault/suicide/homicide group might have
more drug-gene and drug-drug-gene interactions compared to the altered emotional state
group, but that only became evident with the drug-drug-interactions. The number of
subjects on medication in the control subgroup altered emotional state (30), was larger
than the number of subjects on medication in the control group of nonviolent medication
users (18). Therefore, it is reasonable that a non-random distribution of the number of
interactions between drugs and genes is more evident in the comparison between the
assault/suicide/homicide and the altered emotional state group, than in the violent versus
the nonviolent group. Comparing the A/S/H and the AES group, the fourth hypothesis
can also be rejected.
The risk factors for acts of violence or an altered emotional state are:

1. More than four variant alleles for the six CYP450s that were tested.
2. More than two drugs, especially when an antidepressant or other psychoactive
medication is prescribed.
3. Having an intermediate metabolizer (IM) phenotype at CYP3A4.
4. Fluctuations in the levels of psychoactive medication in the blood.
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With over-diagnosing and polypharmacy on the rise, an increasing number of people
will be exposed to psychoactive medication, with all the risks of side effects e.g., suicide
and homicide that go with it.[231, 304, 305] This is substantiated by the growing numbers of
suicide and mass shootings in the US.
The guidelines, as provided by Clinical Pharmacogenetics Implementation
Consortium (19) and the Dutch Pharmacogenetics Working Group (47), only apply in
cases of one drug and one gene. Given the result of this study of an increased risk in
individuals with more than four variant alleles and/or more than two drugs, the guidelines
are of limited use. There are essential differences between the two consortia in assigning
phenotype based on genotype and with respect to recommendations regarding dose.
To decrease the number of people dying due to acts of violence, doctors and patients
need to acknowledge there is an association between psychoactive medication and acts of
violence. These adverse effects need to be discussed between physicians and patients
when one or the other is considering psychoactive medication, for whatever indication.
Pharmacogenetic testing is becoming cheaper every year and more and more insurance
companies are paying for it.[306] The majority of people have one or more variant alleles
for the tested CYP450s, and given that three or more drugs can put a patient at risk,
pharmacogenetic testing should become standard practice.
Once a physician has the genotypes for the six CYP450s tested in this research for his
patients on file, he/she needs to acquaint himself with databases like Transformer. If a
patient needs two or more drugs, this medication can be looked up in Transformer and the
prescriber can check for drug and gene interactions. With the results of the CYP450
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testing, drug-gene interactions can be noted. If a person has an IM phenotype for
CYP3A4, drugs metabolized through this enzyme can be identified and, if possible,
replaced. If a patient has more than four variants alleles for these CYP450s,
indiscriminant of what kind of variant, or there are DDIs and DGIs, medication can be
adjusted or discontinued. Special care should be rendered to patients on antidepressants
or other psychoactive medication, or patients at risk for fluctuating drug levels in the
blood. These could be due to initiating or discontinuing co-medication, and co-morbidity
(e.g., liver or kidney problems). This strategy could bridge the gap between academia and
the day-to-day practice, where clinicians only have limited time and expertise to make the
right therapeutic choices for their patients.
Finally, the awareness that comes with signing an informed consent, in which the
side effects of acts of violence or an altered emotional state are clearly mentioned, could
prevent unnecessary deaths as well.
For further research, it would be interesting to test a group of subjects who are on
psychoactive medication and who do not show altered emotional states or acts of
violence. To establish causality, prospective studies are warranted. Closely following a
group of patients with known CYP450 profiles and naïve in the use of psychoactive
medication, could shed further light on the likelihood of developing an altered emotional
state or acts of violence after starting psychoactive prescription medication.
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Appendix A: Raw Data on Gender, Violence Type and CYP Genotypes
CYP Genotypes
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Subject

Gender

Violence
Type

CYP2B6
(Metabol.)

CYP2C8
(Metabol.)

CYP2C9
(Metabol.)

CYP2C19
(Metabol.)

1

M

A/S/H

*1/*1
(EM)

*1/*1
(EM)

*1/*1
(EM)

*1/*2
(IM)

2

M

A/S/H

*1/*6
(IM)

*1/*1
(EM)

*1/*1
(EM)

*1/*2
(IM)

CYP2D6
(Metabol.)
*1/*2
(EM)
(IM-EM)
*1/*4
(IM)

3

F

A/S/H

*1/*1
(EM)

*1/*1
(EM)

*1/*1
(EM)

*2/*17
(IM)

*1/*4
(IM)

4

M

AES

*1/*1
(EM)

*1/*1
(EM)

*1/*2
(IM)

*1/*17
(RM)

5

M

A/S/H

*1/*6
(IM)

*1/*1
(EM)

*1/*1
(EM)

*6/*17
(EM)

6

M

A/S/H

*1/*5
(IM)

*1/*3
(IM)

*1/*2
(IM)

*1/*17
(RM)

*5/*5
(PM)
*2/*9
(EM)
(IM-EM)
*1/*2
(EM)
(IM-EM)

7

M

AES

*6/*6
(PM)

*1/*1
(EM)

*1/*1
(EM)

*17/*17
(URM)

*1/*1
(EM)

8

F

AES

*1/*5
(IM)

*1/*3
(IM)

*1/*2
(IM)

*1/*1
(EM)

*1/*1
(EM)

9

M

A/S/H

*1/*1
(EM)

*1/*1
(EM)

*1/*1
(EM)

*1/*1
(EM)

*1/*29
(EM)

CYP3A4
(Metabol.)
*1B/*1G
(EM)
(IM-EM)
*1/*1
(EM)
*1/*1G
(EM)
(IM-EM)
*1/*1
(EM)
*1/*1
(EM)
*1/*1
(EM)
*1B/*1G
(EM)
(IM-EM)
*1/*1G
(EM)
(IM-EM)
*1G/*1G
(IM)
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Subject

Gender

Violence
Type

CYP2B6
(Metabol.)

CYP2C8
(Metabol.)

CYP2C9
(Metabol.)

CYP2C19
(Metabol.)

CYP2D6
(Metabol.)
(IM-EM)

CYP3A4
(Metabol.)
(PM-IM)

10

F

AES

*1/*1
(EM)

*1/*3
(IM)

*1/*2
(IM)

*1/*1
(EM)

*1/*1
(EM)

11

F

0

*1/*1
(EM)

*1/*1
(EM)

*1/*1
(EM)

*1/*1
(EM)

12

M

A/S/H

*1/*1
(EM)

*1/*3
(IM)

*2/*2
(PM)

*1/*1
(EM)

13

M

AES

*1/*1
(EM)

*1/*1
(EM)

*1/*1
(EM)

*1/*1
(EM)

14

F

A/S/H

*1/*1
(EM)

*1/*1
(EM)

*1/*3
(IM)

*1/*1
(EM)

15

F

A/S/H

*1/*6
(IM)

*1/*1
(EM)

*1/*1
(EM)

*2/*17
(IM)

16

F

A/S/H

*1/*1
(EM)

*1/*1
(EM)

*1/*1
(EM)

*1/*1
(EM)

17

F

AES

*1/*1
(EM)

*1/*1
(EM)

*1/*1
(EM)

*1/*1
(EM)

*2/*4
(IM)
*1/*10
(EM)
(IM-EM)
*2/*10
(EM)
(IM-EM)
*1/*29
(EM)
(IM-EM)
*2/*2
(EM)
(IM)
*5/*41
(PM)
*4/*9
(IM)
(PM-IM)
*5/*9
(IM)
(PM-IM)

18

F

AES

*6/*13
(PM)

*1/*1
(EM)

*1/*1
(EM)

*1/*17
(RM)

*2/*4
(IM)

*1/*1
(EM)
*1/*22
(IM)
*1G/*1G
(IM)
(PM-IM)
*3/*22
(IM)
(PM-IM)
*1/*22
(IM)
*1/*1G
(EM)
(IM-EM)
*1/*1
(EM)
*1/*1G
(EM)
(IM-EM)

CYP Genotypes
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Subject

Gender

Violence
Type

CYP2B6
(Metabol.)

CYP2C8
(Metabol.)

CYP2C9
(Metabol.)

CYP2C19
(Metabol.)

19

M

A/S/H

*4/*6
(IM)

*1/*1
(EM)

*1/*1
(EM)

*1/*1
(EM)

20

M

A/S/H

21

M

A/S/H

*1/*5
(IM)
*1/*6
(IM)

*1/*1
(EM)
*1/*1
(EM)

*1/*1
(EM)
*1/*1
(EM)

*1/*17
(RM)
*1/*1
(EM)

22

F

0

*1/*1
(EM)

*1/*3
(IM)

*1/*2
(IM)

*1/*1
(EM)

23

M

AES

*1/*1
(EM)

*1/*1
(EM)

*1/*1
(EM)

*2/*17
(IM)

24

F

AES

*1/*1
(EM)

*1/*1
(EM)

*1/*3
(IM)

*1/*17
(RM)

25

F

AES

*1/*4
(EM)

*1/*3
(IM)

*1/*2
(IM)

*1/*2
(IM)

26

F

0

27

M

0

28

M

0

*1/*1
(EM)
*1/*1
(EM)
*1/*6
(IM)

*1/*1
(EM)
*1/*3
(IM)
*1/*1
(EM)

*1/*1
(EM)
*1/*2
(IM)
*1/*1
(EM)

*2/*17
(IM)
*1/*17
(RM)
*1/*1
(EM)

29

M

A/S/H

*5/*5
(PM)

*1/*1
(EM)

*1/*1
(EM)

*2/*2
(PM)

CYP2D6
(Metabol.)
*10/*41
(IM)
(PM-IM)
*1/*5
(IM)
*1/*4
(IM)
*1/*41
(EM)
(IM-EM)
*3/*9
(IM)
(PM-IM)
*1/*4
(IM)
*2/*41
(EM)
(IM-EM)
*1/*4
(IM)
*1/*1
(EM)
*2/*4
(IM)
*1/*41
(EM)
(IM-EM)

CYP3A4
(Metabol.)
*1/*1
(EM)
*1/*1
(EM)
*1/*1
(EM)
*1/*1
(EM)
*1/*1
(EM)
*1/*22
(IM)
*1/*1
(EM)
*1/*1
(EM)
*1/*22
(IM)
*1/*1
(EM)
*1/*1
(EM)

CYP Genotypes
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Subject

Gender

Violence
Type

CYP2B6
(Metabol.)

CYP2C8
(Metabol.)

CYP2C9
(Metabol.)

CYP2C19
(Metabol.)

30

F

A/S/H

*1/*5
(IM)

*1/*3
(IM)

*1/*2
(IM)

*1/*1
(EM)

31

M

A/S/H

*1/*6
(IM)

*1/*1
(EM)

*1/*1
(EM)

*17/*17
(URM)

32

M

0

*1/*5
(IM)

*1/*1
(EM)

*1/*1
(EM)

*1/*2
(IM)

33

M

AES

*1/*1
(EM)

*1/*1
(EM)

*1/*1
(EM)

*2/*17
(IM)

34

F

A/S/H

*1/*6
(IM)

*1/*1
(EM)

*1/*1
(EM)

*17/*17
(URM)

*1/*3
(IM)

*1/*2
(IM)

*1/*1
(EM)

CYP2D6
(Metabol.)
*1/*41
(EM)
(IM-EM)
*1/*41
(EM)
(IM-EM)
*1/*4
(IM)
*1/*41
(EM)
(IM-EM)
*1/*4
(IM)
*1/*2
(EM)
(IM-EM)
*1/*1
(EM)
*1/*2
(EM)
(IM-EM)

35

F

AES

*1/*5
(IM)

36

F

AES

*1/*5
(IM)

*1/*1
(EM)

*1/*1
(EM)

*1/*1
(EM)

37

M

AES

*1/*1
(EM)

*1/*1
(EM)

*1/*3
(IM)

*1/*2
(IM)

38

M

A/S/H

*1/*1
(EM)

*1/*1
(EM)

*1/*1
(EM)

*1/*1
(EM)

*4xN/*35
(IM)

39

M

AES

*1/*1
(EM)

*1/*1
(EM)

*1/*1
(EM)

*17/*17
(URM)

*9/*41
(IM)

CYP3A4
(Metabol.)
*1/*1G
(EM)
(IM-EM)
*1/*1
(EM)
*1/*1
(EM)
*1/*1G
(EM)
(IM-EM)
*1G/*1G
(IM)
(PM-IM)
*1/*1
(EM)
*1/*1
(EM)
*1B/*1G
(EM)
(IM-EM)
*1/*1G
(EM)
(IM-EM)
*1/*1
(EM)

CYP Genotypes
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Subject

Gender

Violence
Type

CYP2B6
(Metabol.)
*1/*6
(IM)
*1/*1
(EM)
*1/*5
(IM)
*1/*1
(EM)

CYP2C8
(Metabol.)
*1/*1
(EM)
*1/*3
(IM)
*1/*1
(EM)
*1/*1
(EM)

CYP2C9
(Metabol.)
*1/*2
(IM)
*1/*2
(IM)
*1/*1
(EM)
*1/*1
(EM)

CYP2C19
(Metabol.)
*1/*17
(RM)
*1/*1
(EM)
*1/*2
(IM)
*2/*17
(IM)

40

F

0

41

M

0

42

F

AES

43

F

AES

44

F

AES

*6/*6
(PM)

*1/*1
(EM)

*1/*1
(EM)

*2/*17
(IM)

45

F

0

*1/*6
(IM)

*1/*1
(EM)

*1/*1
(EM)

*1/*1
(EM)

46

F

AES

47

F

A/S/H

48

M

A/S/H

49

M

0

50

F

AES

51

M

A/S/H

*1/*1
(EM)
*1/*5
(IM)
*1/*1
(EM)
*5/*6
(PM)
*1/*6
(IM)
*1/*6
(IM)

*1/*3
(IM)
*1/*1
(EM)
*1/*1
(EM)
*1/*1
(EM)
*1/*1
(EM)
*1/*1
(EM)

*2/*2
(PM)
*1/*1
(EM)
*1/*1
(EM)
*1/*18
(IM)
*1/*18
(IM)
*1/*1
(EM)

*1/*1
(EM)
*1/*17
(RM)
*1/*2
(IM)
*1/*17
(RM)
*1/*17
(RM)
*1/*2
(IM)

CYP2D6
(Metabol.)
*1/*35
(EM)
*1/*2A
(EM)
*1/*4
(IM)
*9/*41
(IM)
*1/*41
(EM)
(IM-EM)
*1/*41
(EM)
(IM-EM)
*4/*41
(IM)
*1/*4xN
(IM)
*4/*35
(IM)
*1/*35
(EM)
*1/*2A
(EM)
*1/*6
(IM)

CYP3A4
(Metabol.)
*1/*1
(EM)
*1/*22
(IM)
*1/*22
(IM)
*1B/*22
(IM)
*1/*1
(EM)
*1/*1
(EM)
*1/*1B
(EM)
*1/*1
(EM)
*1/*22
(IM)
*1/*1
(EM)
*1/*1
(EM)
*1/*22
(IM)

CYP Genotypes
Subject

Gender

Violence
Type
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CYP2B6
(Metabol.)
*1/*6
(IM)

CYP2C8
(Metabol.)
*1/*1
(EM)

CYP2C9
(Metabol.)
*1/*1
(EM)

CYP2C19
(Metabol.)
*1/*17
(RM)

AES

*4/*5
(PM)

*1/*1
(EM)

*1/*18
(IM)

*1/*17
(RM)

M

0

*1/*1
(EM)

*1/*1
(EM)

*1/*1
(EM)

*1/*17
(RM)

CYP2D6
(Metabol.)
*1/*1
(EM)
*4/*10
(IM)
(PM-IM)
*2A/*4
(IM)

52

M

A/S/H

53

M

54
55

F

0

*1/*6
(IM)

*1/*1
(EM)

*3/*3
(PM)

*1/*1
(EM)

*4/*4
(PM)

56

M

0

57

F

0

*1/*6
(IM)
*1/*6
(IM)

*1/*1
(EM)
*1/*1
(EM)

*1/*1
(EM)
*1/*1
(EM)

*1/*17
(RM)
*1/*1
(EM)

58

M

A/S/H

*1/*1
(EM)

*1/*1
(EM)

*1/*1
(EM)

*17/*17
(URM)

59

M

0

*1/*1
(EM)

*1/*1
(EM)

*1/*1
(EM)

*2/*17
(IM)

60

F

0

*1/*1
(EM)

*1/*1
(EM)

*1/*1
(EM)

*2/*17
(IM)

61

M

0

*1/*6
(IM)

*1/*1
(EM)

*1/*1
(EM)

*1/*17
(RM)

62

F

0

*1/*5
(IM)

*1/*3
(IM)

*1/*2
(IM)

*1/*2
(IM)

*41/*41
(IM)
*1/*4
(IM)
*1/*41
(EM)
(IM-EM)
*1/*2
(EM)
(IM-EM)
*1/*4
(IM)
*1/*41
(EM)
(IM-EM)
*1/*1
(EM)

CYP3A4
(Metabol.)
*1/*22
(IM)
*1/*1
(EM)
*1/*1
(EM)
*1B/*1G
(EM)
(IM-EM)
*1/*1
(EM)
*1/*1
(EM)
*1/*1G
(EM)
(IM-EM)
*1/*1
(EM)
*1/*1
(EM)
*1/*1
(EM)
*1/*1G
(EM)

CYP Genotypes
Subject

Gender

Violence
Type

CYP2B6
(Metabol.)

CYP2C8
(Metabol.)

CYP2C9
(Metabol.)

CYP2C19
(Metabol.)

CYP2D6
(Metabol.)

CYP3A4
(Metabol.)
(IM-EM)

*1/*1
(EM)

*1/*1
(EM)

*1/*2
(IM)

*1/*4
(IM)

*1/*1G
(EM)
(IM-EM)
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63

F

0

*1/*9
(IM)

64

M

0

*1/*1
(EM)

*1/*1
(EM)

*1/*1
(EM)

*1/*17
(RM)

*1/*2
(EM)
(IM-EM)

*1/*1
(EM)

65

M

0

*1/*6
(IM)

*1/*1
(EM)

*1/*1
(EM)

*1/*1
(EM)

*4/*41
(IM)

*1B/*1G
(EM)
(IM-EM)

*1/*1
(EM)

*1/*1
(EM)

*1/*2
(IM)

66

F

0

*1/*1
(EM)

67

F

0

*1/*7
(IM)

*1/*3
(IM)

*1/*2
(IM)

*1/*1
(EM)

68

M

0

69

M

0

*1/*5
(IM)
*1/*9
(IM)

*1/*1
(EM)
*1/*1
(EM)

*1/*1
(EM)
*1/*1
(EM)

*2/*2
(PM)
*1/*17
(RM)

*1/*2
(EM)
(IM-EM)
*1/*10
(EM)
(IM-EM)
*1/*5
(IM)
*4/*4
(PM)

70

F

0

*1/*6
(IM)

*1/*1
(EM)

*1/*1
(EM)

*1/*17
(RM)

*1/*1xN
(URM)

71

F

0

*1/*1
(EM)

*1/*1
(EM)

*1/*3
(IM)

*1/*1
(EM)

*2/*4
(IM)

*1/*1
(EM)
*1/*1
(EM)
*1/*1
(EM)
*1/*1
(EM)
*1/*1G
(EM)
(IM-EM)
*1/*1G
(EM)
(IM-EM)

CYP Genotypes
Subject

Gender

Violence
Type

CYP2C8
(Metabol.)
*1/*3
(IM)
*1/*3
(IM)
*1/*1
(EM)

CYP2C9
(Metabol.)
*1/*2
(IM)
*1/*2
(IM)
*1/*1
(EM)

CYP2C19
(Metabol.)
*1/*1
(EM)
*1/*1
(EM)
*2/*17
(IM)

72

F

0

73

M

0

74

F

0

75

M

AES

*1/*6
(IM)

*1/*1
(EM)

*1/*2
(IM)

*1/*17
(RM)

76

F

0

*1/*1
(EM)

*1/*3
(IM)

*1/*2
(IM)

*1/*1
(EM)

77

M

0

78

M

0

79

M

0

*1/*1
(EM)
*1/*1
(EM)
*1/*5
(IM)

*1/*1
(EM)
*1/*1
(EM)
*1/*1
(EM)

*1/*1
(EM)
*1/*1
(EM)
*1/*1
(EM)

*1/*1
(EM)
*1/*1
(EM)
*2/*17
(IM)

80

M

0

*6/*6
(PM)

*1/*1
(EM)

*1/*1
(EM)

*17/*17
(URM)

81

F

0

*1/*6
(IM)

*1/*1
(EM)

*1/*1
(EM)

*1/*1
(EM)

82

F

0

*1/*6
(IM)

*1/*1
(EM)

*1/*1
(EM)

*1/*1
(EM)

287

CYP2B6
(Metabol.)
*1/*6
(IM)
*1/*6
(IM)
*1/*1
(EM)

CYP2D6
(Metabol.)
*1/*1
(EM)
*1/*1
(EM)
*1/*6
(IM)
*1/*41
(EM)
(IM-EM)
*1/*41
(EM)
(IM-EM)
*1/*4
(IM)
*1/*4
(IM)
*2/*4
(IM)
*2/*3
(IM)
(PM-IM)
*1/*2
(EM)
(IM-EM)
*1/*5
(IM)

CYP3A4
(Metabol.)
*1/*1
(EM)
*1/*1
(EM)
*1/*1
(EM)
*1/*1
(EM)
*1/*1
(EM)
*1/*1
(EM)
*1/*1
(EM)
*1/*1
(EM)
*1/*1
(EM)
*1/*1
(EM)
*1/*1
(EM)

CYP Genotypes
Subject

Gender

Violence
Type
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CYP2B6
(Metabol.)
*1/*1
(EM)

CYP2C8
(Metabol.)
*1/*1
(EM)

CYP2C9
(Metabol.)
*1/*1
(EM)

CYP2C19
(Metabol.)
*1/*2
(IM)

0

*1/*1
(EM)

*1/*1
(EM)

*1/*1
(EM)

*1/*1
(EM)

M

AES

*1/*1
(EM)

*1/*1
(EM)

*1/*3
(IM)

*1/*17
(RM)

86

F

0

87

F

AES

*1/*6
(IM)
*1/*13
(IM)

*1/*1
(EM)
*1/*1
(EM)

*1/*1
(EM)
*1/*1
(EM)

*2/*17
(IM)
*17/*17
(URM)

88

M

0

*1/*1
(EM)

*1/*1
(EM)

*1/*1
(EM)

*1/*17
(RM)

89

M

0

*1/*6
(IM)

*1/*1
(EM)

*1/*1
(EM)

*1/*1
(EM)

CYP2D6
(Metabol.)
*1/*4
(IM)
*2/*5
(IM)
(PM-IM)
*1/*41
(EM)
(IM-EM)
*1/*4
(IM)
*1/*1
(EM)
*5/*41
(IM)
(PM-IM)
*2/*4
(IM)

83

F

0

84

F

85

90

M

0

*1/*1
(EM)

*1/*1
(EM)

*1/*1
(EM)

*1/*2
(IM)

*2/*4
(IM)

91

F

AES

*1/*6
(IM)

*1/*1
(EM)

*1/*2
(IM)

*1/*1
(EM)

92

F

0

*1/*6
(IM)

*1/*1
(EM)

*1/*1
(EM)

*1/*1
(EM)

93

F

0

*1/*5
(IM)

*1/*1
(EM)

*1/*1
(EM)

*1/*1
(EM)

*4/*41
(IM)
*1/*41
(EM)
(IM-EM)
*4/*41
(IM)

CYP3A4
(Metabol.)
*1/*1
(EM)
*1/*1
(EM)
*1/*1
(EM)
*1/*1
(EM)
*1/*1
(EM)
*1/*1
(EM)
*1/*1
(EM)
*1B/*1G
(EM)
(IM-EM)
*1/*1
(EM)
*1/*1
(EM)
*1/*22
(IM)

CYP Genotypes
Subject

Gender

Violence
Type

289

CYP2B6
(Metabol.)
*1/*6
(IM)

CYP2C8
(Metabol.)
*1/*1
(EM)

CYP2C9
(Metabol.)
*1/*1
(EM)

CYP2C19
(Metabol.)
*1/*2
(IM)

94

M

0

95

M

AES

*1/*5
(IM)

*1/*1
(EM)

*1/*2
(IM)

*1/*1
(EM)

96

M

0

*1/*5
(IM)

*1/*3
(IM)

*1/*2
(IM)

*1/*1
(EM)

97

F

0

*1/*1
(EM)

*1/*1
(EM)

*1/*1
(EM)

*2/*17
(IM)

98

M

0

*1/*6
(IM)

*1/*1
(EM)

*1/*1
(EM)

*1/*2
(IM)

99

M

A/S/H

100

M

0

*1/*1
(EM)
*1/*5
(IM)

*1/*1
(EM)
*1/*1
(EM)

*1/*18
(IM)
*1/*1
(EM)

*1/*1
(EM)
*1/*17
(RM)

101

F

0

*1/*6
(IM)

*1/*1
(EM)

*1/*1
(EM)

*1/*17
(RM)

102

M

0

*1/*1
(EM)

*1/*1
(EM)

*1/*1
(EM)

*1/*1
(EM)

103

M

0

104

F

0

*1/*6
(IM)
*1/*1
(EM)

*1/*1
(EM)
*1/*1
(EM)

*1/*1
(EM)
*1/*1
(EM)

*17/*17
(URM)
*1/*1
(EM)

CYP2D6
(Metabol.)
*4/*4
(PM)
*1/*41
(EM)
(IM-EM)
*1/*41
(EM)
(IM-EM)
*9/*41
(IM)
*1/*2
(EM)
(IM-EM)
*1/*5
(IM)
*4xN/*68
(PM)
*2A/*41
(EM)
(IM-EM)
*4/*68/*41
(IM)
(PM-IM)
*2A/*4
(IM)
*4/*10
(IM)

CYP3A4
(Metabol.)
*1/*22
(IM)
*1/*1
(EM)
*1/*1
(EM)
*1/*1
(EM)
*1/*1G
(EM)
(IM-EM)
*1/*1
(EM)
*1/*1
(EM)
*1/*1
(EM)
*1/*1
(EM)
*1/*1
(EM)
*1/*1
(EM)

CYP Genotypes
Subject

Gender

Violence
Type

CYP2C8
(Metabol.)

CYP2C9
(Metabol.)

CYP2C19
(Metabol.)

CYP2D6
(Metabol.)
(PM-IM)

CYP3A4
(Metabol.)

105

F

0

*1/*6
(IM)
*1/*6
(IM)

*1/*1
(EM)
*1/*1
(EM)

*1/*1
(EM)
*1/*1
(EM)

*1/*2
(IM)
*1/*1
(EM)

*1/*1
(EM)
*1/*1
(EM)

AES

*1/*6
(IM)

*1/*1
(EM)

*1/*1
(EM)

*1/*1
(EM)

F

0

*1/*1
(EM)

*1/*1
(EM)

*1/*1
(EM)

*1/*2
(IM)

*1/*4
(IM)
*1/*4
(IM)
*4/*29
(IM)
(PM-IM)
*2/*9
(EM)
(IM-EM)

106

F

0

107

M

108
109

M

0

*1/*1
(EM)

*1/*3
(IM)

*2/*2
(PM)

*1/*1
(EM)

110

M

AES

*1/*1
(EM)

*1/*3
(IM)

*1/*2
(IM)

*1/*1
(EM)

111

F

AES

*6/*6
(PM)

*1/*1
(EM)

*1/*1
(EM)

*1/*17
(RM)

112

M

A/S/H

*1/*1
(EM)

*1/*1
(EM)

*1/*1
(EM)

*1/*1
(EM)

113

F

AES

*1/*6
(IM)

*1/*3
(IM)

*1/*2
(IM)

*1/*2
(IM)
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CYP2B6
(Metabol.)

*4/*41
(IM)
*4/*9
(IM)
(PM-IM)
*2/*41
(EM)
(IM-EM)
*1/*4
(IM)
*1/*2
(EM)
(IM-EM)

*1/*1
(EM)
*1B/*1G
(EM)
(IM-EM)
*1/*1G
(EM)
(IM-EM)
*1/*1
(EM)
*1/*1B
(EM)
*1/*1
(EM)
*1/*1B
(EM)

Appendix B: Raw Data on Medications and Interactions
Number of
Medications
Medications
Subject Used (see
Active
footnotes) Meds Meta- Tot.
bolites

Classification of Medications
AntiAntiDepressants Psychotics

Hypnotics

Interactions

ADHD/
Mood
Other Alc.
Stabilizers

DGI DDI DDGI
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1
2

1,2,3
4,5

3
2

3
0

6
2

2
1

0
0

0
0

1
0

3
1

1
0

7
4

8
6

15
10

3

1,6

2

2

4

1

0

1

0

0

0

6

5

11

4
5

7,8
4,9,10
1,11,12,13,
14,15,16,17
7,8,10,18
19,20,21
4
22,23,24
25,26
10,27
1,12,28,29,
30,31,32
33
1,10,15,34
4,5,35,36
5,37,38
5,12,35,106

2
3

2
3

4
6

0
1

0
0

0
2

1
0

1
0

0
1

2
3

0
17

2
20

8

3

11

1

0

1

0

6

0

5

20

25

4
3
1
3
2
2

2
3
0
3
0
1

6
6
1
6
2
3

0
1
1
0
0
1

0
0
0
3
0
0

1
0
0
0
0
1

1
0
0
0
0
0

2
2
0
0
2
0

1
0
0
0
0
0

2
4
1
1
1
2

3
2
0
4
0
1

5
6
1
5
0
3

7

2

9

2

0

0

1

2

0

2

9

11

1
4
4
3
4

1
2
1
0
0

2
6
5
3
4

1
2
1
1
0

0
0
0
0
0

0
1
0
0
2

0
0
0
0
0

0
1
3
2
2

0
0
1
0
0

3
4
2
1
2

0
12
8
10
1

3
16
10
11
3

6
7
8
9
10
11
12
13
14
15
16
17
18

Number of
Medications
Medications
Subject Used (see
Active
footnotes) Meds Meta- Tot.
bolites

19
20
21
22
23
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24
25
26
27
28
29
30
31
32
33
34
35

10,23,40
2,10,24,41,
42
12,43
4,33,44,45,
46
27,47
15,25,26
27
11,12,48
4,6,10,
1,34,40,51,
52,53,54,55
4
19,56
8,16,58,
59,60,61
15,19,25,36,
37,62,63,64,
65
15,17,19,66,
67

Classification of Medications
AntiAntiDepressants Psychotics

Hypnotics

Interactions

ADHD/
Mood
Other Alc.
Stabilizers

DGI DDI DDGI

3

1

4

0

1

1

0

1

0

1

6

7

5

2

7

1

1

1

0

2

0

2

4

6

2
0

1
0

3
0

1
0

0
0

0
0

0
0

1
0

1
0

1
0

6
0

7
0

5

3

8

1

0

0

0

4

0

2

13

15

2
3
1
3
0
3

1
0
1
3
0
1

3
3
2
6
0
4

1
1
0
0
0
1

0
0
0
0
0
0

1
0
0
0
0
2

0
0
0
0
0
0

0
2
1
3
0
0

0
0
0
0
0
1

3
5
1
2
0
3

0
4
0
3
0
10

3
9
0
5
0
13

8

1

9

1

0

0

0

7

0

5

16

21

1
2

0
1

1
3

1
1

0
0

0
0

0
0

0
1

0
0

1
3

0
1

1
4

6

1

7

0

0

1

1

4

0

2

2

4

9

4

13

3

0

2

0

4

0

4

21

25

5

4

9

1

0

3

0

1

0

2

5

7

Number of
Medications
Medications
Subject Used (see
Active
footnotes) Meds Meta- Tot.
bolites

36
37
38
39
40
41
42
43
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44
45
46
47
48
49
50
51
52
53
54
55

1,23,35
4
29,64
44
66
15
2,15,34,54,
67,68,69,71
72,73
4,15
74,75
18,33,36,76,
77
10,37
35
33
44,78
79
12,35,66,80,
81

Classification of Medications
AntiAntiDepressants Psychotics

Hypnotics

Interactions

ADHD/
Mood
Other Alc.
Stabilizers

DGI DDI DDGI

3
1
2
1
1
0
1

2
0
1
2
0
0
0

5
1
3
3
1
0
1

2
1
2
0
0
0
0

0
0
0
0
0
0
0

1
0
0
0
0
0
1

0
0
0
0
0
0
0

0
0
0
1
1
0
0

0
0
0
0
0
0
0

1
1
2
1
1
0
3

7
0
1
1
0
0
0

8
1
3
2
0
0
3

8

2

10

2

0

0

0

6

0

3

17

21

2
2
2

1
0
2

3
2
4

0
0
0

0
0
0

0
1
0

2
0
0

0
1
2

0
0
0

1
1
3

0
0
3

1
1
6

5

2

7

1

0

0

0

4

0

2

13

15

2
0
1
1
2
1
0

0
0
0
1
3
2
0

2
0
1
2
5
3
0

1
0
0
1
0
0
0

0
0
0
0
0
0
0

1
0
0
0
1
0
0

0
0
0
0
0
0
0

0
0
1
0
1
1
0

0
0
0
1
0
0
0

3
0
0
3
3
1
0

1
0
0
2
3
0
0

4
0
0
5
6
1
0

5

0

5

0

0

0

0

5

0

7

6

15

Number of
Medications
Medications
Subject Used (see
Active
footnotes) Meds Meta- Tot.
bolites
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56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75

23
3,82
36
35, 36
83
80,84,85,86,
87,88,89,90,
91
33
10,82,92,93
1,47

Classification of Medications
AntiAntiDepressants Psychotics

Hypnotics

Interactions

ADHD/
Mood
Other Alc.
Stabilizers

DGI DDI DDGI

0
1
2
1
2
0
1
0
0
0

0
1
2
0
1
0
2
0
0
0

0
2
4
1
3
0
3
0
0
0

0
1
0
0
0
0
0
0
0
0

0
0
0
0
0
0
0
0
0
0

0
0
1
0
0
0
0
0
0
0

0
0
1
0
0
0
0
0
0
0

0
0
0
1
2
0
1
0
0
0

0
0
0
0
0
0
1
0
0
0

0
2
2
1
0
0
2
0
0
0

0
0
0
0
1
0
0
0
0
0

0
0
2
0
0
0
0
0
0
0

9

2

11

0

0

0

0

9

0

2

3

5

1
0
0
4
0
0
0
0
2

1
0
0
1
0
0
0
0
1

2
0
0
5
0
0
0
0
3

2
0
0
1
0
0
0
0
1

0
0
0
0
0
0
0
0
0

0
0
0
0
0
0
0
0
1

0
0
0
0
0
0
0
0
0

0
0
0
3
0
0
0
0
0

0
0
0
0
0
0
0
0
0

1
0
0
7
0
0
0
0
2

2
0
0
6
0
0
0
0
1

3
0
0
13
0
0
0
0
3

Number of
Medications
Medications
Subject Used (see
Active
footnotes) Meds Meta- Tot.
bolites
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76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95

57
12,19,49,94
21
5
18,34,36,37,
77,95,96,97
54, 59
98
4,18,50,55,
69,70,77
10,37,47

Classification of Medications
AntiAntiDepressants Psychotics

Hypnotics

Interactions

ADHD/
Mood
Other Alc.
Stabilizers

DGI DDI DDGI

1
0
0
0
0
0
4
0
0
1
0
1

0
0
0
0
0
0
3
0
0
0
0
0

1
0
0
0
0
0
7
0
0
1
0
1

0
0
0
0
0
0
0
0
0
0
0
0

0
0
0
0
0
0
0
0
0
0
0
0

0
0
0
0
0
0
0
0
0
0
0
0

0
0
0
0
0
0
0
0
0
0
0
0

1
0
0
0
0
0
3
0
0
1
0
1

0
0
0
0
0
0
0
0
0
0
0
0

0
0
0
0
0
0
3
0
0
1
0
2

0
0
0
0
0
0
4
0
0
0
0
0

0
0
0
0
0
0
7
0
0
1
0
2

8

2

10

0

0

1

0

7

1

2

5

7

2
0
1

0
0
0

2
0
1

0
0
0

0
0
0

0
0
0

0
0
0

2
0
1

0
0
0

2
0
1

1
0
3

3
0
4

7

1

8

1

0

0

0

6

1

5

12

17

0
0
3

0
0
0

0
0
3

0
0
1

0
0
0

0
0
2

0
0
0

0
0
0

0
0
0

0
0
2

0
0
1

0
0
3

Number of
Medications
Medications
Subject Used (see
Active
footnotes) Meds Meta- Tot.
bolites
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96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113

39,99,100
5,12
64,82,101
102,103
4
23,104,105
12,19,46

0
0
0
3
2
0
0
0
0
0
0
3
0
0
2
1
3
3

1

sertraline (Zoloft)

2

mirtazapine (Remeron)

0
0
0
3
0
0
0
0
0
0
0
2
0
0
2
0
1
1

0
0
0
6
2
0
0
0
0
0
0
5
0
0
4
1
4
4

Classification of Medications
AntiAntiDepressants Psychotics

0
0
0
0
0
0
0
0
0
0
0
2
0
0
0
1
0
1

0
0
0
0
0
0
0
0
0
0
0
0
0
0
2
0
1
0

Hypnotics

0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0

Interactions

ADHD/
Mood
Other Alc.
Stabilizers

0
0
0
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0

0
0
0
0
2
0
0
0
0
0
0
1
0
0
0
0
2
2

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0

DGI DDI DDGI

0
0
0
1
2
0
0
0
0
0
0
2
0
0
3
2
1
5

0
0
0
1
0
0
0
0
0
0
0
2
0
0
4
0
1
4

0
0
0
2
0
0
0
0
0
0
0
4
0
0
7
2
2
9

3

dextroamphetamine (Dexedrine, Metamina)

4

paroxetine (Paxil, Paxil CR, Pexeva)

5

diclofenac (Cataflam, Voltaren)

6

temazepam (Restoril, Normison)

7

methylphendate (Ritalin, Concerta)

8

cannabis

9

diazepam (Valium, Vazepam)
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10

oxazepam (Serax, Alepam)

11

hydrocodone (Hysingla ER, Zohydro ER)

12

acetaminophen (Tylenol, Panadol)

13

diphenhydramine (Benadryl, Unisom, Sominex)

14

lidocaine (Xylocaine)

15

zolpidem (Ambien)

16

clonazepam (Klonopin, Rivotril, Paxam)

17

loratadine (Claritin, Claratyne)

18

melatonin (Melatonin Teva XL PR, Melatonina)

19

amitriptyline (Elavil)

20

hydromorphone (Dilaudid, Hydromorph Contin)

21

morphine (Statex, MSContin, Oramorph, Sevredol)
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22

aripiprazole (Abilify)

23

quetiapine (Seroquel, Temprolide)

24

risperidone (Risperdal)

25

estrogen

26

progesterone (Prometrium, Utrogestan, Endometrin, Crinone)

27

clomipramine (Anafranil, Clomicalm)

28

modafinil (Provigil, Alertec, Modavigil)

29

duloxetine (Cymbalta)

30

butalbital

31

caffeine (Vivarin, Cafcit, 357 HR Magnum, Molie)

32

metaxalone (Skelaxin)

33

venlafaxine (Effexor)

34

levothyroxine (Levoxyl, Synthroid, Tirosint, Unithroid, Eutirox)

35

levonorgestrel (Plan B)

36

ibuprofen (Advil, Motrin, Nurofen)

37

citalopram (Celexa, Cipramil)

38

omeprazole (Losec, Prilosec, Zegerid)

39

dextroamphetamine (Adderall, Adderall XR, Mydayis)

40

pantoprazole (Protonix)
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41

promethazine (Phenergan)

42

biperiden (Akineton)

43

ketamine (Ketalar)

44

oxycodone (OxyContin)

45

methadone (Dolophine, Methadose)

46

thiamazole (Tapazole)

47

lorazepam (Ativan, Tavor, Temesta)

48

nebivolol (Nebilet, Bystolic)

49

codeine (PMS-codeine, Ratio-codeine, Teva-codeine)

50

insulin aspart (NovoLog, NovoRapid, Fiasp)

51

telmisartan (Micardis, Actavis)

52

desloratadine (Clarinex, Aerius, Dasselta, Deslordis)

53

rosuvastatin (Crestor, Rosulip, Zuvamor)

54

amlodipine (Norvasc)

55

clopidogrel (Plavix)

56

tadalafil (Cialis, Adcirca, Tadacip)

57

salbutamol (Ventolin, Proventil)

58

fluticasone (ArmonAir RespiClick, Flovent)

59

clonidine (Catapres, Kapvay, Nexiclon)
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60

tetrahydrocannabinol (Marinol)

61

bupropion (Wellbutrin, Zyban)

62

tizanidine (Zanaflex, Sirdalud)

63

cyclobenzaprine (Flexeril)

64

trazodone (Desyrel, Desyrel Dividose, Oleptro)

65

doxepin (Sinequan, Quitaxon, Aponal)

66

ranitidine (Zantac)

67

losartan (Cozaar)

68

ubiquinone (ubidecarenone, coenzyme Q10)

69

metoprolol (Lopressor, Metolar XR)

70

metformin (Glucophage)

71

cetirizine (Zyrtec, Incidal)

72

levetiracetam (Keppra, Elepsia)

73

carbamazepine (Tegretol)

74

propofol (Diprivan)

75

pethidine (Demerol)

76

amoxicillin/clavulanic acid (Augmentin, Clavulin)

77

simvastatin (Zocor)

78

zopiclone (Imovane, Zimovane, Dopareel)
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79

cocaine (Neurocaine)

80

formoterol (Oxeze, Foradil)

81

indometacin (Indocid, Indocin)

82

fluoxetine (Prozac, Sarafem, Selfemra, Prozac Weekly)

83

ezetimibe (Zetia, Ezetrol)

84

bumetanide (Bumex, Burinex)

85

celiprolol (Cardem, Selectol, Celipres, Celipro, Celol, Cordiax, Dilanorm)

86

ferrous fumarate (Feostat)

87

acenocoumarol (Sintrom, Mini-sintrom, Sincumar)

88

ciclesonide (Alvesco, Omnaris, Zetonna)

89

tiotropium bromide (Spiriva, Braltus)

90

digoxin (Lanoxin)

91

cholecalciferol (Vitamin D, Colecalciferol)

92

hydroxyurea (Droxia, Hydrea)

93

deferasirox (Exjade, Desirox, Defrijet, Desifer, Rasiroxpine, Jadenu)

94

sumatriptan (Imitrex, Imigran)

95

aspirin (Bayer Aspirin)

96

mirabegron (Myrbetriq, Betanis, Betmiga)

97

dipyridamole (Persantine)

98

bupivacaine (Marcaine, Sensorcaine, Vivacaine)

99

alprazolam (Xanax, Xanor, Niravam)

100

oxcarbazepine (Trileptal, Oxtellar XR)

101

hydrochlorothiazide (Apo-hydro, Esidrix)

102

haloperidol (Haldol, Serenace)

103

clozapine (Clozaril, Leponex, Versacloz)

104

cetirizine (Zyrtec, Incidal)

105

hydroxuzine (Atarax, Vistaril)

106

busulfan (Myleran, Busilvex, Busulfex IV)
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